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ABSTRACT 
Signal Transducers and Activators of Transcription factors (STATs) are a class of latent 
cytoplasmic proteins that regulate cell growth and survival by modulating the expression of 
specific target genes. One member of the STAT family, STAT3, has received particular 
attention since it has been found constitutively activated in a broad spectrum of cancer cell 
lines and human tumors. These compelling results, combined with a well-known selectivity of 
STAT3 inhibitors for tumor cells, validated STAT3 as a promising anticancer drug target. 
Although the experimental studies on STAT3 inhibitors seem very interesting, to date, there is 
no evidence in literature of any impending clinical development.  
The aim of this research project was the identification of new small molecules able to inhibit 
STAT3 activity through the direct binding to STAT3 protein. Starting from the structures of 
molecules which were known in the literature for their STAT3 inhibitory activity, three 
classes of compounds were developed: the oxadiazoles, the pyridazinones and the ortho-
quinone derivatives. The oxadiazoles were structurally related to AVS-0288, which was 
identified through a screening of a Korean chemical library for its ability to inhibit STAT3 
activity, although the exact mechanism of action had not been clarified yet. These derivatives 
were designed using the most classical approaches for a ‘hit to lead generation’: 
bioisosterism, vinilogy, homology. The second series of molecules, the pyridazinones, 
derived from the natural compound Cryptotanshinone, a direct STAT3 inhibitor, and was 
designed with the support of molecular modeling studies. These latter studies suggested a 
structural similarity between Cryptotanshinone and a series of pyridazinone derivatives, 
previously investigated by our research group.  
Moreover, in order to combine the structural characteristics of the two series of molecules 
above, chimeric compounds, on the basis of an accurate conformational analysis, were 
designed and synthesized. Finally, with the aim to understand the mode of interaction of the 
parent compound Cryptotanshinone with the SH2 domain of STAT3, docking studies and in 
vitro screening were carried out. These suggested a key role of the ortho-quinone moiety, 
since it resembled the phosphotyrosine of the natural peptide able to bind SH2 domain. 
Therefore, ortho-quinone compounds, derived from a simplification of Cryptotanshinone 
iii 
 
structure, were synthesized. However, due to the instability and high volatility of some of the 
designed compounds, only two representative terms have been prepared to date. 
All synthesized molecules were evaluated by a cell-based preliminary screening, the dual-
luciferase assay, which selected for compounds able to exert an inhibition on STAT3 activity. 
Although some of these assays showed interesting preliminary results, a deeper investigation 
was fundamental, in order to determine their target and/or mechanism of action. With this 
aim, an in vitro competitive binding assay, the AlphaScreen technology system, was 
performed to check the ability of these compounds to bind the SH2 domain of STAT3 and 
inhibit its dimerization, a crucial step for STAT3 activation. 
This biological investigation led to the identification of the oxadiazole amidic derivative F2e, 
which was found to exert positive results both in the luciferase assay (20% inhibition at 5 µM) 
and in the AlphaScreen-based assay (IC50 = 17.7 µM), and moreover, its inhibitory activity 
was found to be dose-dependent. The effect of F2e on the tumor cell growth was also checked 
and shown to have a good profile of inhibitory activity on cell proliferation, with an GI50 
around 2 µM for most of the screened tumor cell lines. Due to these encouraging results, F2e 
is considered the lead compound for the development of a new series of derivatives. 
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1. INTRODUCTION 
 
The proliferation and differentiation of mammalian cells is modulated by a number of specific 
signal molecules that regulate gene expression. Among these signals are: i) the steroid 
hormones (e.g.  glucocorticoids, mineralocorticoids, estrogens, progestins, and androgens), 
chemical messengers produced by the body in response to a variety of stimuli; ii) small-
molecule hormones including thyroid hormone, calcitriol (a vitamin D3 metabolite), and the 
retinoids; and iii) the cytokine superfamily of proteins. The latter cytokines are a large and 
diverse family of circulating polypeptides produced by many different cell types. They 
include various types of interferons (e.g. IFN-α, -β, -γ) the interleukins (e.g. IL-6), the 
colony-stimulating factors (e.g. granulocyte colony-stimulating factor, G-CSF), and growth 
factors (e.g. epidermal growth factor, EGF). Individual cytokines act upon a variety of cell 
types. As polypeptides, cytokines cannot freely enter into the cells, but instead act by binding 
to specific cell surface receptors. Thus they can indirectly initiate a chain of events that 
culminate in changes in the pattern of cellular gene expression, causing cells to alter their 
metabolism in many different ways. The understanding of biochemical events by which some 
of the cytokines achieve their distinctive biological effects has increased significantly in the 
early 1990's, when the first signaling pathway was unearthed in detail: IFN signaling.1, 2, 3 
This involved JAK tyrosine kinases and the activation of latent cytoplasmic transcription 
factors termed STATs (Signal Transducers and Activators of Transcription). STAT proteins 
were activated through phosphorylation on a tyrosyl residue within minutes after the binding 
of an extracellular protein to its cell surface receptor. This phophorylation of STAT was 
mediated by specific tyrosine kinases (such as JAKs) and resulted in their conversion from 
latent to active transcription factors, which migrated into the nucleus and affected 
transcription of specific target genes. Afterwards, STATs were found to mediate signal 
transduction for the majority of the cytokines, and it was surprising the similarity in the way 
that cytokines, with their myriad of distinctive biological effects, acted to control gene 
expression. Since STATs discovery, a great deal of infomation has accumulated about the 
specificity in their activation, their functional domains and the variety of their biological 
functions, as well as their effect on transcriptional changes. Although this thesis will 
concentrate on the role of STAT3 in cancer and on the development of STAT3 inhibitors, it 
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will be useful first to summarize the structure of the STATs, and their interaction with other 
proteins, as they function in transcriptional control.  
 
1.1 The Signal Transducers and Activators of 
Transcription (STATs) family 
 
STAT members (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6), 
encoded in distinct genes, have been identified in various mammalian cells.4 With the 
exception of STAT4, which is expressed mainly in the thymus and testes,5 the other STAT 
proteins are ubiquitous. They range in size from 750 and 900 amino acids and have a 
molecular weight from 90 to 115 kDa. Despite functional differences of individual STAT 
proteins, crystallographic studies of the cores of STAT1 and STAT3 (from residues 130-712; 
lacking an N-terminal proteins are a family of latent transcription factors that are abundantly 
produced in many cell types. So far a total of seven different STAT family and C-terminal 
domain) and the NH2 terminus of STAT4, as well as sequence comparisons and deletion 
mutagenesis experiments, has revealed common STAT structural features. The overall amino 
acid sequence identity between STATs is 28-54%  (Table 1).6 
 
  
STAT1 STAT2 mSTAT3 mSTAT4 sSTAT5 STAT6 
STAT1 100% 44.1% 52.8% 53.5% 32.2% 31.5% 
STAT2 62.3% 100% 41.0% 40.9% 28.3% 30.2% 
mSTAT3 70.9% 61.3% 100% 47.3% 30.5% 28.2% 
mSTAT4 71.6% 60.0% 70.0% 100% 32.8% 30.3% 
sSTAT5 55.2% 50.0% 53.2% 53.9% 100% 39.5% 
STAT6 52.3% 52.2% 50.7% 51.6% 59.6% 100% 
              
 
Table 1. Amino acid sequence similarity and identity of STATs.6 
Per cent identity is above the 100% line, per cent similarity below. 
 
 
Seven structurally and/or functionally conserved domains can be identified (Figure 1). 
i) The amino terminal domain (NH2; ∼125 amino acids) is well conserved and is important 
for dimer-dimer interactions to form tetrameric STAT molecules. The tetramer formation has 
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been shown to be necessary for a strong STAT–DNA interaction at adjacent sites and is 
important for maximal transcriptional stimulation.7 Additionally it has been shown that the N-
terminus is involved in receptor recognition, phosphorylation, nuclear translocation, and 
dephosphorylation.8 The crystal structure of the amino terminus of STAT4 was solved 
independently of the core structure and comprises a series of eight short interactive helices 
(Figure 1, b). Other STAT amino termini probably have similar structures, because of the 
similarity of structurally important amino acid residues in their amino termini, although 
experiments in which the domains were swapped indicate that they might not be completely 
equivalent.9 
ii) The coiled-coil domain (amino acids ∼135 to ∼315) consists of a potentially dynamic 
four-helix bundle that protrudes laterally (∼80 Å) from the core. This domain associates with 
regulatory proteins and has also been implicated in controlling the process of nuclear import 
and export.10, 11  
iii) The DNA Binding Domain (DBD; amino acids ∼320 to ∼480) is also well conserved and 
mediates a robust binding to GAS palindromes. All activated STAT homodimers, except 
STAT2, directly bind GAS elements. The DBD has also been implicated in the regulation of 
nuclear import and export.11,12  
iv) The Linker Domain (amino acids ∼480 to ∼575) structurally translates active 
dimerization to the DNA binding motif. Studies also suggest that it regulates a process of 
continual basal (i.e. in resting cells) nuclear export.13  
 v) The SH2 Domain (amino acids ∼575 to ∼680) is the most highly conserved motif. It 
mediates specific recruitment to receptor chains, as well as the formation of active STAT 
dimers.14,15  
vi) The Tyrosine Activation Motif consists of a conserved tyrosine along with 5-7 specific 
carboxy terminal amino acids, usually near residue 700: like the corresponding SH2 domain, 
this motif resides on the exposed surface of the inactive homodimer, facilitating its JAK-
dependent phosphorylation during receptor recruitment.16 Upon phosphorylation, this motif is 
recognized and bound by the corresponding SH2 domain of the partner STAT, directing the 
critical structural changes required for an active conformation.17  
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vii) The Transcriptional Activation Domain (TAD) resides at the carboxy terminus and is 
highly variable in length and sequence between STAT family members. However, for each 
specific STAT, except STAT2, this sequence is conserved in humans and mice.10,18 Many 
TADs include conserved serine phosphorylation sites that facilitate the recruitment of 
coactivators (e.g. CBP, p300 and the MCM complex).19 Moreover, the phosphorylation of this 
specific serine residue (Ser727 in STAT3) contributes to maximal STAT3 transcriptional 
activity.20 The STAT TAD also appears to regulate protein stability. Specifically, STAT4, 
STAT5 and STAT6 can be targeted for ubiquitin-dependent destruction, whereas STAT1, 
STAT2 and STAT3 are more stable.21, 22  
              a) 
 
 
 
 
    
                 b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. STATs structure. a) Functional domains of STAT proteins. b) Core structure (amino acids ~130-712) 
of STAT1 dimer bound to DNA. The placement of the amino-terminal domain in the intact structure in 
undefined.23 
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Finally, a number of native carboxy terminally truncated STAT isoforms have been shown to 
direct unique programs of gene expression through their association with other transcription 
factors (e.g. STAT1b with STAT2 in ISGF-3 and STAT3b with c-jun24, 25). These truncated 
isoforms still get tyrosine phosphorylated, dimerize and bind DNA, but they exert a dominant 
negative effect by blocking the DNA-binding sites in STAT responsive gene promoter 
elements. So far, splice variants of STAT1, STAT3 and STAT5 have been identified, namely 
STAT1β, STAT3β, and STAT5β, and are generated by two distinct mechanisms: alternative 
mRNA splicing and proteolytic processing. 26 As an example, compared to wild-type STAT3, 
STAT3β has seven new amino acids and lacks an internal domain of 50 base pairs from the 
C-terminal of STAT3. This splice product is a naturally occurring isoform of STAT3 and 
encodes a 80 kDa protein which also lacks the Ser727 phosphorylation site. STAT3β has been 
and still is widely considered as a dominant negative factor, because its overexpression can 
suppress specific STAT3 functions. However, STAT3β activities have not only been linked to 
repression. Although STAT3β is not required for viability, it is also involved in inflammatory 
processes. Moreover, the observation that both up and downregulation of genes occurs in 
mice specifically lacking STAT3β also indicates its transcriptional activator properties.27 
 
1.2 Mechanism of STATs activation and regulation  
 
STATs are activated by over 40 different polypeptides binding cytokine receptors, G-protein-
coupled receptors, receptor tyrosine kinases like epidermal growth factor receptor and 
platelet-derived growth factor receptor (EGFR and PDGFR), as well as numerous non-
receptor tyrosine kinases (e.g. Src and Abl) (Figure 2). 
 
 
 
 
 
 
 
 
 
 Chapter 1 - INTRODUCTION 
6 
 
Figure 2. Schematic illustration of 
STAT family members and factors that 
induce phosphorylation. EGF: epidermal 
growth factor; LIF: leukemia inhibitory 
factor; CNTF: ciliary neutrophic factor; 
OM: oncostatin M; CT-1: cardiotrophin 1; 
G-CSF: granulocyte colony-stimulating 
factor; GM-CSF: granulocyte-macrophage 
colony stimulating factor; Epo: 
erythropoietin.28 
 
 
 
The best-studied pathway for STAT activation is through the JAKs (Chapter 1.2.1), otherwise 
known as the JAK/STAT pathway (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Signaling pathways that converge on STATs.29 Binding of growth factors or cytokines to their 
receptors results in the activation of intrinsic receptor tyrosine-kinase activity or of receptor-associated kinases, 
such as the Janus kinase (JAK) or Src tyrosine kinases. Non-receptor tyrosine kinases, such as the oncoproteins 
Src and Bcr-Abl can phosphorylate STATs independently of receptor engagement. Phosphorylated STATs 
dimerize and translocate to the nucleus, where the dimers directly regulate gene expression. 
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Cytokine receptors (e.g. IL-6R and IFNgR) have constitutive association of JAKs within the 
intracytoplasmic portion of the receptor.30 Ligand binding leads to dimerization of the 
receptor and activation of the JAKs, which trans-phosphorylate tyrosine residues within the 
intracytoplasmic portion of the receptor chains. The tyrosine phosphorylated receptor allows 
for docking of STATs through their SH2 domains. The JAKs subsequently phosphorylate the 
recruited STAT on a specific tyrosine residue near the carboxy terminus (e.g. position 701 for 
STAT131 and position 705 for STAT32). STAT activation is not mediated exclusively by 
cytokine receptors that lack intrinsic tyrosine kinase domains. STAT proteins are also 
activated by receptor tyrosine kinases such as epidermal growth factor-receptor (EGF R), 
PDGF-R,32 and colony stimulating factor-1R (CSF-1R),33 seven transmembrane G-protein-
coupled receptors such as angiotensin II receptor34 and serotonin 5-HT2A receptor35, and 
through the T cell receptor complex36 and the CD40 receptor37. Both the EGF and PDGF 
receptors are capable of directly phosphorylating STAT proteins in the absence of JAK 
activation. In addition, other TKs, such as Src and Abl, were found to directly phosphorylate 
STATs. Upon tyrosine phosphorylation, STATs form homodimers (most commonly) as well 
as heterodimers (e.g. STAT1/STAT2 in response to IFN-α/β activity, STAT1/STAT3 in 
response to IL-6 activity and STAT5a/STAT5b in response to growth hormone activity38) and 
are subsequently released from the receptor. Dimeric STATs enter the nucleus (Chapter 1.2.2) 
where they bind to specific DNA-binding elements (Chapter 1.2.3) and activate transcription 
of target genes. STATs activation is normally rapid and transient, lasting from several 
minutes to a few hours, and is usually quickly down-regulated to keep cytokine responses 
under control (Chapter 1.2.4).  
 
1.2.1 Janus Kinases (JAKs) 
The JAKs proteins are highly related intracellular protein tyrosine kinases of about 1200 
amino acids (120-140 kDa) and are able to activate a large number of receptors. JAKs are 
characterized by an amino-terminal portion of approximately 600 amino acids and two kinase 
domains, each of about 250 residues, separated by a short hinge region39 (Figure 4).  
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Figure 4. Schematic representation of the primary structure of Janus kinases (JAKs).40 JAKs are made up 
of FERM, SH2-like, pseudokinase and kinase domains. An alternative nomenclature for the putative domains is 
as a series of Janus homology (JH) domains. The FERM domain mediates binding to cytokine receptors. Both 
the FERM and the pseudokinase domains regulate catalytic activity and appear to interact with the kinase 
domain. JAKs autophosphorylate at multiple sites (P), including two in the activation loop of the kinase domain, 
but the precise function of these modifications is just beginning to be understood. 
 
A canonical tyrosine kinase domain (JAK homology region 1 or JH1), located at the carboxyl 
end of the protein, is constituted by a central kinase-like domain  (also referred to as 
pseudokinase or JH2 domain) unique to the family. The function of the kinase-like domain in 
the catalytic activation of JAKs remains unknown: it seems to regulate catalysis negatively 
and might have a role in substrate recognition.41 Despite considerable sequence similarity 
with other kinase domains, the kinase-like domain lacks key motifs essential for phosphate 
transfer. A non-conserved amino terminus of approximately 30-50 amino acids is followed by 
five JH regions of variable lengths and degrees of identity (JH3-JH7). Among these, the most 
conserved is JH4 which has a central core of 18 residues identical in all family members.  
 
There are four members that belong to these family of proteins: JAK1, JAK2, JAK3 and 
Tyk2. JAK1, JAK2 and Tyr2 were identified through different cDNA-cloning approaches. 
Their ubiquitous expression gave no hint to their function. JAK3, was cloned on the basis of 
similarity, and was found to be expressed predominantly in haematopoietic cells. The four 
mammalian JAKs are activated upon high-affinity binding of a variety of cytokines to their 
multimeric cell-surface receptors. Ligand-induced conformational changes and the increased 
local concentration of JAKs promoted by receptor dimerization could lead to their activation. 
A critical determinant of the involvement of a JAK family member in cytokine signaling 
pertains to its ability to associate with the intracellular portion of receptor components. 
Therefore, much effort has been recently devoted to determine the structural features of this 
interaction. Closer inspection of the intracellular portions of cytokine receptors has revealed 
the presence of short membrane-proximal motifs that were originally found to be required for 
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induction of proliferative signals. In a number of cases, these variably conserved motifs were 
found to mediate JAK2 activation. JAK activation is generally measured as an increase in the 
tyrosine phosphorylation of the protein, which correlates with its increased catalytic activity. 
A first level of control of the catalytic activity of the JAKs appears common to that of most 
protein kinases and involves auto(trans)phosphorylation of a conserved activation loop of the 
kinase domain. Phosphorylation of critical tyrosine residues might relieve steric blocking in 
the catalytic site and allow access of the substrate. The activated JAK protein kinases are 
likely to act on a multiple substrate, among which are juxtaposed JAKs, receptor components 
and signaling proteins that are recruited to the receptor-JAK complex upon ligand binding. 
STATs are among the best characterized substrates. Currently, they do not seem to have 
specificity for a particular STAT protein. For example, different receptors can activate the 
same STAT molecule through phosphorylation of the same tyrosine site, even though they 
activate distinct JAKs. The interchangeability of the JAKs in heterodimeric receptors suggests 
that, to some extent, what governs substrate specificity is not the JAK itself, but rather the 
receptor component to which the JAK is associated. When JAKs are overexpressed and 
hyperphosphorylated in mammalian cells, they were shown to phosphorylate STATs in a 
ligand-independent manner, possibly through a direct interaction. Involvement of aberrant 
JAK activation in human cancer is linked to a chromosomal abnormality in acute lymphocytic 
leukemia (ALL).11 Chromosomal translocation of the short arm of chromosome 9, containing 
the kinase domain of JAK2, to the short arm of chromosome 12, containing the 
oligomerization domain of the ETS transcription factor, results in a fusion protein (Tel-JAK2) 
possessing constitutive kinase activity.42  
 
1.2.2 STAT nucleocytoplasmic transport 
The translocation of STATs into the nucleus dependents on active transport through the 
nuclear pore complex (NPC), since STAT dimers are too large (~180 kDa) for passive 
diffusion. The mechanism of nuclear translocation has been unknown for several years. 
Subsequent studies have demonstrated that nuclear import of STAT proteins is directed by 
short amino acid sequences, rich in arginine and lysine, termed Nuclear Localization Signals 
(NLSs). These latter are recognized by specific cytoplasmic receptors, called importins. 
Importins are constituted by two subunits, importin α and importin β. To date, six human 
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importin α isoforms have been identified: importin α1, α3, α4, α5, α6 and α7. Upon binding 
with NLS of the STAT, importin α binds to importin β, which docks the importin-cargo 
complex on the cytoplasmic side of the nuclear pore complex and mediates the movement of 
the complex into the nucleus.43 The energy for this active nuclear transport is provided by the 
small G protein, Ran (Figure 5, a).44  
 
                         a) 
 
 
 
 
 
                        b) 
 
 
 
 
 
 
 
Figure 5. a) Nuclear import of Nuclear Localization Sequence (NLS) cargo mediated by the importin α/β. b) 
Nuclear export of NES cargo mediated by Crm1. 45 See text for details. 
 
Classical NLSs have not been identified in STATs. The first report of the existence of NLS 
signals in STAT molecules emerged when an unconventional, structural and dimer-specific 
NLS was identified in STAT1 and STAT2.46 This structural NLS is situated in the DNA-
binding domain of the molecule, and two of these elements, one in each monomer, were 
shown to be required for nuclear import of STAT1 and STAT2. The amino acids required for 
nuclear import were mapped to lysines 410 and 413 of STAT1, and to arginine 409 and lysine 
415 of STAT2. Another study has described leucine 407 to be essential for STAT1 nuclear 
import.47 STAT3 has been shown to contain two distinct arginine-rich sequence elements, 
which are required for its nuclear import.48 These elements are situated in the coiled-coil 
(arginines 214 and 215) and DNA-binding (arginines 414 and 417) domains of STAT3. The 
NLSs of STAT1, STAT2 and STAT3 differ from the classical NLS signals to some extent. 
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They do not resemble the consensus sequences of classical mono- or bi-partite NLSs, and 
they become active only in dimers. Recently, it has been presented that the nuclear import of 
STAT3 is mediated by importin α5 and importin α7 in a cytokine-stimulation dependent 
fashion.49 However, it has also been suggested that signal-dependent nuclear import of 
STAT3 is mediated by other importin α isoforms.50 In addition, it has been proven that 
nuclear import of STAT3 is independent of tyrosine phosphorylation and mediated by 
importin α3.51 At present, there is no detailed information describing the molecular 
mechanisms of nuclear import of STAT4, STAT5a, STAT5b or STAT6. It has been suggested 
that unphosphorylated STATs shuttle continuously between the nucleus and cytoplasm. It has 
also been proposed that the nuclear import of unphosphorylated STATs and tyrosine 
phosphorylated STAT dimers are mechanistically distinct from each other. It was revealed 
that only unphosphorylated STAT1 could enter the nucleus in the absence of cytosolic 
proteins, whereas the nuclear import of tyrosine phosphorylated STAT1 dimers required 
importins and metabolic energy.52 Similar results were obtained also for unphosphorylated 
mouse STAT3 and sheep STAT5.52 These distinct pathways are most likely the consequence 
of the conformational differences between the unphosphorylated dimers and the 
phosphorylation-activated STAT dimers. 
 
Nuclear export, similar to the nuclear import, requires the presence of special hydrophobic 
amino acid sequences, rich in leucine, called Nuclear Export Signal (NES), as well as soluble 
carriers named exportins. There are specific exportins such as CAS, which are important for 
export of importins α, and more general exportins like Crm1 (Chromosome region 
maintenance 1). Crm1 identifies NESs and binds the NES carrying cargo together with Ran-
GTP to form a stable ternary complex. The complex travels through the NPC and dissociates 
in the cytoplasm after the hydrolysis of Ran GTP (Figure 5, b). STAT1 nuclear export is 
achieved via a NES, residues 399-410, within the DNA binding domain, and Crm1 binding to 
this area.53 A second NES domain, a leucine-rich helical segment, has been described in the N 
terminus of STAT1.54 However, Crm1 binding to this region has as of yet been reported, 
which leads to the assumption that this region participates in a different manner in nuclear 
export. Interestingly, the NES of STAT1 seems to be hidden when STAT1 is bound to the 
DNA and it is therefore essential to dislodge STAT1 from the DNA for tyrosine 
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dephosphorylation, which leads to the accessibility of the NES by Crm1 and the nuclear 
export of STAT1.55 Regarding STAT3, three nuclear export signal (NES) elements has been 
identified. Two of these elements, 306-318 and 404-414, correspond to those recently 
identified in STAT1 399-410, and a third, STAT3 524-535, is novel.13 
 
1.2.3 The DNA response elements 
The DNA sequence elements in the promoters 
of genes that bind STAT3 proteins can be 
classified into two groups (Table 2).                                                   
The prototype of the first class is the interferon-
stimulated response elements (ISRE). The 
second class comprises the GAS-like response 
elements. The IFN-γ activation site (GAS) was 
originally identified as the IFN-γ  response 
element in the promoter of the GBP gene.6 An 
ever-growing number of GAS-like sequences 
have been identified  in promoters of genes 
activated by hormones, growth factors, 
cytokines and interleukines. STAT1 
homodimers, STAT1-STAT3 dimers, STAT3 
homodimers, STAT4 homodimers, STAT5 
homodimers and STAT6 homodimers have been 
shown to bind to at least one of the GAS-like 
elements.56, 57 All these elements have the palindromic core sequence TTNNNNNAA, but 
differ in the five inner nucleotides (Table 2). Variations of the inner nucleotides between 
different elements have been shown to influence the binding affinity towards specific STAT 
dimers. A STAT1 homodimer binds to the GAS element found in the promoter of the FcγR1 
gene, whereas STAT3 homodimer does not.58 The STAT3 homodimer, however, binds the 
SIE (sis-inducible element) element found in the promoter of the c-fos gene.59 Selective and 
specific activation of genes by different STAT dimers could therefore stem from differential 
binding affinities to slightly different response elements. 
Table 2. Response elements.6 
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1.2.4 STAT inactivation 
The transient nature of STAT activation suggests that nature has also invented sophisticated 
mechanisms to turn off the signaling pathway. In fact, recent studies have shown that STAT 
activation is negatively regulated by several mechanisms, including proteolytic degradation 
via ubiquitin-proteasome pathway and dephosphorylation of JAKs and STATs, as well as 
inhibition of STAT activity via two different protein families: the suppressors of cytokine 
signaling family (SOCS) and proteins that inhibit activated STAT proteins family (PIAS).  
 
Proteolytic degradation 
Ubiquitin-proteosomal degradation is essential for the degradation of proteins whose levels 
have to be regulated either constitutively, or in response to extracellular stimuli and changes 
in the cellular environment and is thus an important mechanism for the downregulation of 
JAK/STAT signaling pathways. It was demonstrated that JAK1, JAK2 and JAK3 are targets 
for degradation,60 as well as tyrosine phosphorylated STAT1, STAT4, STAT5 and STAT6, 
with only marginal effects on STAT2 and STAT3.61, 62 
 
Protein tyrosine phosphatases (PTPases) 
Dephosphorylation is an important way to inhibit the STAT signaling pathway and can occur 
both in cytoplasm, where the JAKs and the STATs are targets, and in the nucleus where 
dephosphorylation of the STATs takes place. Several PTPs have been identified that 
negatively regulate the JAK/STAT pathway (Table 3). The cytoplasmic tyrosine 
phosphatases found to be involved in inhibiting JAK/STAT activity were the closely related 
SH2-containing phosphatases (SHP), SHP1 and SHP2.63 SHP1 is mainly expressed in 
hematopoietic tissues, whereas SHP2 is ubiquitously expressed. All tyrosine-phosphorylated 
signaling molecules, such as receptors, JAKs or STATs, have to be considered as possible 
targets for SHP2. However, direct interaction has only been shown for SHP1 with JAK1 and 
JAK2,64 and for SHP2 with JAK1 and STAT5.65 PTP1B has also been implicated in the 
dephosphorylation of STAT5 under overexpression conditions.66 However, whether STAT5 is 
a physiological substrate of PTP1B remains to be established. Earlier studies indicated the 
existence of a PTP activity in the nucleus to inactivate STAT1. Through biochemical 
purification, TC45, the nuclear isoform of TCPTP, has been identified as a STAT1 PTP.67  
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Inhibitor Target 
JAK PTPs JAKs 
SHP1 JAK2, JAK1 
SHP2 JAK1 
CD45 JAK1, JAK2, JAK3, TYK2 
PTP1B JAK2, TYK2 
TCPTP JAK1, JAK3 
Cytoplasmic STAT PTPs STATs 
SHP2 STAT5 
PTP1B STAT5 
TCPTP STAT1, STAT3 
Nuclear STAT PTPs STATs 
SHP2 STAT1 
TCPTP STAT1, STAT3 
 
Table 3. Negative regulation of JAK-STAT signaling.63 JAK, Janus-family kinase; PTP, protein tyrosine 
phosphatase; SHP, SH2-domain-containing PTP; TCPTP, T-cell PTP; TYK2, tyrosine kinase 2. 
 
 
TC45 can directly dephosphorylate STAT1. In addition to TC45, SHP2 is also involved in the 
nuclear dephosphorylation of STAT1.68 How other STATs become dephosphorylate remains 
unknown, but recent studies have shown that there is specificity in the dephosphorylation of 
STATs by PTPs. For example, it has been shown that TCPTP is involved in the 
dephosphorylation of both STAT1 and STAT3, but not STAT5 or STAT6.67  
 
The SOCS family of inhibitors 
The suppressors of cytokine signaling (SOCS) are a family of intracellular proteins that play a 
crucial role in negatively regulating the response of the immune system to cytokines. These 
inhibitors have been variously named by independent discoverers as suppressor of cytokine 
signaling (SOCS), JAK-binding proteins (JABs), STAT-induced STAT inhibitors (SSIs) or 
cytokine-induced SH2 (CIS) proteins. The eight proteins that belong to the SOCS family 
include cytokine-inducible SH2 domain protein (CIS) and SOCS1-SOCS7. SOCS proteins 
contain a central SH2 domain, an amino-terminal domain of variable length and a divergent 
sequence that carries, in the case of SOCS1 and SOCS3, a kinase inhibitory region and a 
carboxy-terminal 40 amino-acid module known as the SOCS box69 (Figure 6, a). The SOCS 
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box can bind to elongins B and C, which are known components of the ubiquitin E3 ligase 
complex, suggesting that SOCS proteins may target signaling molecules like JAK2, to the 
proteasome for degradation.70 SOCS proteins are generally expressed at low levels in 
unstimulated cells and expression is largely increased upon cytokine, insulin and EGF 
stimulation. The fact that they subsequently inhibit JAK/STAT signaling leads to the 
conclusion that they act as classical feedback loop inhibitors.71 The mechanism of inhibition 
varies between the different SOCS proteins (Figure 6, b). SOCS1 binds directly via its SH2 
domain to tyrosine phosphorylated JAKs, and as a consequence, JAK activity is directly 
inhibited. SOCS3 uses a different mechanism for inhibition of JAKs: it binds to the activated 
receptor directly.72 By contrast, CIS does not affect the activity of JAKs. Instead, CIS inhibits 
STATs by competing with STATs for docking sites on the receptor.73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The SOCS family of proteins. a) Domain 
structure of suppressor of cytokine signaling (SOCS) 
proteins. b) Inhibition of the Janus kinase (JAK)- and the 
signal transducer and activator of transcription (STAT)-
signaling pathway by SOCS proteins through distinct 
mechanisms.63 
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The PIAS family of inhibitors 
In the nucleus, protein inhibitors of activated STATs (PIAS) inhibit the DNA binding of 
active STATs. The mammalian PIAS family consists of four members: PIAS1, PIAS3, 
PIASX and PIASY.74 After cytokine stimulation, PIAS1, PIAS3 and PIASX interact with 
STAT1, STAT3 and STAT4 respectively.75, 76, 77 In addition, PIASY has also been shown to 
be associated with STAT1. The PIAS–STAT interaction is cytokine dependent and PIAS 
proteins do not interact with STATs in unstimulated cells. The cytokine dependency of the 
interaction might be explained by the finding that PIAS1 can bind to the dimeric, but not the 
monomeric, form of STAT1.78 Each member of the PIAS family has been shown to inhibit 
STAT-mediated gene activation. Distinct mechanisms for PIAS-mediated inhibition of 
STATs have been indicated (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Proposed mechanisms for inhibiting the JAK–STAT pathway by PIAS proteins. a) PIAS1 and 
PIAS3 block the DNA-binding activity of STAT dimers. b) PIASX and PIASY might act as transcriptional co-
repressors of STAT by recruiting other co-repressor proteins, such as histone deacetylase (HDAC). c) PIAS 
proteins can promote the conjugation of small ubiquitin-related modifier (SUMO) to STAT1. The significance of 
STAT1 sumoylation in regulating STAT1 activity is controversial and needs to be clarified.63 
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 PIAS1 and PIAS3 can inhibit the DNA binding activity of STAT1 and STAT3, 
respectively.75, 76 By contrast, PIASX and PIASY can inhibit STAT4- and STAT1-dependent 
transcription without affecting the DNA-binding activity of STAT4 and STAT1.77,79 The 
interaction of PIAS proteins with histone deactylases (HDACs) has been described. PIASX 
has been shown to interact with HDAX3.80 PIASY has also been found to interact with 
HDAC1.81 So, it is probable that PIASX and PIASY function as transcriptional co-repressors 
of STATs, possibly by recruiting HDACs and other co-repressor molecules. Interestingly, 
PIAS proteins have been shown to have SUMO E3 ligase activity.82 It has been suggested that 
PIAS proteins might regulate transcription by promoting SUMO conjugation of transcription 
factors.  
 
1.3 Roles of STATs in physiological processes   
 
Activation of STATs results in the expression of genes that control critical cellular functions, 
including cell proliferation, survival, differentiation and development, as well as specialized 
cellular functions, such as those associated with immune responses. The contribution of 
specific STAT family members to control the normal cellular processes has been elucidated 
on the base of studies of homozygous deletion, or more recently, by tissue-specific, 
conditional knockout of each STAT family member in mice. These studies indicate that 
STAT proteins are highly specific in their function and that they are responsible for mediating 
the immune response in mammals (Table 4). 
 
STAT1 
STAT1 knockout mice are viable and fertile and display no developmental defects. However, 
STAT1-/- mice failed to induce transcription of target genes after stimulation with IFNα/β and 
IFNγ; these mice are highly susceptible to microbial and viral infections.83, 84 Atypical 
susceptibility to mycobacterial, but not to viral infection, has also been identified in patients 
suffering with a natural heterozygous germline STAT1 mutation, further strengthening the 
importance of STAT1 in contributing to immune responses.85 Interestingly, STAT1 deficient 
mice also showed sensitivity for both spontaneous tumor development and tumor 
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development after methylcholanthrene treatment.86 This suggests that STAT1 has a 
proapoptotic function. 
 
Table 4. Role of STAT proteins as revealed by gene-targeting in mice23 
 
STAT2 
STAT2 is a particular member of the STAT family, since it does not bind to GAS elements 
and it does not homodimerize. Instead, upon activation by IFNα STAT2 forms the 
transcription factor complex ISGF3, together with STAT1 and p48/ISGF3γ. Therefore, it is 
not surprising that the STAT2 knockout exhibits similarities with the STAT1 knockout. The 
mice are viable, fertile and display no developmental defects. Nevertheless, they are also 
susceptible to viral infections due to their impaired ability to respond to IFNα/β signaling. 
Additionally, STAT1 tyrosine phosphorylation and activation after IFNα stimulation is 
weakened in the STAT2 deficient mice, arguing for an enhancer effect of STAT2 in binding 
to the receptor complex in the STAT1/STAT2 heterodimers.87  
 
STAT3 
Will be discussed in detail in Chapter 2. 
 
 
 
STAT protein Phenotype of null mice 
STAT1 Impaired responses to interferons; increased susceptibility to tumours; impaired growth control 
STAT2 Impaired responses to interferons 
STAT3 
Embryonic lethality; multiple defect in adult tissues including 
impaired cell survival (both positive and negative) and impaired 
response to pathogens 
STAT4 Impaired TH1 differentiation owning to loss of IL-12 responsiveness 
STAT5a Impaired mammary gland development owing to loss of prolactin 
responsiveness 
STAT5b Impaired growth owing to loss of growth hormone responsiveness 
STAT6 Impaired TH1 differentiation owning to loss of IL-4 responsiveness 
TH1: T helper 1 cell; IL: interleukin 
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STAT4 
STAT4 is only expressed in natural killer cells (NK cells), dentritic cells and T lymphocytes, 
and is mainly activated by IL-12. CD4+ T cells differentiate with the help of IL-12 to Th1 
cells, which in turn leads to the expression of IFNγ. Th1 cells are involved in hostdefense 
against intracellular pathogens and tumors, and in the development of autoimmune diseases, 
for example, rheumatoid arthritis, diabetes and multiple sclerosis. Consequently, it was no 
surprise that the STAT4 and IL-12 deficient mice show a similar phenotype, i.e., loss of Th1 
differentiation, loss of IFNγ expression and enhanced tendency towards Th2 differentiation, 
which is usually inhibited by Th1 cells.88 Recent data indicate that STAT4 deficient mice 
show a resistance to autoimmune diseases like rheumatoid arthritis, diabetes and experimental 
allergic encephalomyelitis (EAE).89 In humans, it was shown that IFNα/β can stimulate T 
cells to drive Th1 development, bypassing the need for IL-12-induced signaling. In contrast, 
IFNα does not cause Th1 differentiation in mice.90 The reason for this is that IFNα/β is able to 
activate STAT4, by recruitment of STAT4 to the IFNα receptor complex exclusively via the 
C-terminus of STAT2 in human cells. The difference between mouse and human signaling is 
that the mouse STAT2 gene harbors a minisatellite insertion, which changes the C terminus 
sequence and selectively disrupts its ability to activate STAT4, but not other STATs.91 
 
STAT5 
STAT5 was originally characterized as a prolactin-responsive transcription factor in sheep, 
and exists as two closely related isoforms, STAT5a and STAT5b, which share 95% identity at 
the N-terminus and some variability at the C-terminus.92, 93 Both genes are expressed in all 
tissues and are activated by a wide variety of cytokines. Given the broad range of activation it 
might be thought that the knockout of these proteins would have many effects. However, the 
STAT5 specific knockouts exhibited a very precise phenotype for the individual gene. Both of 
the STAT5a and STAT5b deficient mice are viable, fertile and display no developmental 
defects. STAT5a -/- mice are impaired in prolactin activated mammary gland development, 
necessary for lactation94 while STAT5b -/- mice have impaired GH signaling effects, similar 
to GH deficient mice.94 Since high GH levels are mainly observed in males, female STAT5b -
/- showed almost no phenotype, whilst males were smaller and revealed the loss of male-
specific liver genes (as MUP and CYP2D9). Interestingly the STAT5a/b double knockout 
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mice are infertile, small, die after a few weeks of birth, and are defective in the development 
of the mammary gland and the corpus luteum.94 
 
STAT6 
STAT6 is ubiquitously expressed and is mainly activated by IL-4 and IL-13.95 IL-4 is 
expressed by activated T and B cells, and regulates differentiation of CD4+ T cells to Th2 
cells and class switching of B cells, which results in the secretion of IgE. Th2 helper cells are 
essential for host defense against helminthes and further allergic responses. STAT6 and IL-4 
deficient mice show similar phenotypes; neither are able to differentiate into Th2 cells and are 
inoperative to class switch to IgE. Otherwise they are viable, fertile and display no 
developmental defects.96,  97,  98 In addition, STAT6 deficient mice, have a predominantly Th1 
phenotype, experience a severe clinical course of EAE, are inhibited in host defense against 
helminthes, are resistant to septic peritonitis because of enhanced local bacterial clearance, 
show resistance to tumor recurrence and deregulated activation of NF-κB, leading to reduced 
expression of proinflammatory cytokines and chemokines induced by endotoxins.99, 100  
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2. STAT3 PROTEIN 
 
2.1 Influence of STAT3 on biological functions 
 
STAT3 was initially identified as the acute-phase response factor (APRF), activated by IL-
6.101 The authors further showed that STAT3 activation through phosphorylation occurred in 
the cytoplasm and that STAT3 migrates into the nucleus and binds IL-6 response elements of 
various acute-phase protein genes (e.g., the alpha 2-macroglobulin, fibrinogen, and alpha 1-
acid glycoprotein genes).101 The STAT3 cDNA was cloned one year later and encodes an 
open reading frame of 770 amino acids resulting in a protein of 88 kDa.102 STAT3 is 
ubiquitously expressed and its expression starts very early during post-implantation 
development in the mouse. STAT3 can be activated by many different cytokines, growth 
factors and oncogenes (Figure 2). The IL-6 family of cytokines has many biological functions 
and STAT3 plays a major role in these processes.103 IL-6 activation in mouse myeloid 
leukemia M1 cells has been shown to lead to growth arrest and terminal differentiation into 
macrophages. Overexpression of STAT3DN (a STAT3 dominant negative protein which 
lacks the C-terminal portion and is able to block STAT3 transcriptional activity) abrogated 
the IL-6 induced effects, leading to the inhibition of IL-6-induced repression of c-myb and c-
myc.104 These experiments demonstrated for the first time that STAT3 activation is essential 
for IL-6 mediated growth arrest. Conversely, other studies demonstrated that STAT3 is 
involved in anti-apoptosis, proliferation and upregulation of Bcl-2 by overexpression of 
STAT3DN in mouse pro-B (BAF/B03) cells.105 It has been demonstrated in the following 
years that STAT3 activation was not only essential for cell survival but also required for cell 
cycle transition, via STAT3 mediated upregulation of cyclins D2, D3 and A, and cdc25A, and 
the associated downregulation of p21 and p27.105 Interestingly, in a few cases STAT3 was 
also able to inhibit cell differentiation, following its activation with IL-6 or LIF. IL-6 was 
shown to induce differentiation of PC12 cells that have been pretreated with nerve growth 
factor (NGF). Stimulation of the MAPK pathway is important for neurite outgrowth, since 
cells overexpression gp130 mutants incapable of activating the MAPK cascade, or cells 
treated with the MEK inhibitor PD98059 treatment with IL-6, both failed to induce 
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differentiation of PC12. Conversely, overexpression of a mutant gp130, which is defective in 
STAT3 signaling but not in SHP2 signaling, did not inhibit, but rather stimulated neurite 
outgrowth. NGF pretreatment inhibited the IL-6-induced activation of STAT3 and 
overexpression of STAT3DN did not require NGF pretreatment for neurite outgrowth. These 
facts indicate that STAT3 is negatively involved in PC12 differentiation.106 Likewise, STAT3 
is essential for self renewal of embryonic stem (ES) cells, that are continuously propagated in 
an undifferentiated pluripotent state with LIF, since overexpression of a dominant negative 
STAT3 is able to abrogate LIF mediated self-renewal and promote differentiation.107,  108,  109 
Concordant with this finding is a study of ES cells expressing a fusion protein composed of 
the entire coding region of STAT3 and the ligand binding domain of the estrogen receptor 
(STAT3ER), that can be activated by the synthetic ligand 4-hydroxytamoxifen (4HT), 
maintained an undifferentiated state upon stimulation with 4HT.110 
 
STAT3 knockout mice 
STAT3 is the only STAT family member whose knockout leads to embryonic lethality. 
STAT3 deficient mice develop into the egg cylinder stage but show a rapid degeneration 
between embryonic days 6.5 and 7.5. This is probably due to nutritional insufficiency, since 
STAT3 is expressed at day 7.5 in the embryonic visceral endoderm, which is important for 
nutrient exchange between the maternal and embryonic environment.111 Some knockouts of 
components of STAT3 activating pathways also lead to embryonic lethality, such as gp130 
and LIFRβ.  STAT3-deficient T cells showed a loss of proliferative response due to a defect 
in IL-6 mediated prevention of apoptosis. The anti-apoptotic protein, Bcl-2, is normally 
upregulated in response to IL-6 even in STAT3-deficient T cells.112 This suggests that STAT3 
has a Bcl-2 independent anti-apoptotic function. Targeted STAT3 knockout in macrophages 
and neutrophils results in mutant mice that are highly susceptible to endotoxin shock and 
develop chronic enterocolitis with age, due to abolished inhibitory effects of IL-10 on 
inflammatory cytokine production.113  In addition, STAT3 -/- plus IL-10 -/- mice show similar 
phenotypes and it has been shown that IL-10 suppresses expression of TNF-α via STAT3.114 
STAT3 phosphorylation occurs at the onset of mammary gland involution and STAT3 null 
mammary glands show a decrease in apoptosis and a dramatic delay of involution, a stage of 
mammary gland development that is characterized by an extensive apoptosis of the epithelial 
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cells. In normal glands involution is accompanied by increase in insulin-like growth factor 
binding protein (IGFBP5) levels, which binds the survival factor insulin-like growth factor 
(IGF1) and inhibits IGF1. There was evidence to suggest that IGFBP-5 is a direct or indirect 
target for STAT3, since IGFBP5 upregulation is not observed in STAT3 null mammary 
glands.115 These data have showen for the first time that STAT3 is important for apoptosis in 
vivo. 
Mice with STAT3 deficient epidermal and follicular keratinocytes were viable and did not 
have any defects in the development of epidermis and hair follicles. However, the mice had 
sparse hair, their wound-healing processes were severely impaired and they spontaneously 
developed ulcers with age. Considering that migration and proliferation are essential for 
wound healing, motility and growth of keratinocytes were examined. Results illustrated that 
migration of STAT3-disrupted keratinocytes in response to growth factor stimulation, in vitro, 
was impaired while proliferation was not disturbed. Furthermore, the mice exhibited a normal 
first hair cycle (morphogenesis), but an impaired second hair cycle (skin remodeling).116 This 
analysis provided the first in vivo data showing that STAT3 has a function in cell migration 
and that STAT3 is necessary for skin remodeling, including hair cycle and wound healing.  
STAT3 is required for the neurotrophic actions of CNTF and LIF on developing cytokine 
dependent sensory neurons: STAT3-deleted nodose neurons showed a reduced response to 
CNTF and LIF in vitro and they had an enhanced death rate in vivo. These results provide the 
first evidence for a role for STAT3 signaling in regulating neuronal survival.117, 118 Knockout 
of STAT3 in cardiomyocytes showed that STAT3 is involved in regulation of inflammatory 
responses and survival.119 STAT3 deficient hepatocytes severely impaired IL-6 induced 
acute-phase response in the liver during inflammation.120 Interestingly, STAT3β deficient 
mice exhibited reduced recovery from endotoxic shock and showed hyperresponsiveness to a 
subset of endotoxin-inducible genes in the liver. These findings revealed a critical negative 
regulatory role for STAT3β in the control of systemic inflammation.121 
Considering all knockout data together it is surprising that STAT3 has such mild phenotypes 
in the conditional knockout mice compared to the early embryonic lethality in the full 
knockout. The data suggests that the STAT3 activators in early development are different 
from the known activators in the adult and it will be of interest to identify them. Moreover, 
STAT3 elicits diverse functions in various cell types since the readout of the STAT3 tissue 
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deficient mice is diverse and ranges from apoptosis, survival, and effects on migration up to 
proliferation. It will be a challenge to solve the riddle why STAT3 activation has diverse 
biological functions and the more information will be gained about the different sets of genes 
that are regulated by STAT3, in different cell types, the more it will be possible to understand 
the function of STAT3 molecule. 
 
2.2 Validation of STAT3 as a target for cancer therapy 
 
STAT3 is persistently activated in over a dozen types of human cancers, including all the 
major carcinomas as well as some hematologic tumors. In some cancers, enough clinical 
samples have been examined to state the approximate frequency of persistently active 
STAT3, which occurs in more than half of breast and lung cancers, hepatocellular 
carcinomas, multiple myelomas and more than 95% of head and neck cancers (Table 5). 
Moreover, in cultured tumor cells from several different cancers, interruption of this persistent 
STAT3 activity, by dominant negative proteins or antisense oligonucleotides, leads to 
apoptosis.122 Targeted deletion of STAT3 in skin cells was recently shown to prevent 
epithelial cancer123 and in this issue a dependence on STAT3 was demonstrated in 
lymphomas and myelomas.124 These studies took advantage of sophisticated genetic 
manipulations to delete STAT3 specifically in B and T cells, which along with previous 
experiments deleting STAT3 in epidermal precursor cells, clinches the importance of STAT3 
in tumor cells both in vivo and in vitro. They also showed that administration of antisense 
oligonucleotides targeted against STAT3 to animals can substantially reduce the growth of the 
hematologic tumors, highlighting the potential of anti-STAT3 therapy in clinical medicine. 
Overactive kinases or dysfunctional receptors are the culprits in head and neck cancer, some 
multiple myelomas, leukemias and lymphomas. Studies of leukemias, lymphomas, 
hepatocellular carcinomas and non-small cell lung cancer report the loss of proteins that 
negatively regulate STAT3, such as PIAS or SOCS (Chapter 1.2.4). 125, 126, 127 
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Table 5. Activation of STATs in human primary tumors and tumor cell lines.128 
SCCHN: squamous cell carcinoma of the head and neck; HTLV: human T-cell leukemia-virus type-I 
 
One oncogene that persistently activates STAT3 is ALK kinase, a tyrosine kinase persistently 
activated in a human disease called anaplastic large cell lymphoma.129 Chromosomal 
translocations join the nucleoplasmin gene to the gene that encodes ALK kinase, producing 
the persistently active NMP-ALK oncogene. To investigate the role of STAT3 in malignant 
transformation by NMP-ALK and in cancer cell survival, for the first time it has been studied 
bone marrow-derived cancer cells in which the STAT3 gene has been deleted.124 It was 
showed that fibroblasts containing one functional STAT3 allele could be transformed by the 
NMP-ALK oncogene, as measured by growth in soft agar. In contrast, STAT3-deficient 
fibroblasts could not be transformed. NMP-ALK activity can be expressed in lymphocytes 
both in cultured cells and in the whole animal. Animals bearing NPM-ALK and molecularly 
marked STAT3 genes capable of being deleted specifically in lymphocytes were studied. T 
lymphocytes retaining a single STAT3 allele and T lymphocytes lacking both STAT3 alleles 
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formed NMP-ALK–induced lymphomas that killed the animals in about 40 weeks. In culture, 
however, the lymphomas without STAT3 grew less well than those still retaining one STAT3 
allele. Most important, in the NMPALK-bearing animals with a single STAT3 allele, every 
one of the induced lymphomas had persistently active, tyrosine phosphorylated STAT3 and 
when the lymphoma cells in these animals were engineered to lose the STAT3 gene, the cells 
promptly underwent apoptosis. It was demonstrated that NMP-ALK can induce myeloma, a B 
cell-specific tumor. In mice that had STAT3 ablated in about 80% of B cells, all NMP-ALK-
induced myeloma cells still had STAT3 and it was persistently activated. These genetic 
experiments indicate clearly that the presence of persistently active STAT3 favors the 
development of T- and B-cell tumors and is required for their maintenance. In additional 
studies, the injection of antisense oligonucleotides to STAT3 at a site distant from transplanted 
lymphoma or myeloma tissue was performed. This treatment successfully restricted growth of 
either T-cell lymphomas or B-cell myelomas. It is noteworthy that the antisense 
oligonucleotides against STAT3 killed tumor cells but had little effect on the animal. These 
experiments with hematologic tumors build on other studies suggesting that anti-STAT3 
therapy would limit tumor growth. For instance, tumors in mice, resulting from 
transplantation of human head and neck squamous carcinoma cells, shrink when injected 
directly with an antisense STAT3 synthetic DNA derivative.130 
 
STAT3 activation can suppress apoptosis 
In most cells, STAT3 activation can suppress apoptosis.131 This effect is mediated through the 
expression of various cell survival gene products, regulated by STAT3, including bcl-xl,132, 133 
bcl-2,134 survivin,135 Mcl-1,136 and cIAP213 (Figure 8). Additionally, most tumor cells that 
exhibit constitutive activation of STAT3, also express the above mentioned cell survival gene 
products:137, 138 thus, suppression of STAT3 activation can inhibit their expression and 
potentiate apoptosis.139 The downregulation of STAT3 also leads to expression of Fas protein, 
which can promote apoptosis.25 
Importantly, numerous published reports showed that blocking constitutively activated 
STAT3 signaling leads to apoptosis of tumor cells128, 140, 141. By contrast, the blockage of  
STAT3 signaling in normal cell does not generally lead to apoptosis142, 143. This selective 
inhibition might reflect an irreversible dependence of tumor cells on high levels of activated 
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STAT3 for growth and survival, whereas normal cells might be able to withstand lower levels 
of STAT3 activity or use alternative pathways for growth and survival.  
 
Figure 8. Control of cell growth and survival by STATs.29 
 
STAT3 activation can lead to cellular proliferation and cellular invasion. 
STAT3 activation has also been linked with proliferation of tumor cells (Figure 8). This 
effect of STAT3 is mediated through its ability to induce the expression of cyclin D1.144 
STAT3 has also been shown to upregulate the expression of several growth-promoting genes, 
such as myc145 and pim-1.146 The pro-apoptotic factors, such as Fas, are downmodulated by 
STAT3 activation.25 There are other reports, however, which describe the activation of the 
expression of the cell cycle inhibitor p21(waf1) by this Fas protein,147 suggesting that STAT3 
can also block cell cycle progression and prevent abnormal cell proliferation.  
 
Numerous studies indicate that STAT3 activation plays a major role in tumor cell invasion, 
and inhibition of STAT3 reduces it.131 STAT3 activation regulates the expression of matrix 
metalloproteinase MMP-1 and MMP-2, which then mediate tumor invasion and metastasis.148, 
149
 STAT3 upregulates the transcription of MMP-2 through direct interaction with the MMP-2 
promoter. Furthermore, blockage of activated STAT3 in highly metastatic cells significantly 
suppresses the invasiveness of the tumor cells, inhibits tumor growth, and prevents metastasis 
in nude mice. Also, overexpression of phosphorylated STAT3 correlates with the invasion 
 Chapter 2 – STAT3 PROTEIN 
28 
 
and metastasis of cutaneous squamous cell carcinoma.150 STAT3, however, is also known to 
upregulate tissue inhibitors of metalloproteinase (TIMP)-1, a cytokine known to block 
metalloproteinases and decrease invasiveness in certain cancer cell types.151  STAT3, 
moreover, controls the expression of the MUC1 gene, which can mediate tumor invasion.152 
Thus, STAT3 mediates tumor invasion through numerous mechanisms. 
 
STAT3 can mediate angiogenesis  
Most tumors hold their growth unless they are supplied with oxygen and nutrients from newly 
formed blood vessels. A role of activated oncogene products in stimulating angiogenesis was 
established (Figure 8).78, 79 The most potent angiogenesis-inducing signal is the vascular 
endothelial growth factor (VEGF).80 VEGF is over-expressed in cancer cells and it binds 
tyrosine kinases receptor of endothelial cells. This activated endothelial-cell migration and 
proliferation is needed for the formation of new blood vessels81. STAT3 activates the 
transcription of the VEGF gene82, 83 and it has been shown that over-expression of mutant 
STAT3C increases VEGF expression and induces angiogenesis in vivo.82  
All of these results, together with the requirement of STAT3 for survival in many tumor cells 
in culture, promise that whereas all tumors may not have persistently active STAT3, the very 
large number that do may well respond to anti-STAT3 therapy. To this end, efforts are 
underway to discover small molecules capable of directly inhibiting STAT3. Given the 
preliminary success in developing small molecules, plus experimental evidences, including 
the effective antisense treatment in whole animals, it is not at all unreasonable to hope that 
effective anticancer therapy can derive form inhibiting persistently active STAT3. 
 
2.3 Classification of STAT3 inhibitors153 
 
There are two different approaches to inhibit STAT signaling: 
- direct, by interaction of molecules with the protein; 
- indirect, by inhibition of the upstream tyrosine kinases that are responsible for STAT3 
activation or by blockage of factors that are involved in the activation of STAT3 
signaling.  
The direct inhibitors can be divided into:  
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- peptides 
- peptidomimetics 
- natural compounds 
- synthetic compounds 
- oligonucleotides.  
 
The indirect inhibitors can be classified as either natural or synthetic compounds. However, 
the poorly specific mechanism of action highlights the limits of the indirect approach. 
 
2.3.1 Direct inhibitors 
Peptides  
The dimerization of STAT3 is a key event for its activation and to interfere with 
dimerization can compromise STAT3 biological activity. In particular, the SH2 domain, 
with pTyr, is crucial for the dimerization process. From this consideration, a 
phosphopeptide-based compound was initially designed on the basis of molecular 
modeling of STAT3 docking sites. Its lead sequence PY*LKTK (1, Figure 9) derives 
from the consensus sequence in the STAT3-SH2 domain surrounding pTyr-705. Y* 
(pTyr of the peptide) interacts with STAT3-SH2 domain, and reduces the number of 
STAT3-STAT3 dimers available to bind DNA, splitting and replacing them with 
STAT3-phosphopeptide dimers. 
Further studies defined the structure activity relationships for this kind of inhibitors:  
- XY*L (X is any amino acid) is the basic sequence able to interrupt dimerization and 
DNA binding: the derived tripeptides PY*L (2, Figure 9) and AY*L (3, Figure 9) 
had different amino acid in (Y*-1) position but comparable activities on STAT3. In 
particular, the in vitro activity of 2 and 3 showed a significant decrease of STAT3-
DNA binding in a dose-dependent manner; 
- the amidic bond between X and Y* is critical and cannot be substituted;  
- lysine (Y*+2 and Y*+4) and threonine (Y*+3) are not essential.  
- the corresponding unphosphorylated sequence had no inhibitory effects: this highlights 
the importance of the phosphate group for SH2-domain recognition. 
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However, peptides can’t be administered orally because of their low stability in the 
stomach, where they can be hydrolyzed by acidity or peptidase. Moreover, they have 
poor membrane permeability. Considering PY*LKTK, this latter problem was overcome 
by linking a hydrophobic sequence to the C-terminus; this allowed the entry of the 
peptide into the cell. 
Another phosphopeptide lead was the hexapeptide Ac-Y*LPQTV-NH2 (4, Figure 9) 
derived from the amino acid sequence of receptor docking sites of STAT3 on gp130. It 
was able to inhibit with high affinity dimer formation and DNA binding. The peptide 
bound to STAT3-SH2 domain was crystallized and for this reason it was used as a 
standard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Structures of peptide 
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Peptidomimetics  
Peptides present lots of limitations due to low membrane permeability and low stability, 
that do not allow their use in vivo at therapeutic doses. However, the lead compounds of 
their class provide a starting point for the developement of peptidomimetics with higher 
membrane permeability. 
The indication of the essential tripeptide 2 for the DNA-binding inhibitory activity, led 
to structural modifications which involved the N-terminal proline. This amino acid was 
replaced with groups of different dimensions, polarity and orientations (Figure 10) as: 
- 4-cyanobenzoyl or 2,6-dimethoxybenzoyl: a fivefold increase of the inhibition was 
observed, probably due to the fact that these peptides have access to a hydrophobic 
domain and are involved in additional H-bonds on the protein surface. Furthermore, 
these compounds selectively disrupted STAT3-STAT3 dimers with respect to the 
STAT1 and STAT5 dimers; 
- phenyl-(7,8), pyridyl and pyrazinyl-based carboxylic acids were well tolerated; bulky 
carboxylic acids such as quinoline, naphtalene or biphenyl derivates, led to loss of 
activity. 
Subsequently, derivatives of 5, which had previously shown the best inhibitory activity, 
were developed functionalizing the C-terminus domain: among these compounds, 
ISS840 (6, Figure 10) exhibited 20-fold higher STAT1 (IC50 = 31 µM) inhibition 
activity compared with STAT3 (IC50 = 560 µM). 
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Figure 10. a) Structural modifications at the N-terminal proline of the tripeptide PY*L; b) Structure of 
ISS840 (6). 
 
 
A new library of approximately 50 compounds was synthesized, in order to rationalize 
the importance of the backbone and side chain interactions between compound 4 and the 
STAT3-SH2 domain. The phosphopeptide Ac-Y*LPQT-NH2 (7, Figure 11) gave 
indication of a hydrophobic patch where Y* interacts in the surface of the SH2 domain. 
A SAR investigation was performed on derivative 7 and led to the identification of the 
peptidomimetic 8 (Figure 11), showing an IC50 value of 125 µM. 
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Figure 11. Structural modification and SAR study of peptidomimetics derived from the phosphopeptide 4. 
 
On the bases of molecular modeling experiments, new conformationally constrained 
macrocyclic peptidomimetic inhibitors were designed (Figure 12), with the aim to 
synthesize cyclic derivatives more resistant to proteases, and able to interact with the 
protein in an entropic favoured manner, as confirmed by their biological activity 
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determined in whole cell assays. The constrained analogue 9 (Figure 12, a) was 
prepared and found to exhibit a threefold improvement in STAT3 inhibition. 
 
 
 
Figure 12. a) Example of the structure of a conformationally constrained macrocyclic peptidomimetic 
inhibitor; b) examples of permeable prodrugs (10 and 11) containing POM group.  
 
To increase the membrane permeability, the pivaloyloxymethyl (POM) prodrug method 
has been applied; this approach was used for the preparation of two permeable prodrugs 
BP-PM6 (10, Figure 12, b) and BP-PM279G (11, Figure 12, b).  
 
It was assumed that these pro-drugs entered into the cells after the POM cleavage by a 
carboxyesterase and then they bound the SH2 domain. This causes the separation of the 
pre-established STAT3 dimers, exposing the phosphotyrosines to the enzymatic 
cleavage and thus blocking the STAT3 activation. However, despite these efforts, the 
design of potent and cell-permeable STAT3 inhibitors remains a very challenging task.  
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Natural compounds 
Among natural compounds with STAT3 inhibitory activity, Galiellalactone (Figure 13), 
a tetrahydro-isobenzofuranone isolated from the fermentation broth of the ascomycete 
strain A111-95, was identified. It was able to inhibit the IL-6-dependent JAK-STAT 
signaling cascade by the direct inhibition of STAT3 dimers binding to DNA, without 
inhibiting STAT3 tyrosine and serine phosphorylation. 
The phenanthrenequinone derivatives, named tanshinones, were isolated from the roots 
of Salvia miltiorrhiza Bunge. Dried roots of this plant have commonly been used in 
traditional oriental medicine for the treatment of circulatory disorders, liver disease, 
coronary heart disease, hepatitis, and chronic renal failure. Two major tanshinones, 
Cryptotanshinone (Figure 13) and Tanshinone IIA, are well-known active components 
of this plant. Recently, Cryptotanshinone has been identified as a potent STAT3 
inhibitor as it rapidly and selectively inhibits STAT3 Tyr705 phosphorylation in DU145 
prostate cancer cells, but it does not inhibit the upstream tyrosine kinases.154 To 
investigate the Cryptotanshinone inhibitory mechanism in DU145 cells, proteins 
upstream of STAT3 has been analyzed. Although the phosphorylation of JAK2 was 
inhibited by 7 µmol/L Cryptotanshinone at 24 h, the inhibition of STAT3 Tyr705 
phosphorylation occurred within 30 minutes and the activity of the other proteins was 
not affected. These results suggest that inhibition of STAT3 phosphorylation is caused 
by a JAK2-independent mechanism, with suppression of JAK2 phosphorylation as a 
secondary effect of Cryptotanshinone treatment. Moreover, Cryptotanshinone inhibits 
phosphorylation of STAT3 selectively; it is unable to inhibit phosphorylation of STAT1 
or STAT5. Other experiments have revealed the possibility that Cryptotanshinone might 
directly bind to STAT3 molecules. Cryptotanshinone was co-localized with STAT3 
molecules in the cytoplasm, where it inhibited the formation of STAT3 dimers. 
Computational modeling studies have shown that cryptotanshinone could bind to the 
SH2 domain of STAT3. These results suggest that Cryptotanshinone is a potent 
anticancer agent targeting the activation STAT3 protein. The antitumor effects of 
Cryptotanshinone is also mediated by the suppression of the expression of STAT3- 
regulated target genes such as cyclin D1, survivin, and Bcl-xL, causing an accumulation 
of cells in the G0-G1 phase. In particular, the last effect could be attributed to the down-
 Chapter 2 – STAT3 PROTEIN 
36 
 
regulation of cyclin D1 expression, as it is required for cell cycle progression from the 
G1 phase to the S phase. 
 
 
Figure 13. Structures of natural compounds 
 
 
Synthetic compounds 
Among the small molecules that are able to inhibit STAT3 activity, several promising 
candidates have been identified through the screening of chemical libraries and 
computational studies. They include: 
- compounds that structurally mimic the peptidomimetic inhibitors: a large number of 
these molecules, presenting substituted oxazole and thiazole scaffolds, disrupted the 
STAT3-DNA binding activity at low concentration;    
- compounds related to STA 21 (Figure 14): 
its mechanism of action seems to involve the binding to the SH2 domain and 
subsequently the blockage of STAT3 dimerization. The derivates, which exhibited in 
vitro significant anti-tumor activities, were obtained by simplifying the original moiety 
of STA-21 and by structure-based design; 
- porphyrine derivatives  
- catechol derivatives: docking studies highlighted the possibility that the catechol 
moiety may bind to the SH2 domain mimicking the tyrosine residue. 
- purine derivatives 
- platinum-based compounds: the effects of platinum complexes were explored on the 
STAT3 signaling pathway. Two platinum (IV) complexes, CPA-1 and CPA-7 (Figure 
14), and one platinum (II) complex, CPA-3 (Figure 14), showed a selective inhibition 
of STAT3-DNA binding at low concentration.25 Among them, CPA-7 was the most 
potent inhibitor (IC50 = 1.5 µM). Studies of the effects on cell proliferation has 
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revealed a strong inhibition of cells that only harbor persistently activated STAT3 but 
the exact mode of inhibition is still not completely known.  
Another compound that belongs to this class of inhibitors is IS3295 (Figure 14) and it 
is selective for STAT3 over STAT1 and STAT5.  
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Figure 14. Stuctures of synthetic compounds 
 
 
Oligonucleotides 
Besides the SH2 domain, another potential target for the highly selective STAT3 
inhibitors is the DBD domain, since it recognizes and binds DNA motifs in target genes. 
Decoy oligonucleotides (decoy ODNs), containing the TFs’ DNA binding consensus 
sequences, selectively inhibit TFs by binding to the DBD . They can induce, in vitro, the 
death of tumour cells whose growth depends on TFs. This has notably been shown for 
several TFs, including NF-kB and STAT3. Because of the entrapment of activated 
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STAT3 dimers in the cytoplasm STAT3-decoy ODN efficiently induced cell death in 
mouse xenografts of a head and neck squamous cell carcinoma. One limitation of 
STAT3-decoy ODN is that despite the different functions of STAT1 and STAT3 in the 
cell, they recognize very similar DNA targets, with the result that STAT3-decoy ODN 
can inhibit both. The decoy ODNs do not need to enter the nucleus to exert their 
inhibitory effect, but new efforts must be done to solve the problem of the low 
membrane-permeability, caused by chemical and physical characteristics of 
oligonucleotides. 
 
2.3.2 Indirect inhibitors 
The indirect approach for STAT3 inhibition consists of blocking STAT3 upstream activators 
in the signal transduction pathway, leading to impairment of STAT3 function and, for certain 
types of cancer, induction of tumor-cell apoptosis. Several strategies to target STAT signaling 
have been developed, due to the acquired knowledge of the mechanism of constitutive STAT3 
activation and its transcriptional activity from cell surface to the nucleus.  
Among these approaches we can find a blockage of receptor-ligand interaction, inhibition of 
tyrosine or serine kinases, or an interruption of physiological protein modulators of STAT 
activity (e.g. SOCS, PIAS or phosphatases). However, these indirect strategies have some 
important limitations. Firstly, STAT3 can be activated by many different receptors and 
kinases and therefore, only in specific cases the inhibition of one receptor or kinase can block  
STAT3 phosphorylation. Additionally, it would be necessary to develop many different 
kinase inhibitors to treat all the possible disorders that present STAT3 activation, since in 
each case phosphorylation can be due to different kinases. Finally, these strategies lacks 
specificity of action, as they block multiple downstream signaling pathways in addition to 
STAT proteins, increasing the likelihood of undesirable toxicity. Therefore targeting the 
upstream regulators does not seem to be an optimal way to prevent STAT3 activation. A 
concise list of both natural and synthetic compounds is reported. It must be underlined that 
most of them have multiple targets and their spectrum of biological activities and effects is 
very wide and complex. Moreover the mechanisms of action in relation to STAT3 inhibition 
for some of these agents remain to be clearly defined. Among natural compounds, some 
examples of molecules which exert their effect on STAT3 pathway are: Epigallocatechin-3-
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gallate (EGCG), Piceatannol, Curcumin, Plumbagin (Figure 15). 
 
Figure 15. Structures of natural compounds 
 
Among the synthetic compounds, a large number of molecules with different chemical 
structures has been found to play an important inhibitory role on STAT3 pathway, beyond 
various other primary effects on cells. 153 These derivatives can be classified as follows:  
- compounds endowed with JAK inhibition: these molecules selectively bind a JAK protein 
implicated in STAT3 signaling pathway (e.g. FLLL31, NFD, Ruxolitinib (INCB018424) 
(Figure 16)). 
- Compounds interfering with STAT3 phosphorylation (e.g. GO-Y030, CDDO-Me (Figure 
16)) 
-
 Patented compounds: several patented compounds, belonging to different chemical 
classes, exhibited various mechanism of action. Among them, an oxadiazol ureidic 
derivative, AVS-0288 (Figure 16) was identified through a biological screening of a 
Korean chemical library. It was able to inhibit STAT3-dependent luciferase activity with 
an IC50 of 3 µM and suppress the growth of HCT-116 colon cancer cells (GI50 = 20 µM). 
However, its exact mechanism of action on STAT3 pathway has still not been elucidated 
yet. 
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Figure 16. Structures of synthetic compounds 
 
 
2.4 Conclusions and future perspectives 
 
It has been 13 years since the original discovery of the association of constitutive STAT3 
activation with malignant transformation.155 Since then, a large number of studies have been 
undertaken for the validation of STAT3 as a cancer drug target, and substantial efforts have 
been poured into the discovery of novel STAT3 inhibitors. There is a large number of 
compounds with STAT3 inhibitory activity reported to date, which denotes an enhanced 
investigation in this field in recent years. Of these molecules, a few show good activity in 
terms of inhibition of STAT3 biological functions and the associated antitumor cell effects in 
vitro, as well as the suppression of tumor growth in mouse models of human tumors. 
However, these compounds are mostly at the experimental stage and not in a suitable form for 
clinical utility. Therefore the challenge is the discovery of new selective drug candidates, with 
high potency and in vivo activity.  
In order to achieve this goal, a direct inhibitory approach should be preferred because the non-
specific nature of the mechanism of action of indirect inhibitors could cause important 
adverse effects. Regarding the direct approach, much of the efforts has been directed at 
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disrupting the STAT3:STAT3 dimerization, which is a fundamental step in STAT3 activation. 
The slow progress of obtaining suitable STAT3 inhibitors for preclinical investigation and for 
clinical development could be attributed to the challenge of targeting protein-protein 
interactions (PPIs), given the large surface area of the target, and the chemistry of these 
interactions,156 which are very different from those of more-established targets such as 
enzymes and G-protein-coupled receptors. Nonetheless, a number of successful examples 
have started to prove that it is possible to overcome these hurdles and develop PPI modulators 
as drugs.157 
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3. RESEARCH PROJECT 
This thesis is focused on the discovery of new small molecules as potential STAT3 inhibitors, 
preferably endowed with a direct mechanism of action in order to avoid all the possible side 
effects typical of an indirect approach. This project began from the investigation of AVS-
0288, a STAT3 inhibitor which was identified through a screening of a Korean chemical 
library158 by Prof. Kwon research group, with whom our research group has been 
collaborating for several years. AVS-0288 showed an interesting dose-response profile of 
STAT3 inhibitory activity, but its exact mechanism of action had not been clarified yet. With 
the aim to identify the essential requirements for the development of novel lead compounds, 
several derivatives of AVS-0288 were design and synthesized: the 4-subtituted-3-amino-
1,2,5-oxadiazole (F1-F3) (Chapter 3.1).  
Subsequently, another different class of molecules were studied: the pyridazinone derivatives 
(P1-P26) (Chapter 3.2). They derived from the structure of the natural compound 
Cryptotanshinone, which had been discovered by Prof. Kwon research group as a direct 
STAT3 inhibitor.154 
Furthermore, in order to combine the structural characteristics of the two series of molecules 
above, "chimera" compounds (C1-C3) (Chapter 3.3), with the support of conformational 
studies, were designed and synthesized.  
Finally, another series of compounds more directly related to Cryptotanshinone was 
developed (O1, O2). These oxidised derivatives (Chapter 3.4) were characterized by the 
ortho-quinone moiety of Cryptotanshinone, since both molecular modeling studies and in 
vitro screening had suggested the importance of this structural feature for STAT3 inhibitory 
activity. 
Synthetic procedures, conformational, crystallographic and docking studies, as well as 
biological studies performed, will be presented for each series of derivatives.  
 
In detail, the conformational analysis was carried out by Dr. L. Legnani and Prof. L. Toma of the 
University of Pavia (Italy), the crystallographic studies were perfomed by Dr. F. Meneghetti of the 
University of Milan (Italy) and the docking studies by Dr. A. Pedretti of the University of Milan (Italy). 
Regarding the biological evaluation, the luciferase assay was performed by Prof. B-M. Kwon research 
group at the Korean Research Institute of Bioscience and Biotechnology (KRIBB) of Daejeon (South 
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Korea). I had the opportunity to spend six months of my PhD at KRIBB Institute, where, under the 
guidance of Prof. B-M. Kwon, I learned the basic molecular biologic techniques for the analysis of 
STAT3 inhibitors, thus contributing to the investigation on my compounds. Finally, the AlphaScreen-
based assay was carried out by Prof. A.Asai research group of the University of Shizuoka (Japan).  
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3.1. The 1,2,5-oxadiazole derivatives 
 
3.1.1 Project description 
The oxadiazole ureidic derivative, AVS-0288, was identified through a screening of a Korean 
chemical library158 as a potent STAT3 inhibitor. This screening was performed using the dual-
luciferase assay,159 a cell-based test able to identify inhibitors of the STAT3 pathway. A dose-
dependent STAT3 inhibitory activity of AVS-0288 was detected and an IC50 of 2.5 µM was 
calculated after 24 h of treatment (Figure 17).  
                                                                             
 
 
  
 
 
  a)                                                                      b) 
 
 
 
 
 
 
 
 
 
Figure 17. a) Inhibitory activity of AVS-0288 against STAT3 evaluated by dual-luciferase assay in HCT-116 
colon cancer cells after 24 h of treatment; b) dose-dependent effect of AVS-0288 on STAT3 activity after 
incubation for 24 h. 
 
On the basis of these promising results, a series of derivatives structurally related to AVS-
0288 were designed and synthesized.160, 161, 162 In detail, the central 1,2,5-oxadiazole ring was 
kept unchanged, whereas various substituents, characterized by different steric and electronics 
% Inhibitiona 
2 µM 5 µM 
31 82 
aValues presented are the mean calculated 
from three experiments, which differ by 
less than 10% 
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features, were introduced at position 3 and 4. The performed structural modifications are 
summarized in Chart I and consist of: i) the replacement of the chlorophenyl moiety at 
position 4 of the heterocycle with groups which differed in size and polarity (R3= CH3, 
COOCH3, CH2OH, Ph); ii) the elimination of the trifluoromethyl group on the N-phenyl (R1= 
H); iii) the subtitution of the urea with a carboxamido or a sulfonamido function (Y= CO, 
SO2); iv) the insertion of a methylene between the group of item iii and the phenyl linked to it 
(n = 1). 
 
 
Chart I 
 
 
3.1.2  Chemistry 
 
3.1.2.1 Synthesis of key intermediates: 3-amino-1,2,5-oxadiazoles (1a-e) 
Three series of 3,4-disubstituted-1,2,5-oxadiazole derivatives were synthesized: the ureido 
(F1), carboxamido (F2) and sulfonamido (F3) derivatives. They were prepared from the key 
intermediates (1a-e), which were prepared according to literature methods.163, 164, 165 In detail, 
compound 1a and 1d were obtained through a one pot reaction starting from the appropriate 
β-keto esters: ethyl acetoacetate and ethyl benzoylacetate respectively. The key intermediate 
1b was derived from the Fisher esterification of 2, which was in turn synthesized via a one pot 
reaction from ethyl cyanoacetate (Scheme 1). Compound 1c was obtained by reduction with 
LiAlH4 of 1b (Scheme 1). 
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The key intermediate 1e was synthesized following the five-step procedure depicted in 
Scheme 2. This synthesis was based on the construction of the 1,2,5-oxadiazole ring starting 
from the commercially available 4-chloro benzaldehyde, which was condensed with 
hydroxylamine hydrochloride to obtain the correspondent the aldoxime 3 which was readily 
converted to the hydroxyimidoyl chloride 4 using the chlorinating agent N-
chlorosuccinimmide (NCS) in dimethylformamide. The substitution of the chlorine of 4 with 
a cyano group, performed with potassium cyanide, led to the intermediate 5. This latter was 
then treated with an alkaline solution of hydroxylamine to afford the bis-oxime 6, which was 
refluxed in basic conditions to carry out its cyclization and product 1e was thus obtained. 
Since 1e precipitated from the reaction mixture, it could be easily isolated by filtration. 
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Scheme 2. Reagents and conditions: i) NH2OH HCl, NaHCO3, CH3OH, ref lux; ii) NCS,
DMF, rt; iii) KCN, (CH3CH2)2O, H2O, 0 °C; iv) NH2OH HCl, NaHCO3, CH3OH, ref lux; v)
2N NaOH, ref lux.
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3.1.2.2 Synthesis of  the 3-ureido (F1a-d), 3-amido (F2a-e) and 3–
sulfonamido (F3a-e) 1,2,5-oxadiazoles 
Key intermediates (1a-e) underwent coupling reactions with isocyanates with various chains 
length to afford the target compounds, which were divided in three main classes: ureido (F1a-
d), amido (F2a-e) and sulfonamido derivatives (F3a-e).  
The ureidic compounds (F1a-d) were obtained as shown in Scheme 3. The corresponding 1 
was condensed with the required isocyanates, either in conventional conditions (for the 
obtainment of F1a and F1aa) or under microwave irradiation (for F1b-d). Compound F1aa 
was also synthesized using microwave synthesizer at high temperature but in this case a 
mixture of other ureidic by-products was obtained.166 The key intermediate 1c had to be 
firstly protected at the alcoholic function by methyl chloroformate  (compound 7). The final 
deprotection of 8 (n = 0) and 9 (n = 1), using K2CO3 in methanol, gave the corresponding 
compounds F1c and F1cc.  
 
 Chapter 3 – THE 1,2,5-OXADIAZOLE DERIVATIVES 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The synthesis of the final styryl products (E,Z)-F1g and (E,Z)-F1gg started from the oxidation 
of the alcoholic function of the correspondent F1c and F1cc with Dess-Martin Periodinane in 
dry dichloromethane to give the cyclic hemiaminal 10 and 11, respectively (Scheme 4). The 
aldehydic derivatives could not be isolated since they underwent a spontaneous cyclization 
forming 10 and 11, obtained through the intramolecular reaction between the ureidic 
nitrogen and the aldehydic function. This is in agreement with the intramolecular ring 
closure originated when aldehydes bind to nitrogens able to give hemiaminals inside the 
stable medium-sized rings.167 The equilibrium was completely shifted versus the cyclic 
form, and compounds 10 and 11 were the only products isolated, as established by 1H 
NMR. The cyclic hemiaminals 10 and 11 underwent a Wittig reaction with benzyl 
triphenyl phosphonium chloride under basic conditions in tetrahydrofurane at reflux, 
yielding a 3:1 mixture of E and Z isomers of F1g and F1gg (Scheme 4). Isomers E and Z 
were easily separated by silica gel chromatography. The attribution of the cis/trans 
geometry about the styryl π-bond was determined by proton–proton coupling constants for 
the olefinic proton signals and confirmed by X-ray analysis.  
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The amidic compounds (F2a-e) were prepared from the required intermediate 1 by reaction 
with a suitable acyl chloride in a proper medium. When necessary, the condensing agent 
EDAC was used (Scheme 5). 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, the sulfonamidic compounds (F3a-e) were obtained by reaction of the appropriate 1 
with the suitable sulfonyl chloride in pyridine (Scheme 6). The key intermediate 1c had to be 
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Scheme 6. Reagents and conditions: i) R1-Ph-(CH2)n-SO2Cl, Py, rt ii) CH3OCOCl, TEA,THF, rt
iii) 1% K2CO3, CH3OH, rt
ii
firstly protected at the alcoholic function by methyl chloroformate (compound 7) and the final 
deprotection of 12, to obtain compound F3c, was performed with K2CO3 in methanol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.3 Pharmacological studies 
 
3.1.3.1 High-throughput screening in drug discovery  
A high-throughput screening (HTS) for early stage drug discovery has enabled researchers to 
screen more than a hundred thousand chemicals per day. Cell-free assay based on energy 
transfer, fluorescence polarization spectroscopy provide the sensitivity, ease and speed. Novel 
cell-based assays have been adapted for high-throughput screening, providing in situ analysis 
of a variety of biological targets. A number of assay systems have been developed and 
modified over the past few years to compensate the limitations on HTS; these assays can be 
divided into two groups: cell-free assays that measure the biological activity of a pure protein 
target in vitro and cell-based assays that investigate the activity of a target by monitoring a 
biological response of a cell. The advantage of these assay systems is that they both can be 
performed automatically in relatively small volumes, yield robust responses and are relatively 
stable to solvents and compounds used in drug screening.  
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The primary goal in cell-free assays is to simplify the steps required in setting up the assay 
and in detecting the activity. This goal has been met to a large extent by development of 
detection systems that do not require separation of the product of the reaction from the 
substrate, or other components of the assay mixture. Earlier approaches to such homogeneous 
assay formats relied on proximity-dependent energy transfer.  
Cell-based assays are an increasingly attractive alternative to in vitro biochemical assays for 
HTS. These types of screening system have an ability to examine a specific cellular process. 
For instance, activation of a cell surface receptor can induce a change in the transcription 
pattern of a number of genes. This induced change in transcription can be readily captured by 
using enzymatic and proteomic techniques. It is the biggest merit of cell-based assay that a 
modulator regulating a target protein can be screened in vivo condition. Moreover, unexpected 
target proteins or modulators also can be detected on the screening process. 
 
3.1.3.2 The cell-based luciferase assay system 
Several types of screening system have been used for the evaluation of STAT3 activity in 
cell-based assays. For example, cell-based STAT3 (Tyr705) ELISA system and the luciferase 
assay system have been developed for high-throughput screening systems.168 The luciferase 
assay, which is a rapid, convenient and sensitive method, has been used for signal 
transduction activity detection of epidermal growth factor displayed on phage.169 Recently, 
the luciferase assay system has been commonly used in activity measurements of transcription 
factors such as STAT3, NF-κB and HSF1. Moreover, the assay system can be used for 
screening of modulators, such as siRNA and small molecules, targeting transcription factors 
in cultured human, mouse and rat cell lines. Since it is a cell-based assay, it can detect 
inhibitors with similar conditions to in vivo, unlike other screening methods such as virtual or 
in vitro screening systems. Furthermore, dual-luciferase assay systems using STAT3 sensitive 
reporter genes can screen a broad range of small-molecules inhibiting different points on 
JAK/STAT pathway (Figure 18).  
For these reasons, the dual-luciferase assay system was used to screen the synthesized 
compounds to check their ability to inhibit STAT3 activation pathway in human cancer cells. 
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Figure 18. Scheme of predicted inhibition points on STAT3 activation pathway.170 
 
The term “dual” refers to the simultaneous expression and measurement of two individual 
reporter enzymes within a single system. Three plasmids were used for dual-luciferase assay 
(Figure 19). The pSTAT3-TA-Luc has STAT3 binding sequences in its promoter region, and 
therefore the expression of firefly luciferase is regulated by STAT3 activity. On the contrary, 
the only pTA-Luc plasmid, which does not have the STAT3 binding sequence, was not able to 
bind STAT3 protein and therefore it was used for evaluation of basal luciferase expression in 
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cancer cells. The pRL-TK, which expresses Renilla luciferase, is driven by a constitutive 
promoter and it was used for normalization of firefly luciferase in each well. 
 
 
 
 
 
 
 
Figure 19. Reporter plasmids used for transient transfection.  The  pSTAT3-TA-Luc and  pRL-TK were 
transiently transfected into host cells. The pTA-Luc was used for evaluation of basal activity of reporter gene.170 
 
Cell line is an important factor for dual-luciferase assays because the activity of reporter 
genes reflecting STAT3 activity may vary at different cell lines. The primary concerns, when 
selecting a host cell line for the dual-luciferase assay using transient transfection, are its 
endogenous level of transcription factors, its transfection efficiency of reporter genes, and its 
biological relevance to transcription factor. HCT-116 cells were used for the biological assay 
performed on the synthesized compounds since these cells had all the features mentioned 
above. The dual-luciferase assay was carried by a modified manufacturer’s protocol (see 
‘Chapter 6’ for the experimental procedure). 
 
3.1.3.3 Dual-luciferase assay results 
The three series of 3,4-substituted-1,2,5-oxadiazoles were evaluated in the dual-luciferase 
assay to determine their ability to lower STAT3 activity. The compounds were tested at a 
concentration of 2 µM and the cells were incubated for 24 h.160 The results, reported in    
Table 6  as percentage inhibition, clearly indicate that none of the synthesized compounds 
had a better inhibitory activity than the parent compound AVS-0288. 
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NN
O
R HN Y (CH2)n R1
 
 
 
Compound R R1 Y n 
% Inhibitiona       
(2 µM) 
F1a CH3 H CONH 0 2 
F1aa CH3 H CONH 1 <1 
F1b COOCH3 H CONH 0 <1 
F1c CH2OH H CONH 0 nt 
F1cc CH2OH H CONH 1 <1 
F1d Ph H CONH 0 36 
F1e Ph H CONH 1 11 
F1f Ph CF3 CONH 0 <1 
E-F1g PhCH=CH H CONH 0 <1 
Z-F1g PhCH=CH H CONH 0 <1 
E-F1gg PhCH=CH H CONH 1 16 
Z-F1gg PhCH=CH H CONH 1 21 
F2a CH3 H CO 1 6 
F2b COOCH3 H CO 1 9 
F2c CH2OH H CO 1 14 
F2d Ph H CO 1 11 
F2e p-Cl-Ph CF3 CO 0 <1 
F3a CH3 H SO2 1 6 
F3b COOCH3 H SO2 1 7 
F3c CH2OH H SO2 1 <1 
F3d Ph H SO2 1 <1 
F3e p-Cl-Ph CF3 SO2 0 <1 
AVS-0288 p-Cl-Ph CF3 CONH 0 45 
nt: not tested 
aInhibitory activity against STAT3 was evaluated by a dual-luciferase assay system 
in human colorectal carcinoma HCT-116 cells after 24 h treatment with the tested 
compounds. The values are the means of 3 experiments. The maximum deviation 
from the mean was less than 10%. 
                                
 
Table 6. Percentage inhibition of the synthesized oxadiazoles derivatives (F1-F3) evaluated with the dual-
luciferase assay system. 
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3.1.3.4 AlphaScreen-based assay 
In parallel, in order to investigate the ability of the synthesized compounds to bind STAT3 
directly, an in vitro assay was performed. Previous studies have showen that AlphaScreen 
technology was capable of analyzing protein-protein or protein-peptide interactions,171 and 
moreover it turned out to be a useful method to detect the interactions between the SH2 
domain and the pTyr-containing peptide.172 In detail, the AlphaScreen-based assay is a bead-
based non-radioactive assay system for detecting biomolecular interactions in a microlitre 
plate format. It allows the detection of phosphorylated proteins in cellular lysates in a highly 
sensitive, quantitive and user friendly assay. In this test, sandwich antibody complexes, which 
are only formed in the presence of analyte, are captured by AlphaScreen donor and acceptor 
beads, bringing them into close proximity. The excitation of the donor bead provokes the 
release of a singlet oxygen molecules that triggers a cascade of energy transfer in the acceptor 
bead, resulting in a fluorescent signal between 520 and 620 nm. 
The synthesized compounds were tested in this assay system to evaluate their ability to inhibit 
the binding of SH2-containing proteins to their correspondent phosphopeptides, the 
physiological ligands. 
 
3.1.3.5 AlphaScreen-based assay results 
All the 3,4-substituted-1,2,5-oxadiazoles were tested in the AlphaScreen-based assay (Chapter 
6) at a concentration of 50 µM and the results (Table 7) are expressed as percentage of 
inhibition of the interaction between SH2 domain and pTyr-containing peptides. In particular, 
besides STAT3, other SH2-containing proteins, such as STAT1 and Gbr2 ("Growth factor 
receptor-bound protein 2"), having a high degree of sequence homology to STAT3 (78% and 
65%, respectively), were also tested. 
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Compound 
 
 
R 
 
 
R1 
 
 
Y 
 
 
n 
% inhibition 
(50 µM) 
ST
A
T3
 
ST
A
T1
 
G
rb
2a
 
F1a CH3 H CONH - 0.9 7.7 6.6 
F1aa CH3 H CONH 1 < 1 < 1 < 1 
F1b COOCH3 H CONH - 6.8 2.2 < 1 
F1c CH2OH H CONH - nt nt nt 
F1cc CH2OH H CONH 1 < 1 0.2 < 1 
F1d Ph H CONH - < 1 4.9 8.2 
F1e Ph H CONH 1 < 1 11.6 11.0 
F1f Ph CF3 CONH - < 1 < 1 < 1 
E-F1g PhCH=CH H CONH - nt nt nt 
Z-F1g PhCH=CH H CONH - nt nt nt 
E-F1gg PhCH=CH H CONH 1 < 1 10.6 6.6 
Z-F1gg PhCH=CH H CONH 1 < 1 10.9 2.3 
F2a CH3 H CO 1 < 1 13.0 7.2 
F2b COOCH3 H CO 1 < 1 11.6 4.2 
F2c CH2OH H CO 1 < 1 9.3 6.3 
F2d Ph H CO 1 < 1 11.8 2.2 
F2e p-Cl-Ph CF3 CO - 36.5 61.5 10.7 
F3a CH3 H SO2 1 22.9 7.8 < 1 
F3b COOCH3 H SO2 1 44.0 23.8 2.1 
F3c CH2OH H SO2 1 < 1 5.9 3.6 
F3d Ph H SO2 1 42.5 20.4 4.5 
F3e p-Cl-Ph CF3 SO2 - < 1 10.7 < 1 
 nt: not tested 
 
a Growth factor receptor-bound protein 2 
 
Table 7. Percentage  inhibition of STAT3, STAT1 and Grb2 as determined in the AlphaScreen assay by F1, F2 
and F3 compounds.  
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The results show interesting inhibitory activities versus STAT3 for a few derivatives: the 
carboxamido compound F2e had a percentage inhibition of 36.5%, while the sulfonamido 
derivatives F3b and F3d showed an inhibitory activity of 44% and 42.5%, respectively. As 
regards the selectivity of these compounds versus STAT3, F2e selectively antagonized 
STAT3-SH2 domain with respect to Grb2-SH2 domain (36.5% versus 10.7%), although it 
exhibited a higher affinity toward STAT1-SH2 domain (61.5% versus 36.5%). The other two 
sulfonamide derivatives selectively antagonized STAT3 with respect to Grb2 domain and 
only a low affinity was detected for STAT1-SH2 domain. 
 
In light of these results, the compounds which showed positive trend in the AlphaScreen-
based assay were re-tested in the dual-luciferase assay at a higher concentration (5 µM) than 
the previous one (2 µM). The results showed that only F2e exhibited an interesting percentage 
of inhibition (20%). Therefore a deeper biological investigation was performed on F2e and it 
turned out that its inhibitory activity in the AlphaScreen-based assay was dose-dependent 
(Figure 20) with calculated IC50 values of 17.7 µM for STAT3, 7.2 µM for STAT1 and 
higher than 100 µM for Grb2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Dose-response curves of the inhibition of STAT3, STAT1, and Grb2 binding to pTyr-containing 
peptides by compound F2e as determined by AlphaScreen-based assay (% of activity versus concentration 
expressed in logarithmic scale) 
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3.1.3.6 Anti-proliferative assay on compound F2e 
The oxadiazoles derivatives, which had showed a positive results in the luciferase-based 
assay, were submitted to National Cancer Institute (NCI) in Bethesda, Maryland (USA) under 
the Developmental Therapeutic Program (DTP) which operates a two-stage anticancer 
compound screening course for the benefit of the general research community with the goal of 
identifying novel chemical leads and biological mechanisms. Among the compounds 
submitted for the screening, only the structures which were able to add diversity to the NCI 
small molecule compound collection were selected. In addition, the submission of compounds 
with drug-like properties utilizing the concept of privileged scaffold or structures based on 
computer-aided design were preferred. 
The selected compounds were exposed, at a single dose of 10 µM,173 to a panel of 58 human 
tumor cell lines, derived nine neoplastic cancer types (leukemia, lung, colon, CNS, 
melanoma, ovarian, renal, prostate, and breast cancers) (see ‘Chapter 6’ for the experimental 
procedure). In this preliminary screening, only compound F2e exhibited a significant growth 
inhibition value and thus, it was subjected to a complete analysis at five different doses for 48 
h. The data are expressed as dose response parameters GI50, TGI and LD50 referred to F2e 
molar concentration that produces 50% of growth inhibition, total growth inhibition and 50% 
of cytotoxicity, respectively (Appendix I). In this assay, F2e exhibited a good profile of 
inhibitory activity on the cell proliferation, with GI50 values ranging from 6.75×10-6 µM 
(renal cancer, TK10) to 5.46×10-7 µM (leukemia, HL60TB), and showed TGI values lower 
than 1.00×10-4 µM in most of the cell lines. The dose-response curves showing the activity of 
F2e on the panel/cell lines are represented in Appendix II. As expected, F2e inhibits the 
growth of the cell lines which are known to overexpress STAT3 (for instance HCT116, 
DU145, MDAMB-231), although several cell lines, as HL60TB (leukemia cells) and HOP-92 
(non-small cells lung cancer) are the most sensitive. 
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3.1.4 X-Ray and conformational analysis of compound F2e174 
 
The crystallographic structure of F2e is represented in Figure 21. 
 
 
 
 
 
 
 
 
Figure 21. ORTEP175 view of F2e and the relative arbitrary 
atom numbering scheme (thermal ellipsoids at 40% probability). 
 
Bond lengths and angles assume the expected standard values. The overall conformation of 
the compound is defined by four torsional angles: N2-C2-N3-C11 (τ1) of -118(1)°, C2-N3-
C11-C5 (τ2) of 175(1)°, N3-C11-C5-C6 (τ3) of -150(1)° and C2-C1-C3-C13 (τ4) of 22(1)°. 
The oxadiazole ring is rotated by 25(1)° and 88(1)° with respect to the chlorophenyl and 
trifluoromethyl-phenyl moieties, respectively. The latter two rings are perpendicular to each 
other, with a dihedral angle of 87(1)°. The analysis of the crystal packing has shown the 
important role played by the halogen atoms in connecting adjacent molecules, through Cπ-
H…F, Cπ-H…Cl and C=O…F type contacts, influencing in this way the molecular 
conformation. The oxadiazole ring in the crystal gives rise to π interactions with the chloro-
phenyl group of symmetry related molecules along the b axis, indicating the ability of the 
compound to interact through molecular stacking with a biological counterpart. The 
crystallographic structure represents only one of the accessible molecular conformations. 
Thus, in order to explore all its conformational space, a complete modeling study of F2e was 
carried out, considering all the degrees of conformational freedom that correspond to the 
above defined torsional angles (Chart 2) and, in particular, the arrangement of the amidic 
group with respect to the oxadiazole ring, described by the torsional angle τ1. 
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The geometry optimizations were performed at the B3LYP/6-311+G(d,p) level176 and the 
energy of the optimized conformations was recalculated using a polarizable continuum 
solvent model (PCM)177 to take into account the effect of water on the conformational 
population.  
 
 
Erel vacuo 
(kcal/mol) 
P vacuo 
(%) 
Erel water 
(kcal/mol) 
P water 
(%) τ1 (°) τ2 (°) τ3 (°) τ4 (°) 
A 2.10 1.9 0.00 40.9 22 -177 -154 43 
B 2.49 1.0 0.17 30.6 0 177 -158 -48 
C 0.00 65.0 0.28 25.5 -126 174 -159 34 
D 0.42 32.1 1.53 3.0 -110 174 -156 -45 
a
 τ1 : N2-C3−N1’−C2’; τ2 : C3−N1’−C2’−C1”; τ3 : N1’−C2’− C1”− C2”; τ4 : C3−C4−C1’”−C2’”. 
 
Table 8. Relative energies (kcal/mol), equilibrium percentages (%) in the gas phase and in water, and significant 
torsional anglesa (°) of the located conformations of compound F2e. 
 
Four minimum energy conformations were located and their geometrical descriptors (τ1-τ4), 
together with their gas-phase and water-solvated energies, and the corresponding percentage 
contributions to the overall population, are reported in Table 8.  It is worth pointing out that a 
mirror image conformation exists for each described conformation; thus, the number of 
conformations accessible to the molecule is double with respect to those reported. 
Conformations A and B are very similar (Figure 22), as evidenced by their values of τ1, τ2, 
and τ3, the only difference being the orientation of the p-chlorophenyl ring (τ4). The same 
occurs for the couple C and D. The most stable conformation in water (A) accounts for 40.9 
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% of the overall population and, together with conformation B, less stable by 0.17 kcal/mol, 
represents 71.5 %, the remaining not negligible 28.5% being due to the in vacuo preferred 
conformations C and D.  
 
  
 
 
 
 
 
 
 
 
 
Figure 22. 3D plots of conformations A-D of compound F2e. 
 
A comparison of conformations A-D, with the above described crystal structure of F2e, 
shows that it corresponds to C, which is the most stable conformation in vacuo. In fact, the 
two structures are characterized by about the same values of the torsional angles τ1-τ4 and the 
overlay of their heavy atoms produces an almost perfect super-imposition (Figure 23) with a 
rms difference value of 0.191 Å. By contrast, the comparison of the solid state structure with 
conformer A gives a rms difference value of 1.067 Å. The crystal structure and A orient their 
amide functionality in very different directions (Figure 23), as evidenced by the significantly 
different values of τ1: -118(1)° in the crystal versus 22° in A. The amide functionality usually 
represents a key moiety for anchoring a ligand at the binding site of the protein, and the 
ability of F2e to vary the orientation of the amide in different conditions is worthy of note. 
The orientation in the crystal is determined by packing interactions, as the molecules form 
chains through the hydrogen bond N3-H3…O2I (I at x, y-1, z), forcing in some way 
molecular bending, and favoring the conformation having the carbonyl oxygen pointing in the 
opposite direction with respect to the chlorophenyl group. 
 
A B   
C D
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Figure 23. Superimposition of the crystal structure of compound F2e (brown) onto the A (magenta) and  C 
(pink) conformers obtained through rms fitting of the heavy atoms. Hydrogen atoms are omitted for the sake of 
clarity.  
 
3.1.5 Docking studies on compound F2e174 
Docking studies were performed on F2e in order to clarify its interaction with the SH2 
domain. In particular, considering the STAT3-MD77 complex and the conformational profile 
of the ligand, the best scored pose showed that the ligand assumes the most stable 
conformation A. The binding mode of F2e is comparable to that of phosphorylated Tyr-705, 
because it involves the same pocket in which pTyr-705 is inserted when two subunits are 
assembled in the dimer. The phenyloxadiazole moiety of F2e, colored in cyan, occupies the 
same pocket (not shown) of pTyr-705, colored in red (Figure 24).  
 
 
Figure 24. Comparison of F2e (cyan) in the docking pose with the pTyr-705 (red) of the second subunit in the 
STAT3 dimer. 
This pocket is placed on the protein surface and it is surrounded by hydrophilic and polar 
aminoacids to better interact with the negatively charged side chain of the phosphorylated 
tyrosine, mimed by the phenyloxadiazole moiety in the STAT3- F2e complex. As shown in 
Figure 25, the favored conformation A of F2e establishes many hydrogen bond interactions 
F2e 
pTyr-705 
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Arg-595 
Lys-591 
Arg-609 
Gln-635 
within the binding pocket. In detail, they involve the trifluoromethyl group of the aromatic 
ring and the guanidine moiety of Arg-595 by three hydrogen bonds, the oxygen of the amidic 
group and the amine of side chain of Lys-591 by one hydrogen bond, the oxygen and the 
nitrogen atoms of the oxadiazole ring and the guanidine group of Arg-609 by two hydrogen 
bonds and finally the chlorine atom of the aromatic ring with one amidic hydrogen of Gln-635 
side chain. Despite the presence of three aromatic rings in F2e, π-π interactions were not 
found in its complex with the macromolecule, due to the absence of aromatic amino acids in 
the binding pocket. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Main interactions between F2e and STAT3. The hydrogen bonds are shown as dotted lines. 
 
Analyzing the other F2e complexes obtained by docking, it was possible to identify a pose in 
which the ligand assumes a conformation referable to the couple C-D, but its interaction 
energy is worse than all calculated complexes and the binding mode is much different if 
compared to the most stable one shown above. In particular, the p-trifluoromethylphenyl 
group is partially inserted in the pTyr-705 pocket while, in the best complex, this pocket is 
occupied by the oxadiazole ring. Moreover, the p-trifluoromethyl is too far to reach the amino 
acids involved in the interaction with the phosphate. In this complex, the oxadiazole ring does 
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not mime the phosphate and stabilizes the complex through hydrogen bonds with Gln-635 and 
Lys-26. Finally, one of the poses of F2e corresponds to the mirror image of conformation A. 
It presents a different binding mode in which the pTyr-705 pocket is not occupied, loosing the 
interaction with Arg-609, but keeping the weak hydrogen bonds between Arg-595 and 
trifluoromethyl group. It should be noted that the sulfonamido bioisoster (F3e) of F2e, which 
was found inactive both in the AlphaScreen and in the dual-luciferase assays, has a different 
conformational behavior with respect to our lead compound. In fact, none of the localized 
conformations of F3e show a relative arrangement of the aromatic groups similar to that 
displayed in the four geometries of F2e. Thus, the identification of its binding mode through 
docking calculations, seemed to be important to clarify the essential features for an efficient 
interaction with STAT3 (Figure 26).  
 
 
Figure 26. Main interactions between compound F3e and STAT3. The hydrogen bonds are shown as dotted 
lines. 
 
Considering the STAT3-compound F3e complex, the pose and interacting conformation of 
the ligand are very different from those shown by F2e. In particular, compound F3e is unable 
to occupy the pTyr-705 pocket and the oxadiazole ring interacts with Arg-595 instead of Arg-
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609, which is the key residue involved in the F2e complex and in the formation of the salt 
bridge with the phosphate group when the protein dimerizes. Despite the different binding 
mode, the compound F3e complex is stabilized by an extended network of hydrogen bonds 
that involve: the oxygen and the nitrogen at position 5 of the oxadiazole ring and the 
guanidine group of Arg-609, one sulfonamide oxygen and the amine group of Lys-591, the 
sulfonamide hydrogen and the backbone oxygen of Ile-634, and finally the trifluoromethyl 
group of the aromatic ring with the amidic hydrogen of Gln-635 side chain. Analyzing the 
docked conformation of compound F3e, the two benzene rings are perpendicular and the 
angle between the planes, defined by the two rings, is 89°, significantly higher than the 
corresponding value of 28° found for F2e. 
 
3.1.6 Conclusions 
The ability to target the STAT3-SH2 domain of a series of 1,2,5 oxadiazole derivatives was 
evaluated in order to identify new direct inhibitors. One term (F2e) proved to be able to 
significantly interact with the SH2 domain: in the AlphaScreen binding assay, it showed an 
interesting dose response profile with an IC50 value of 17.7 µM. This result highlighted its 
potential as a protein-protein interaction inhibitor. In addition, F2e exhibited a significant 
activity (20% inhibition at 5 µM) in a dual-luciferase assay. To investigate the conformational 
behavior and the binding mode of F2e, modeling and docking studies were performed. The 
latter evidenced that in the best scored pose of the STAT3-F2e complex, F2e assumes the 
most stable conformation (calculated in water). It should be noted that the binding mode of 
F2e is comparable to that of pTyr-705, when the latter is involved in the formation of STAT3 
dimers. The computational data were supported by crystallographic studies. Finally, F2e 
displayed a significant growth inhibitory activity on a number of tumor cell lines. On light of 
these interesting results, F2e emerged as a lead for the development of a new series of 
derivatives, that is currently ongoing research in our group. 
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3.2 The pyridazinone derivatives 
 
3.2.1 Project description 
The phenanthrenequinone Cryptotanshinone (Chapter 2.3.1), isolated from the roots of 
Salvia miltiorrhiza Bunge, was a potent direct STAT3 inhibitor and found to induce apoptosis 
in human prostate cancer cell lines (DU145), by selectively inhibiting phosphorylation of 
STAT3 at a concentration of 7 µM.154 This selectivity of action was due to its small effect on 
STAT3 serine 727 phosphorylation and to its inability to inhibit phosphorylation of the 
tyrosine residues of STAT1 and STAT5. Cryptotanshinone was also found to inhibit the 
phosphorylation of JAK2, but only after 4 h of treatment with the compound, whereas 
inhibition of STAT3 phosphorylation occured within 30 min 
after treatment. This result suggested that inhibition of STAT3 
phosphorylation was caused by a JAK2-independent 
mechanism. Further studies showed that Cryptotanshinone was 
localized together with STAT3 proteins in the cytoplasm and 
could inhibit the formation of STAT3 dimers. This implied the 
possibility of a direct binding of Cryptotanshinone to the 
dimerization domain of  STAT3. 
 
A conformational study of the reference compound Cryptotanshinone, and of a generic 
structure of benzo-cinnolinone compounds, which had been already investigated in our 
laboratories for other purposes,178, 179 was performed. The result of these studies revealed a 
structural similarity between these compounds, and the superimposition of the preferred 
conformations of each molecule showed that the two compounds matched very well (Chapter 
3.2.2). Therefore we designed and synthesized several new derivatives180 based on the 
benzocinnolinnone structure, and a series of structural modifications (Chart III) were carried 
out in order to investigate their effects on STAT3 inhibition. In detail, the effects of 
modifications at the pyridazinone ring were first explored: at N-2 various kind of chains were 
inserted, differentiated on the basis of their length as well as the presence of esters, carboxylic 
acids or their bioisosteres, amines and amides. In addition, both saturated and unsaturated 
O
O
O
Cryptotanshinone
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m = 1-3
R = -(CH2)nCOOCH2CH3; n = 1-6
-(CH2)3COOH
-(CH2)3COONHCH2CH3
-(CH2)4NHCH2CH3
-(CH2)3OCOC(NH2)CH2Ph
N N
O
R
m
4
derivatives of all the compounds at position 4 of the pyridazinone ring were obtained. Other 
structural variations were introduced at different positions of the aromatic ring, involving the 
insertion of substituents such as methoxy groups or halogens. Finally, we investigated the 
influence of the size of the central ring, synthesizing five-, six- and seven-membered ring 
compounds.  
 
 
                          
 
 
 
 
                                                               Chart III 
 
 
 
3.2.2 Modeling studies 
A conformational study of the reference compound Cryptotanshinone and of a general 
benzocinnolinone structure (I) was carried out. Particular attention was focused, for 
Cryptotanshinone, on the flexibility of the A and C rings, and, for (I), on the possible 
inversion of C ring.  
 
 
 
 
 
 
 
 
All calculations were carried out using the Gaussian03 program package.181 The 
conformational space of the compounds was explored through optimizations at the B3LYP 
level with the 6-31G(d)182 basis set, and the energy of the optimized conformations was re-
calculated in water, at the same level as above, using a polarizable continuum solvent model 
(PCM)177. 
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Both molecules were found to be quite rigid and characterized by planarity, requisite thought 
important for the inhibitory activity.160 In order to highlight analogies between the two 
structures, the preferred conformations of Cryptotanshinone (blue) and (I) (red) were 
superimposed through rms fitting of the atoms of the BCD tricyclic moiety. The overlap 
shows that the two compounds match very well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cryptotanshinone I 
Cryptotanshinone vs I 
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3.2.3 Chemistry: the benzocinnolinones (P1-18) 
 
3.2.3.1 Synthesis of: 
4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one derivatives (P1a-c)                
and of 5,6-dihydrobenzo[h]cinnolin-3(2H)-one derivatives (P2a-c) 
 
The final six-membered ring compounds (P3-18), N-2 substituted on the pyridazinone ring 
with different lateral chains, were prepared starting from common key intermediates: the 
saturated (P1a-c) and the unsaturated (P2a) derivatives (Scheme 7). The starting materials 
were either commercially available, as α-tetralone (for P1a and P2a), or they were prepared 
as shown in Scheme 8, such as 5,7-dimethoxy tetralone (for P1b) and 6-chloro-tetralone (for 
P1c). These starting materials underwent an aldol condensation with glyoxylic acid in basic 
conditions to give the unsaturated acids 13a-c, which were reduced with zinc in acetic acid to 
afford the 1,2,3,4-tetrahydro-1-oxo-naphtalene-2-acetic acids 14a-c. The reaction of 14a-c 
with hydrazine hydrate in refluxing ethanol led to P1a-c in an overall yield of 57% for P1a, 
60% for P1b and 42% for P1c. Oxidation of P1a to the unsaturated derivative P2a was 
accomplished using sodium m-nitrobenzensulfonic acid. 
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3.2.3.2 Synthesis of  
the 2-substituted-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3-ones (P3-13) 
 
The previously described key intermediates P1a-c and P2a were condensed with appropriate 
side chains to afford the final six-membered ring compounds (P3-18) (Scheme 9 and 10, 
respectively). They were divided in saturated (P3-13) and unsaturated (P14-18) derivatives. 
 
Regarding the saturated derivatives (P3-13, Scheme 9), they were characterized by lateral 
chains which bore six different functional groups: ester, carboxylic acid, amide, amine, alkyl 
and an amino acidic moiety. For the synthesis of the ester derivatives (P3a-P8a), the starting 
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intermediate P1a was condensed with bromo esters with different chain lengths in the 
presence of sodium hydride as a base. The other two starting intermediates, P1b and P1c, 
were condensed only with 3-bromo butanoate to obtain compounds P5b and P5c respectively. 
Regarding the reaction of compound P1b, beyond the obtainment of the saturated ester P5b, 
there was also the formation of the unsaturated derivative P15b. A basic hydrolysis of the 
ester group was then performed on compounds P4a and P5a and this led to the formation of 
the corresponding acids P4aa and P5aa. Finally, P5aa was reacted with ethylamine in the 
presence of the coupling agent HATU and N-methyl-morpholine to afford the amido 
compound P9a. The amino derivatives P10a was synthesized with a two-step procedure 
starting from P1a. The latter was condensed with 1,4-dibromobutane to give the intermediate 
18, which underwent a nucleophilic substitution with ethylamine for the obtainment of the 
final compound P10a. The alkyl derivatives P11a and P12a were obtained through the 
coupling of P1a with bromoalkyl chains made up of four and five carbon atoms respectively. 
Also in these reactions, there was the simultaneous formation of the correspondent 
unsaturated alkyl derivatives P17a and P18a. The amino acidic derivative P13a was 
synthesized starting from compound P1a which was reacted with 3-chloro-1-propanol to give 
the alcoholic intermediate 19. The latter was condensed with N-Boc-Phe–OH in the presence 
of the coupling agent HATU and N-methyl-morpholine to obtain compound 20. Its Boc 
protecting group was hydrolysed with trifluoroacetic acid to afford the final product P13a. 
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3.2.3.3 Synthesis of  
2-substituted-5,6-dihydrobenzo[h]cinnolin-3-ones (P14-18) 
 
The unsaturated derivatives (P14-18) were characterized by side chains containing ester and 
carboxylic acid functionalities and by alkyl chains of different lengths. As depicted in 
Scheme 10, the ester derivatives (P14a-P16a) were obtained by condensing bromoester 
chains with the starting intermediate P2a, using potassium hydroxide as a base and tetra-n-
butylammonium fluoride (TBAF) as a phase transfer catalyst. The synthesis of the 
unsaturated ester P15b is depicted in Scheme 9. The basic hydrolysis of the ester 
functionality of P14a and P15a led to formation of the carboxylic acids (P14aa and P15aa). 
The synthesis of other two unsaturated derivatives P17a and P18a, which bear an alkyl chain 
at N-2, is displayed in Scheme 9. 
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3.2.4 Chemistry: the indeno-pyridazinones (P19-22) and the 
benzocyclohepta-pyridazinones (P23-26) 
 
3.2.4.1 Synthesis of 
the 4,4a-dihydro-(5H)-indeno-[1,2-c]-pyridazin-3-one derivatives (P19- P22) 
and of the 2,4,4a,5,6,7-hexahydro-benzo[6,7] cyclohepta[1,2-c]pyridazin-3-
one derivatives (P23- P26) 
 
The synthesis of the  five- and seven-membered ring compounds was accomplished by 
following a similar procedure to that employed for the six-membered ring compounds 
(Scheme 11). 
Firstly, the key intermediates P19 (m=1) and P23 (m=3) were prepared starting from 1-
indanone (for m=1) and 1-benzosuberone (for m=3). They underwent an aldol condensation 
with glyoxylic acid in basic environment to give intermediates 21 (m=1) and 23 (m=3). The 
following reduction of their double bond with zinc dust in acetic acid led to the intermediates 
22 (m=1) and 24 (m=3), which cyclised in the presence of hydrazine monohydrate in ethanol 
to give the saturated P19 (m=1) and P23 (m=3). The unsaturated key intermediates were 
prepared in two different ways. For the five-membered ring derivatives, the cyclization with 
hydrazine monohydrate was performed on the unsaturated acid 21 to afford P20. For the 
seven-membered ring derivatives the insertion of the double bond was carried out only after 
the cyclization with hydrazine on compound P23 to give the correspondent unsaturated 
derivative P24. This oxidation was performed using sodium m-nitrobenzensulfonic acid. 
The saturated key interemediates (P19, P23) were condensed with ethyl bromobutanoate 
using NaH as a base to obtain the ester derivatives P21 (m=1) and P25 (m=3). The 
unsaturated intermediates (P20, P24) were reacted with the same bromoester chain but 
employing different conditions (potassium hydroxide as a base and tetra-n-butylammonium 
fluoride (TBAF) as a phase transfer catalyst) to obtain the final products P22 (m=1) and P26 
(m=3). 
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3.2.5 Pharmacological studies 
 
3.2.5.1 Dual-luciferase assay results 
All the synthesized pyridazinones derivatives were evaluated in the dual-luciferase assay159 
system as a preliminary screening (see ‘Chapter 3.1.3.2’ for the description of this assay and 
‘Chapter 6’ for the experimental procedure). In Table 9 the inhibitory activities of the tested 
compounds are displayed. The values are reported as percentage of inhibition at 2 µM.  
 Chapter 3 – THE PYRIDAZINONE DERIVATIVES 
76 
 
 
Compound n C at position 4 R1 = R3 R2 R 
% 
Inhibitiona      
(2 µM) 
P1a 2 CH2 H H H < 1 
P1b 2 CH2 OCH3 H H nt 
P1c 2 CH2 H Cl H nt 
P2a 2 CH H H H < 1 
P3a 2 CH2 H H -CH2COOCH2CH3 3 
P4a 2 CH2 H H -(CH2)2COOCH2CH3 30 
P4aa 2 CH2 H H -(CH2)2COOH < 1 
P5a 2 CH2 H H -(CH2)3COOCH2CH3 46 
P5aa 2 CH2 H H -(CH2)3COOH 7 
P5b 2 CH2 OCH3 H -(CH2)3COOCH2CH3 23 
P5c 2 CH2 H Cl -(CH2)3COOCH2CH3 9 
P6a 2 CH2 H H -(CH2)4COOCH2CH3 21 
P7a 2 CH2 H H -(CH2)5COOCH2CH3 24 
P8a 2 CH2 H H -(CH2)6COOCH2CH3 22 
P9a 2 CH2 H H -(CH2)3CONHCH2CH3 16 
P10a 2 CH2 H H -(CH2)4NHCH2CH3 3 
P11a 2 CH2 H H -(CH2)3CH3 < 1 
P12a 2 CH2 H H -(CH2)4CH3 22 
P13a 2 CH2 H H -(CH2)3OCOCH(CH2Ph)NH2 < 1 
P14a 2 CH H H -(CH2)2COOCH2CH3 < 1 
P14aa 2 CH H H -(CH2)2COOH nt 
P15a 2 CH H H -(CH2)3COOCH2CH3 < 1 
P15aa 2 CH H H -(CH2)3COOH < 1 
P15b 2 CH OCH3 H -(CH2)3COOCH2CH3 29 
P16a 2 CH H H -(CH2)4COOCH2CH3 29 
P17a 2 CH H H -(CH2)3CH3 1.31 
P18a 2 CH H H -(CH2)4CH3 < 1 
P19 1 CH2 H H H 37 
P20 1 CH H H H 37 
P21 1 CH2 H H -(CH2)3COOCH2CH3 28 
 Chapter 3 – THE PYRIDAZINONE DERIVATIVES 
77 
 
Compound n C at position 4 R1 = R3 R2 R 
% 
Inhibitiona      
(2 µM) 
P22 1 CH H H -(CH2)3COOCH2CH3 < 1 
P23 3 CH2 H H H 30 
P24 3 CH H H H < 1 
P25 3 CH2 H H -(CH2)3COOCH2CH3 < 1 
P26 3 CH H H -(CH2)3COOCH2CH3 15 
Cryptotanshinone 
     
25 
nt: not tested 
a Inhibitory activity against STAT3 was evaluated by a dual-luciferase assay system in human colorectal      
carcinoma HCT-116 cells after 24 h treatment with the tested compounds. The values are the means of 3 
experiments. The maximum deviation from the mean was less than 10%. 
 
 
Table 9. Percentage inhibition evaluated by dual-luciferase assay in human colorectal carcinoma HCT-116 cells 
at 2 µM concentration. 
 
According to the obtained data, several compounds showed an interesting percentage 
inhibition, comparable of higher than the reference compound Cryptotanshinone. In 
particular, P5a, P19 and P20 were the most active compounds, with an inhibitory activity of 
46%, 37% and 37% respectively. 
Since a positive result in the dual-luciferase assay reflects the ability of the compound to 
block STAT3 activity at any level of its signaling pathway (Figure 18), a deeper investigation 
on the mechanism of action of the compounds was necessary. For this reason all of them were 
subjected to further biological studies.  
 
3.2.5.2 AlphaScreen-based assay results 
All the compounds, with particular attention to P5a, P19 and P20, which showed the most 
interesting inhibitory activities, were tested with the AlphaScreen-based assay172 (see 
‘Chapter 3.1.3.4’ for the description of this assay and ‘Chapter 6’ for the experimental 
procedure) and the results (Table 10) were expressed as a measure of their ability to 
antagonize the interaction between STAT3-SH2 domain and its target pTyr-containing 
peptide. In particular, besides STAT3, other SH2-containing proteins, such as STAT1 and 
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Gbr2, having a high degree of sequence homology to STAT3 (78% and 65%, respectively), 
were tested.  
 
Compound n C at position 4 R1 = R2 R3 R 
% Inhibition                          
(50 µM) 
ST
A
T3
 
ST
A
T1
 
G
rb
2a
 
P1a 2 CH2 H H H < 1 < 1 < 1 
P1b 2 CH2 OCH3 H H < 1 13.3 12.3 
P1c 2 CH2 H Cl H < 1 13.9 5.0 
P2a 2 CH H H H 7.5 6.1 2.9 
P3a 2 CH2 H H -CH2COOCH2CH3 < 1 7.2 2.9 
P4a 2 CH2 H H -(CH2)2COOCH2CH3 19.1 0.7 < 1 
P4aa 2 CH2 H H -(CH2)2COOH < 1 < 1 < 1 
P5a 2 CH2 H H -(CH2)3COOCH2CH3 7.3 < 1 < 1 
P5aa 2 CH2 H H -(CH2)3COOH 5.6 4.5 < 1 
P5b 2 CH2 OCH3 H -(CH2)3COOCH2CH3 < 1 5.8 < 1 
P5c 2 CH2 H Cl -(CH2)3COOCH2CH3 < 1 9.1 2.0 
P6a 2 CH2 H H -(CH2)4COOCH2CH3 11.4 3.5 4.3 
P7a 2 CH2 H H -(CH2)5COOCH2CH3 7.7 6.7 5.5 
P8a 2 CH2 H H -(CH2)6COOCH2CH3 < 1 1.4 5.6 
P9a 2 CH2 H H -(CH2)3CONHCH2CH3 < 1 4.9 < 1 
P10a 2 CH2 H H -(CH2)4NHCH2CH3 < 1 < 1 < 1 
P11a 2 CH2 H H -(CH2)3CH3 < 1 < 1 < 1 
P12a 2 CH2 H H -(CH2)4CH3 18.9 < 1 < 1 
P13a 2 CH2 H H -(CH2)3OCOCH(CH2Ph)NH2 < 1 15.9 7.5 
P14a 2 CH H H -(CH2)2COOCH2CH3 8.1 6.0 1.5 
P14aa 2 CH H H -(CH2)2COOH nt nt nt 
P15a 2 CH H H -(CH2)3COOCH2CH3 10.4 5.4 6.4 
P15aa 2 CH H H -(CH2)3COOH 12.5 5.5 < 1 
P15b 2 CH OCH3 H -(CH2)3COOCH2CH3 < 1 < 1 < 1 
P16a 2 CH H H -(CH2)4COOCH2CH3 2.7 2.7 < 1 
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Compound n C at position 4 R1 = R2 R3 R 
% Inhibition                          
(50 µM) 
ST
A
T3
 
ST
A
T1
 
G
rb
2a
 
P17a 2 CH H H -(CH2)3CH3 4.2 7.1 2.2 
P18a 2 CH H H -(CH2)4CH3 6.2 < 1 < 1 
P19 1 CH2 H H H < 1 12.9 3.2 
P20 1 CH H H H < 1 9.8 5.2 
P21 1 CH2 H H -(CH2)3COOCH2CH3 1.3 13.3 6 
P22 1 CH H H -(CH2)3COOCH2CH3 < 1 9.5 < 1 
P23 3 CH2 H H H 5.8 5.8 2.1 
P24 3 CH H H H nt nt nt 
P25 3 CH2 H H -(CH2)3COOCH2CH3 < 1 7.2 5.4 
P26 3 CH H H -(CH2)3COOCH2CH3 < 1 8.2 1.0 
Cryptotanshinone 
    11.2 40.3 34.7 
  nt: not tested 
a
 Grb2: Growth factor receptor-bound protein 2 
 
Table 10. Percentage  inhibition of STAT3, STAT1 and Grb2 as determined in the AlphaScreen assay by P1-26 
compounds.  
 
None of the molecules was able to antagonize the interaction between the SH2-STAT3 
domain and its target pTyr-containing peptide. However, a binding of the compounds with 
different portions of the SH2 domain or with any other part of STAT3 protein is still 
probable. Further investigations (i.e. Western blotting, ELISA, etc.) will be carried out to 
assess this possibility and to give an explanation of the positive results we obtained in the 
dual-luciferase assay. 
 
3.2.5.3 Anti-proliferative assay 
In order to evaluate the anti-proliferative activity of the synthesized pyridazinone derivatives, 
cell proliferation assays were performed by NCI (Bethesda, USA) under the Developmental 
Therapeutic 20 Program (DTP) to determine its effect on tumor cells growth173 (‘Chapter 
3.1.3.6’ for the description of this assay and ‘Chapter 6’ for the experimental procedure). The 
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compounds were tested at a concentration of 10 µM. All the derivatives turned out to be 
mostly inactive. For instance, the table reported in Appendix II displays the data for 
compounds which showed slight inhibition in some cell lines: e.g. compound P1a had a 
growth inhibitory activity of 36% on EKVX cell line (non-small-cell lung carcinoma), 
compound P5a had a discrete inhibition on SR cell line (leukemia cell line) and compound 
P19 a 19% of growth inhibition on UO-31 cell line (renal cancer cell line).  
 
3.2.6 Conclusions 
In the preliminary dual-luciferase assay screening, the synthesized pyridazinone derivatives 
exerted promising percentage inhibition of STAT3 activity. In order to clarify these 
interesting results, and to understand the mechanism of action of the compounds, a deeper 
biological investigation was carried out. The molecules were firstly tested in the in vitro 
AlphaScreen-based assay, but none antagonized the interaction between the SH2-STAT3 
domain and its target pTyr-containing peptide. However, binding of the compounds with 
different portions of the SH2 domain, or with any other part of STAT3 protein, is still 
probable. The molecules were also submitted to an anti-proliferative assay but did not exert 
any remarkable effect on cell proliferation. Therefore, the dual-luciferase assay was repeated 
on the compounds with the most interesting activities, considering a wide range of 
concentrations (from 1 to 50 µM, data not shown). The obtained data revealed a non-dose 
dependent profile of inhibitory activity of the tested compounds and thus, we could assume 
that the noteworthy percentage inhibition at 2 µM previously obtained in the dual-luciferase 
assay was not significant for the STAT3 inhibition. 
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3.3 The “chimera” compounds 
 
3.3.1 Project description 
 
In parallel with the execution of the AlphaScreen-based assay on the previously synthesized 
compounds (the 1,2,5-oxadiazoles and the pyridazinones), a different approach for the design 
of new derivatives was carried out. The aim was to combine the structural characteristics of 
the different series of molecules, explored in this project, which had showed an ability to 
inhibit STAT3 activity in the dual-luciferase assay. Therefore, the following structures were 
considered:  
 
- the oxadiazole ureido derivative AVS 0288 (Chapter 3.1.1) 
NN
O
H
N
H
N
O
CF3
Cl
 
 
- the natural compound Cryptotanshinone (Chapter 3.2.1) 
O
O
O
 
 
-  P5a, the pyridazinone compound with the best inhibitory activity among all the 
previously synthesized pyridazinone derivatives (% inhibition  at 2 µM = 46%). 
(Chapter 3.2.5.1) 
N
N
O
(CH2)3COOEt
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Conformational studies on the selected compounds were performed and the preferred 
conformations turned out to have a planar arrangement. This feature was supposed to be an 
important requisite for STAT3 inhibitory activity, as it was observed in our previous 
studies.160 The superimposition of their conformations led to the design of two new 
compounds: C2 and C4. The first is characterized by the benzocinnolinone moiety of P5a, 
which resembled the tricyclic system of Cryptotanshinone, and a lateral chain, which 
mimicked the one on AVS-0288. Moreover this new structure can be considered a cyclic 
analogue of AVS-0288, as it can be seen overlapping the oxadiazole ring of AVS-0288 with 
the pyridazinone ring of the new planned compound (Chapter 3.3.2). 
On the contrary, the chimera C4 is constituted by a pyridazinone ring, substituted at position 
3 and 4 with the same groups which are present in AVS-0288: a p-chloro-phenyl group and a 
p-trifluoromethylphenyl urea. This structure clearly resembled AVS-0288 if the pyridazinone 
ring is overlapped to the oxadiazole ring and moreover, it can be considered analogues of C2. 
However, to date, only compound C3, which has a phenyl ring instead of a p-chloro-phenyl 
ring as a substituent, has been synthesized, whereas the synthesis of compound C4 is still in 
progress.  
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 Molecular modeling 
A modeling study of Cryptotanshinone, a potent STAT3 inhibitor,154 and the previously 
synthesized pyridazinone compound P5a, was performed using the Gaussian09 program 
package.181 All the calculations were carried out at the b3lyp/6-311+G(d,p) level. The  solvent 
effects were determined by single-point calculations, at the same level as above, on the gas-
phase optimized geometries, using a self-consistent reaction field (SCRF) method, based on 
the polarizable continuum model (PCM). Particular attention focused on the tricyclic portion 
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of the two molecules, and in detail, on the flexibility of the A and C rings in the case of 
Cryptotanshinone, and on the possible inversion of the C ring in the case of P5a. Both 
molecules were found to be quite rigid and characterized by planarity. 
 
 
 
 
 
 
 
In Figure 27 are shown the located conformations of Cryptotanshinone and P5a together 
with their corresponding energy values in water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. 3D plots of the located conformations of Cryptotanshinone and P5a together with their 
corresponding energy values in water. 
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In a recent paper,160 the conformational space of the oxadiazole ureido AVS-0288 was 
completely explored. All its degrees of conformational freedom were considered with 
particular attention to the different arrangements of the ureido moiety (trans/trans, TT; 
trans/cis, TC; cis/trans, CT; and cis/cis, CC). In water the TT arrangement resulted largely 
preferred (92.2%). 
On the basis of this data, the possible analogies between the three structures of the selected 
compounds were investigated. In Figure 28a the preferred conformations of the three 
compounds are reported and the related portions are highlighted in green. These conformation 
were superimposed and the corresponding overlay is shown in Figure 28b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. a) Preferred conformations of Cryptotanshinone, P5a and AVS-0288 with the tricyclic moiety 
highlighted in green; b) Overlay of the preferred conformations of Cryptotanshinone (blue), P5a (red), and 
AVS-0288  (yellow) through RMS fitting of the tricyclic moiety. 
AVS-0288-TT2 
b) 
a) 
Cryptotanshinone P5a 
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Looking at the evident similarity between the three compounds, the chimera C2 was designed 
and modeled. Finally, the preferred conformation of C2 was overlapped to the conformation 
TT2 of AVS-0288. As can be seen in Figure 29, there is a nice overlap of the two structures: 
in particular the trifluoromethylphenyl groups occupy the same spatial region, such as the 
amidic groups and the oxadiazole and pyridazinone rings, suggesting a good analogy between 
compounds.  
 
 
 
 
 
 
Figure 29. Overlay of the preferred conformation of 
compound C2 (light blue), and TT2 conformation of AVS-
0288 (yellow) with the distances between the heteroatoms 
of the two molecules shown through dotted line and the 
corresponding values in Å. 
 
 
 
Also the preferred conformation of the chimera C3 was overlapped to the conformation TT2 
of AVS-0288 (Figure 30), highlighting the good analogy between the two molecules. 
 
 
 
 
Figure 30. Overlay of the preferred conformation of compound 
C3 (orange), and TT2 conformation of AVS-0288 (yellow) 
with the distances between the heteroatoms of the two 
molecules shown through dotted line and the corresponding 
values in Å. 
 
 
 
2.12 
1.54 
2.36 
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Finally, the overlap of Cryptotanshinone, P5a and C3 was performed (Figure 31).  
 
 
 
 
 
 
 
 
 
Figure 31. Overlay of the preferred conformations of 
Cryptotanshinone (blue), P5a (red), and C3  (orange) through 
RMS fitting of the tricyclic moiety. 
 
 
 
3.3.3 Chemistry 
 
3.3.3.1 Synthesis of  3-oxo-N-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-
hexahydrobenzo [h]cinnoline-6-carboxamides (C1a, b) and 3-oxo-N-(4-
(trifluoromethyl)phenyl)-2,3,5,6-tetrahydrobenzo[h]cinnoline-6-
carboxamide (C2) 
 
The synthesis of compounds C1a, b and C2 is shown in Scheme 12. The commercially 
available α-phenylglutaric anhydride was cyclised with polyphosphoric acid to obtain the 
racemic compound 25. The carboxylic group of 25 was condensed with 4-
(trifluoromethyl)aniline to obtain the amide 26. This reaction was performed with the 
coupling agent TBTU (O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
tetrafluoroborate) in the presence of N-methylmorpholine (pH = 7) at room temperature for 24 
h. The aldol condensation between compound 26 and glyoxylic acid, followed by 
dehydration, led to the α/β-unsaturated acid 27. The reduction of the double bond of 7, by 
means of zinc in acetic acid gave compound 28 as a mixture of two couples of 
diastereoisomers. After the cyclization of 28 with hydrazine monohydrate in ethanol at reflux 
to obtain C1a-b, the separation of the obtained couple of diasteroisomers was performed by 
means of flash chromatography. Their relative configuration was assigned with the support of 
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Scheme 12. Reagents and conditions: i) PPA, 100/110 °C, 30 min; ii) 4-(trif luoromethyl)aniline, CH2Cl2,
TBTU, N-methylmorpholine up to pH=7, rt, 24 h; iii) CHO-COOH, NaOH, H2O, CH3CH2OH, rt, 1 h; iv) Zn,
CH3COOH, H2O, rt, 20 min; v) NH2NH2 H2O, CH3CH2OH, reflux, 2 h; (f ) sodium 3-nitrobenzenesulfonate,
NaOH, H2O, ref lux, 30 min.
25 26 27
28
NMR studies (NOESY experiment). The introduction of a double bond in the pyridazinone 
ring of compounds C1a and C1b was carried out with sodium 3-nitrobenzenesulfonate in 
alkaline acqueous solution and led to the final racemic compound C2. Only one of the two 
diastereoisomers (C1a) led to compound C2 while the other one C1b didn’t react. This is 
probably due to the fact that the hydrogen atoms of the two stereogenic centers have to be 
located in axial position (S,S or R,R) to allow the dehydrogenation, as shown in Figure 32.  
 
. 
 
 
 
 
Figure 32. Structure of compound C1a 
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3.3.3.2 Synthesis of  1-(6-oxo-3-phenyl-1,6-dihydropyridazin-4yl)-3-(4-
(trifluoromethyl) phenyl)urea (C3) 
 
The general synthetic strategy followed for the preparation of the 5-substituted pyridazinone 
C3 is outlined in Scheme 13. The commercially available starting material 3-benzoyl 
propionic acid underwent a hydroxymethylation with formaldehyde and potassium carbonate 
in water and the subsequent cyclization in acidic conditions led to the β-benzoyl-γ-
butyrolactone 29.183 The treatment of 29 with a large excess of hydrazine hydrate gave 5-
hydroxymethyl-6-phenyl-4,5-dihydro-3(2H)-pyridazinone 30, which was firstly protected at 
the alcoholic function with acetic anhydride and then dehydrogenated to the correspondent 
aromatic derivative 32 with activated manganese dioxide. The removal of the protecting 
group of 32, followed by oxidation of the alcohol with activated manganese dioxide led to 
intermediate 34. This underwent a further oxidation to carboxylic acid 35 by means of silver 
oxide.184 The conversion of 35 into the urea C3 was accomplished in moderate yield (20%) by 
Curtius rearrangement with DPPA in toluene, then followed by addition of 
trifluoromethylphenyl aniline. 
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3.3.4 Pharmacological studies 
 
3.3.4.1 Dual-luciferase assay results 
The chimera compounds C1a,b and C2 were evaluated in the dual-luciferase assay159 system 
as a preliminary screening (see ‘Chapter 3.1.3.2’ for the description of this assay and ‘Chapter 
6’ for the experimental procedure). In Table 11 the inhibitory activities of the tested 
compounds are displayed. The values are reported as percentage of inhibition evaluated at 10 
µM and 50 µM. The inhibitory activity of the tested molecules is compared with the reference 
compounds Cryptotanshinone and AVS-0288.  
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Compound 
% Inhibitiona               
(2 µM) 
10 µM 50 µM 
C1a 7 67 
C1b 14 < 1 
C2 13 82 
Cryptotanshinone 78 85 
AVS-0288 70 75 
a The values are the means of 3 
experiments. The maximum deviation 
from the mean was less than 10%. 
 
 
Table 11. Percentage inhibition of the chimera compounds  (C1a, b and C2) evaluated with the dual-luciferase 
assay system. 
 
According to the obtained data, compound C2 is the most active compound: the results 
indicate that at the concentration of 50 µM it shows equivalent activity to the references. 
Despite the inhibitory values of derivative C1a is lower than C2, it still has an interesting 
inhibitory profile. Both molecules C1a and C2 show a dose-dependent inhibition activity. 
 
3.3.4.2 AlphaScreen-based assay results 
To date only the chimeras C1a, b and C2 have been evaluated in biological assays. In 
particular, they were submitted to the in vitro AlphaScreen-based assay.172 (‘Chapter 3.1.3.4’ 
for the description of this assay and ‘Chapter 6’ for the experimental procedure). In Table 12 
the results are presented as percentages of inhibition of the interaction between STAT3-SH2 
domain and its target pTyr-containing peptide. In particular, besides STAT3, other SH2-
containing proteins, such as STAT1 and Gbr2, having a high degree of sequence homology to 
STAT3 (78% and 65%, respectively), were tested. 
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Compound 
% Inhibition 
(50 µM) 
ST
A
T3
 
ST
A
T1
 
G
rb
2a
 
C1a < 1 9.1 < 1 
C1b < 1 6.8 < 1 
C2 < 1 10.3 < 1 
     
                                                a
 Grb2: Growth factor receptor-bound protein 2 
 
Table 12. % inhibition of STAT3, STAT1 and Grb2 as determined by AlphaScreen  assay by C1a, C1b and C2. 
 
According to these results, all these molecules didn’t antagonize pTyr-SH2 interaction. 
Anyway, a binding of the compounds with different portions of the SH2 domain or with any 
other part of STAT3 protein is still probable.  
 
3.3.5 Future perspectives 
 
Regarding the racemic chimera C2, the separation of the two enantiomers will performed by 
chiral chromatography. Moreover, the synthesis of the chimera C4 will be completed. All the 
synthesized compounds will be submitted to a complete biological study, starting from the 
dual-luciferase assay in order to check their inhibitory properties on STAT3 pathway.  
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3.4 The oxidized compounds 
 
3.4.1 Project description 
 
This section of the project was focused on the natural compound Cryptotanshinone154 with 
the aim to design and the synthesize analogues more directly related to it. Preliminary 
modeling studies, performed by our research group, had suggested the importance of the 
ortho-quinone moiety of Cryptotanshinone in the interaction with STAT3. To support this 
hypothesis,  commercially available compounds (ST1-6, Table 13) were selected on the basis 
of their similarity with Cryptotanshinone, and tested by the AlphaScreen-based assay.172 
This allowed the evaluation of the binding of small molecules to a specific portion of STAT3-
SH2 domain, and the results obtained confirmed the positive influence of the ortho-quinone 
moiety in the interaction with STAT3. According to the data (Table 13), the 1,2-naftoquinone 
was the most active compound among the tested ones; the introduction of bulky substituents 
on this molecule reduced its activity. Moreover, despite the activity of derivatives ST2-ST5 
being lower than ST1, they still had interesting inhibitory values. Only ST6, 
dibenzothiophene sulfone, characterized by a five-membered central core with a sulfone 
moiety, was inactive.  
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Structure Chemical name 
% inhibition 
(50 µM) 
ST
A
T3
 
ST
A
T1
 
G
rb
2a
 
 
1,2-naphtoquinone 81,5 99,0 52,2 
 
phenantrene quinone 54,5 31,6 40,9 
 
β-lapachone 22,6 20,2 17,2 
 
4-butoxy-1,2-
naphtoquinone 
21,8 26,9 28,0 
 
phenylanilino-1,2-
naphtoquinone 
52,5 42,8 48,7 
 
dibenzothiophene 
sulfone -14,0 0,3 -9,4 
a
 Grb2: Growth factor receptor-bound protein 2 
 
Table 13. % inhibition of STAT3, STAT1 and Grb2 of compounds ST1-ST6 as determined by AlphaScreen 
assay. 
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In light of these results, a series of compounds, derived from a simplification of the 
Cryptotanshinone structure, were synthesized, characterised by the presence of only two rings 
and by the ortho-quinone moiety (Figure 33). 
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Figure 33. Designed simplified analogues of Cryptotanshinone. 
 
Among the planned derivatives, compounds O1 and O1a, along with O2, were already known 
in the literature.185 However, upon synthesis product O1 was found to be unstable at room 
temperature,186 whilst O1a could not be isolated, due to its volatility and high reactivity.187 
No such problems arose with the synthesis of O2. Since product O1 is most directly related to 
Cryptotanshinone, molecular docking studies have been performed on product O2 (Chapter 
3.4.3) to predict its potential binding to the STAT3-SH2 domain. 
 
3.4.2 Molecular docking studies 
 
Molecular modeling studies were carried out in order to verify if the synthesized products (R)-
O2, (S)-O2, and the intermediate (R)-41, (S)-41 (as a control) (Figure 34), could interact with 
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STAT3. Molecular docking calculations were performed to evaluate the binding affinity of 
these compounds with the STAT3-SH2 domain and to compare the results to those obtained 
in the previous computational studies. STAT3 structure, co-crystallized with a DNA 
fragment, was downloaded from the Protein Data Bank188 (PDB ID 1BG1189) and was 
dimerized applying the transformation matrix as reported in the PDB file. The model was 
completed adding the hydrogens in two steps: 1) to STAT3, applying the algorithm for 
proteins; 2) to DNA, applying the algorithm for nucleic acids. In both cases, we used the 
features included in the VEGA ZZ package.190 Atom charges (Gasteiger – Marsili method191) 
and potentials (CHARMM 22 for proteins192 and nucleic acids 193) were assigned to the 
obtained structure. Finally, the model was optimized through a conjugate gradients 
minimization (30.000 steps) in order to reduce the high-energy sterical interactions. In order 
to preserve the experimental data, atom constraints were applied to protein and DNA 
backbones. This step was carried out by NAMD 2.8194 integrated in the VEGA ZZ graphic 
environment. In order to perform the molecular docking studies, all considered compounds 
were built by ISIS/Draw and automatically converted to 3D by VEGA ZZ. For chiral 
molecules that in the considered set include only one chiral center, both stereoisomers were 
built and docked as two different chemical entities.  
Finally, a semi-empirical calculation was performed to optimize the structures (Mopac 
2009,195 PM6 PRECISE keywords) which were included in a SQLite database, in order to 
convert them in a suitable file format readable by GriDock, the in-home made structure-based 
virtual screening system. This software, especially designed to run on HPC and GRID 
hardware, is a front-end to the well knownAutoDock 4 package.196 More in detail, GriDock is 
able to extract each molecule from a database and to perform a docking calculation running 
AutoDock 4. Before runningGriDock, the grid maps required to evaluate docking score were 
calculated, selecting the atoms included in a sphere of 12 Å radius centred on the 
phosphorylated Tyr-705 (PTR-705 in the PDB file), which is known to play a pivotal role in 
the STAT3 dimerization and activation. This phase was carried out by AutoGrid 4 interfaced 
to VEGA ZZ. All considered potential STAT3 ligands were docked by GriDock/AutoDock 
using the genetic-algorithm search and generating 20 possible solutions for each molecule. 
Previous computational studies showed that at least two binding pockets are present in the 
SH2 domain: the phosphotyrosine binding site (PTR-pocket) involved in the dimerization 
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process and Cryptotanshinone pocket (CRY-pocket) that is close to the previous one, but isn’t 
directly involved in the protein-protein interaction. For this reason, for each ligand, two poses 
were chosen for each binding site on the basis of the binding energy and the quality of the 
ligand-protein interactions. All complexes were minimized by NAMD (conjugate gradients, 
10.000 steps), keeping the atoms fixed outside from the spheroid defined by a layer of 12Å 
thickness around the ligand. For each optimized complex, some docking scores were 
calculated in order to obtain more reliable and comparable results: non-bond R6-R12Lennard-
Johnes interaction energy calculated by both CHARMM 22 and CVFF197 force fields, 
electrostatic energy calculated by classical Coulomb equation and distance-dependent 
equation in which the distance between two charges is considered as square value, binding 
energy calculated by AutoDock 4, molecular lipophilicity potential interaction scores 
(MLPInS)198 to evaluate the hydrophobic interactions. 
 
3.4.3 Docking results 
 
In order to estimate inhibitory activity, the docking results of the proposed molecules (O2 and 
41) were compared to Cryptotanshinone and F2e (Figure 34), whose STAT3 inhibitory 
activity had previously been evaluated by experimental assays. 
 
 
Figure 34. Structures of Cryptotanshinone and compounds F2e, 3, O2. 
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In previous docking studies (Chapter 3.1.5), F2e was found to bind the PTR-pocket, and thus 
was suitable to analyze the complexes in which this binding site is involved. Since this site 
must interact with the large chain bound to the phosphorylated tyrosine of the second subunit, 
to perform the protein dimerization, its cavity is placed on the surface and it is surrounded by 
hydrophilic and polar amino acids. For this reason, the scores taking into account the 
hydrophobic interactions were discarded because they were unable to describe such kinds of 
interactions. In Table 14, the non-bonding interaction energies are shown. 
 
Compound CHARMM Elect ElectDD AutoDock 
F2d -28,55 -18,69 -10,48 -6,07 
(S)-O2 -22,80 -5,16 -7,31 -5,08 
(R)-O2 -17,77 -42,34 -11,40 -4,20 
(S)-41 -18,51 -12,66 -7,88 -3,65 
(R)-41 -19,90 -2,93 -2,60 -3,23 
 
Table 14. Docking scores obtained considering the PTR-pocket as target. CHARMM is the interaction energy 
calculated by CHARMM force field, Elect and ElectDD are the electrostatic energies calculated by Coulomb 
equation. ElectDD includes the distance-dependent dielectric constant. AutoDock is the interaction energy 
calculated by AutoDock software using a modified version of AMBER force field. The data are sorted by 
increasing AutoDock energy. 
 
 
Classifying the molecules by their different energies, F2e is always ranked first, with the 
exception of the electrostatic interaction energy, but this behaviour can be explained 
considering that these scores do not take into account the discontinued dielectric, which is 
typical of a protein. Sorting the compounds by their AutoDock score, recalculated after the 
final minimization, the score difference between product (S)-O2 and F2e is approximately 1 
kcal/mol, meaning that the former could be less active than the latter. Arranging by 
CHARMM energy, product (S)-O2 always shows a good score. Finally, the CVFF energy 
gives very similar results and thus this data has been omitted in Table 14.  
Figure 35 shows the main interactions between (S)-O2 and PTR-pocket amino acids; the 
ligand is placed in the same small pocket in which pTyr-705 is inserted when two subunits are 
assembled in the dimer. The main interactions involve both the oxygens of carbonyl groups 
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Arg609 
Lys591 
Ser636 
Val637 
Pro639 
Ser613 
Glu612 
1.6 Å 2.4 Å 
and the guanidine group of Arg-609 by two hydrogen bonds, even if the interaction with Lys-
591, which played a pivotal role to bond pTyr-705, is missing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Main interactions between product (S)-O2 and PTR-pocket. 
 
 
Analyzing the docking results related to the CRY-pocket, Cryptotanshinone obtains the best 
score only with the AutoDock interaction energy, whereas, products (S)-O2 and (R)-O2 have 
better scores than Cryptotanshinone (Table 15). 
 
Compound MLPInS MLPInS2 MLPIns3 MLPInSF CHARMM AutoDock 
Cryptotanshinone 5,05 0,89 0,17 1,74 -7,74 -5,42 
(R)-O2 -9,79 -1,22 -0,18 -1,53 -19,92 -4,76 
(S)-O2 -9,04 -1,05 -0,14 -0,95 -17,76 -3,83 
(S)-41 9,64 1,29 0,20 1,70 -18,20 -3,61 
(R)-41 9,02 1,27 0,21 1,70 -19,11 -3,16 
 
Table 15. Docking scores obtained considering the CRY-pocket as a target. MLPIns are the molecular 
lipophilicity potential interaction scores, CHARMM is the interaction energy calculated by CHARMM force 
field, AutoDock is the interaction energy calculated by AutoDock software using modified version of AMBER 
force field. The data are sorted by increasing AutoDock energy. The electrostatic energies are omitted to make 
the table more readable. 
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For this binding site, the MLPInS scores were considered because the pocket was lined by a 
number of hydrophobic amino acids, and these scores could evaluate the hydrophobic 
interactions that the others were unable to do. Sorting these results by MLPInS scores, 
products (S)-O2 and (R)-O2 showed good results. However, a comparison of (R)-O2 and 
Cryptotanshinone found that the ligand poses are not fully overlapped (Figure 36); this 
could be due to the different position of the methyl group on the furane ring (2 instead of 3). 
 
 
Figure 36. Product (R)-41 (green carbons) and Cryptotanshinone (gray carbons) poses in CRY-pocket. 
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3.4.4 Chemistry 
 
3.4.4.1 Synthesis of 3-methylbenzofuran-4,5-dione (O1) 199 
 
The synthesis of 3-methylbenzofuran-4,5-dione (O1) started from the condensation of p-
benzoquinone with N-propenylmorpholine 36, prepared in situ from morpholine and 
propionaldehyde.200 The obtained dihydrobenzofuran 37 underwent firstly an acid hydrolysis 
of its hemiaminal functionality, and then an oxidation on the phenol ring with IBX, to afford 
the final 3-methylbenzofuran-4,5-dione (O1) (Scheme 14). 
 
 
 
3.4.4.2 Synthesis of  (RS)-2,6,7-trimethyl-2,3-dihydrobenzofuran-4,5,-dione 
((R)-O2, (S)-O2) 
 
(RS)-2,6,7-trimethyl-2,3-dihydrobenzofuran-4,5,-dione ((RS)-O2) were obtained starting from 
the commercially available 2,3-dimethylhydroquinone. It was treated with allyl iodide and 
potassium carbonate in acetone to obtain a mixture of 4-(allyloxy)2,3-dimethylphenol 39 (the 
monoallyl ether) and 1,4-bis(allyloxy)-2,3-dimethylbenzene (the diallyl ether), which were 
separated by flash chromatography.  A solution of the monoallyl ether 39 in decalin was 
heated at 220 °C under pressure (using an autoclave), obtaining a 5-allyl-2,3-
dimethylbenzene-1,4-diol 40 via Claysen rearrangement. Intermediate 40 the underwent a 
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cyclization to the dihydrobenzofurane 41, which was finally oxidized with IBX to afford a 
racemic mixture of compound O2. (Scheme 15) 
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Scheme 15. Reagents and conditions: i) allyl iodide, K2CO3, acetone, ref lux; ii) decaline, 200 °C,
autoclave; iii) p -toluensulfonic acid, toluene, MW; iv) IBX, CH2Cl2, rt.
 
 
 
3.4.5 Future perspectives 
 
Due to synthetic problems during the preparation of the designed compounds (Figure 33), 
their synthesis has not been completed to date. Therefore, new synthetic pathways will be 
developed in order to obtain the desired molecules. Moreover, as compound O2 is a racemic 
mixture, a separation of its enantiomers, using chiral chromatography will be performed, and 
these will be submitted for biological testing. 
However, according to the docking results on the synthesized products, the racemic mixture 
of compound O2 turned out to have a potential inhibitory activity on the STAT3 pathway, as 
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it was able to interact with two different portions of the SH2 domain: i) phosphotyrosine 
binding site (PTR-pocket), which is directly involved in dimerization process; ii) 
Cryptotanshinone pocket (CRY-pocket), close to the previous one but not directly involved in 
dimerization. In order to verify the hypotheses pointed out in the docking studies, biological 
assays will be performed on all the synthesized compounds. In particular, they will be tested 
using the in vitro AlphaScreen-based assay to check their ability to inhibit STAT3 
dimerization through the interaction with the STAT3-SH2 domain. 
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4. FINAL REMARKS 
 
In this research project, various classes of derivatives have been investigated in order to 
identify lead compounds to further develop as STAT3 inhibitors. Starting from the structure 
of molecules, known in literature for their ability to inhibit STAT3 activity, several 
derivatives, by the support of molecular modeling and docking studies, were designed and 
synthesized. Three main series of molecules were developed: the oxadiazoles, the 
pyridazinones and the ortho-quinone compounds. Their biological investigation lead to the 
identification of the oxadiazole derivative F2e, which resembled the structure of its parent 
compound AVS-0288 but showed a very different, yet promising, biological profile. F2e was 
found to inhibit STAT3 activity in cancer cells, acting through a direct mechanism: its 
binding to the SH2-domain of STAT3 protein was proven by in vitro binding test. Moreover, 
anti-proliferative assays on a panel of 58 cancer cell lines showed its significant growth 
inhibitory activity. Therefore, F2e presents the suitable features to become a lead compound 
for the future development of new derivatives.  
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5. EXPERIMENTAL SECTION: CHEMISTRY 
 
5.1 Materials and Methods 
 
All the reagents including solvents were purchased from Sigma-Aldrich and were used 
without any further purification. All reactions involving air-sensitive reagents were performed 
under nitrogen atmosphere and anhydrous solvents were used when necessary. The Biotage-
Initiator microwave synthesizer was used. The course of the reaction was monitored by thin 
layer chromatography (TLC) analysis on aluminium-backed Silica Gel 60 plates (0.2 mm, 
Merck) and were visualized under a UV lamp operating at wavelengths of 254 and 365 nm. 
Visualisation was aided by opportune staining reagents. Intermediates and final compounds 
were purified by flash chromatography using Merck Silica Gel 60 (70-230 mesh). Melting 
points were determined in open capillary tubes on a Büchi Melting Point B-540. The purity of 
final compounds were determinated by HPLC analysis and were ≥95%. 1H and 13C NMR 
spectra were recorded at room temperature on a Varian 300 MHz Oxford instrument.  CDCl3, 
CD3OD, acetone-d6 and DMSO-d6 were used as deuterated solvents for all spectra run.  
Chemical shifts are expressed in ppm from tetramethylsilane resonance in the indicated 
solvent (TMS: 0.0 ppm) and coupling constants (J-values) are given in Hertz (Hz). 1H NMR 
data are reported in the following order: ppm, multiplicity (s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; br, broad), and number of protons.  
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5.2 Experimental procedures: the oxadiazoles (F1-F3) 
 
5.2.1 Synthesis of the key intermediates: the 3-amino-1,2,5-
oxadiazole derivatives (1a-e) 
 
3-amino-4-methyl-1,2,5-oxadiazole (1a)163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethyl acetoacetate (5 g, 38.4 mmol) was added at 10 °C to a solution of NaOH (1.75 g, 43.8 
mmol) in water (14.7 mL). The resulting emulsion was stirred for 12 h and NaNO2 (2.9 g, 
41.8 mmol) was added. Then 20% HClO4 (5.3 mL, 85.6 mmol) was slowly added dropwise at 
10 to 15 °C. The reaction mixture was warmed to room temperature and stirred for 14 h. 
Sodium hydroxide (4.9 x 10-2 g, 1.23 mmol) followed by a solution of NH2OH·HCl (8.2 g, 
118.15 mmol) in water (14.7 mL) were added dropwise. After half the solution of 
NH2OH·HCl was added, a solution of NaOH (5.32 g, 132.9 mmol) in water (9.8 mL) was 
simultaneously added dropwise keeping the temperature under 30 °C. Then the mixture was 
heated to 95 °C for 1.5 to 2 h and urea (1.98 g, 33 mmol) was added in one portion. The 
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resulting reaction mixture was refluxed for 3 h and then cooled. The product was extracted 
with dichloromethane (3 x 30 mL). The combined extracts were washed with water (1 x 30 
mL), 5% sodium carbonate (1 x 30 mL), brine (1 x 30 mL) and the dried with anhydrous 
Na2SO4. The solvent was removed 1a (0.76 g, 7.7 mmol) was obtained.  
• White solid 
• Yield: 20% 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.27 
• M.p. 72-73°C 
• 
1H NMR (CDCl3) 2.30 (s, 3H, CH3), 4.10 (br s, 2H, NH2, exchangeable with D2O) 
 
3-amino-1,2,5-oxadiazole-4-carboxylic acid (2)164 
 
 
 
 
 
To a stirred emulsion of ethyl cyanoacetate (5 g, 44.2 mmol) and sodium nitrite (3.1 g, 44.2 
mmol) in a mixture of ethanol (3.1 mL) and water (35.4 mL), 85% H3PO4 (1.8 mL) was 
added dropwise at 25-30 °C. After 1 h, the mixture was cooled to 10 °C, stirred for a further 
12 h and treated with sodium hydroxide (4 x 1.8 g, 176.8 mmol) and potassium hydroxide (2 
x 2.5 g, 88.4 mmol). To the resulting emulsion NH2OH·HCl (12.3 g, 176.8 mmol) was slowly 
added at room temperature. The mixture was heated to 95-100 °C for 2 h and a yellow 
solution was obtained, which was then cooled to room temperature and quenched with 
concentrated HCl to pH = 1. Precipitation occurred on cooling to 0-5 °C for 6 h and the 
precipitate was collected by filtration and dried. The filtrate was extracted with diethyl ether 
(3 x 20 mL) and the combined organic extracts were evaporated under reduced pressure. The 
residue was collected with the previously obtained precipitate. Compound 2 was obtained as a 
white solid (4 g, 30.9 mmol).  
• Yield: 70% 
• TLC (dichloromethane/methanol 8.2)  Rf = 0.33 
• M.p. 214-215 °C  
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• 
1H NMR (DMSO-d6): 6.31 (s, 2H, NH2, exchangeable with D2O) 9.1 (br s, 1H, OH, 
exchangeable with D2O). 13C NMR (DMSO-d6): 140.4 (C-CO2H), 156.8 (C-NH2), 
160.5 (C=O). 
 
Ethyl 3-amino-1,2,5-oxadiazole-4-carboxylate (1b) 
 
 
 
 
Compound 2 (4 g, 30.9 mmol) was suspended in methanol (8 mL) and 96% H2SO4 (1 mL) 
was added dropwise. The obtained solution was refluxed for 2 h. Then, the solvent was 
removed, the residue was diluted with dichloromethane (50 mL) and washed with water (1 x 
20 mL) and 0.1 M NaOH (1 x 20 mL). The organic layer was dried over anhydrous Na2SO4 
and concentrated in vacuo to give a solid which was recrystallized from chloroform (1:9) to 
give ester 1b (4.1 g, 28.7 mmol).  
• White solid 
• Yield: 93%  
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.55 
• M.p. 120-122 °C 
• 
1H NMR (CDCl3) 4.0 (s, 3H, CH3), 5.0 (s, 2H, NH2, exchangeable with D2O). 
 
3-amino-4-hydroxymethyl-1,2,5-oxadiazole (1c) 
 
 
 
 
To a stirred suspension of LiAlH4 (1.60 g, 42 mmol) in dry tetrahydrofurane (5 mL) at 0 °C 
under nitrogen atmosphere, a solution of 1b (1.20 g, 8.4 mmol) in dry tetrahydrofurane (2 
mL) was added dropwise. The suspension was then stirred at room temperature for 2 h. The 
reaction was quenched by slowly adding cold water (3 mL) and basified with acqueous 2 N 
NaOH  (2 mL) to pH = 10-11. The mixture was then filtered and the precipitated aluminium 
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salts washed with ethyl acetate (3 x 3 mL). The filtrate was dried with Na2SO4 and 
concentrated under reduced pressure to afford the expected compound 1c as a thick yellow oil 
which was used without any further purification in the next step.  
• Quantitaitve yield  
• TLC  (petroleum ether/ethyl acetate 1:1) Rf = 0.5 
• 
1H NMR (CD3OD) 4.85 (s, 2H, CH2). 
 
(4-amino-1,2,5-oxadiazole-3-yl)methyl-methyl-carbonate (7) 
 
 
 
 
To a stirred solution of 1c (0.1 g, 0.87 mmol) in tetrahydrofurane (2 mL) and triethylamine 
(0.18 mL, 1.3 mmol) at 0 °C was added methyl chloroformate (0.11 mL, 1.3 mmol) dropwise 
and a yellow solid precipitated. The resulting mixture was stirred at rt for 12 h. The reaction 
was diluted with water (2 mL) and extracted with ethyl acetate (3 × 2 mL). The organic layers 
were collected, dried over Na2SO4, and evaporated under reduced pressure. The residue was 
then purified by flash chromatography (eluent: petroleum ether/ethyl acetate 7:3) to afford the 
compound 7 as a yellow/orange oil (0.141 g, 0.82 mmol). 
• Yield: 94%. 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.3 
• 
1H NMR (CDCl3) 3.80 (s, 3H, OCH3), 4.70 (br s, 2H, NH2), 5.25 (s, 2H, CH2O).  
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3-amino-4-phenyl-1,2,5-oxadiazole (1d)165 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethyl benzoylacetate (5 g, 26 mmol) was added at 0 °C to a solution of NaOH (1.14 g, 28.6 
mmol) in water (13 mL) and the resulting mixture was stirred for 12 h. Sodium nitrite (2.15 g, 
31.2 mmol) was added and then 20% HClO4 (3.7 mL, 59.8 mmol) was slowly added dropwise 
at temperature  < 10 °C. After the addition of the acid was completed, the reaction mixture 
was warmed to room temperature and left for 14 h. Then a solution of NH2OH·HCl (7.23 g, 
104 mmol) in water (13 mL) was added dropwise with vigorous stirring. After half the 
solution of NH2OH·HCl was added, a solution of NaOH (4.68 g, 117 mmol) in water (13 mL) 
was simultaneously added dropwise at a temperature lower than 30 °C. Then the mixture was 
heated to 95 °C for 2 h and urea (1.56 g, 26 mmol) was added in one portion. The resulting 
mixture was refluxed for 3 h and cooled. The white precipitate was filtered off, washed with 
water and dried. The obtained solid was purified by flash chromatography (petroleum 
ether/ethyl acetate 7:3) to afford 1d as a white solid (1.42 g, 8.84 mmol).  
• Yield: 34% 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.45 
• M.p. 99.5-100.5 °C 
• 
1H NMR (CDCl3) 4.20 (br s, 2H, NH2, exchangeable with D2O), 7.55 (m, 3H), 7.75 
(m, 2H).  
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4-chloro benzaldehyde oxime (3)  
 
 
 
 
To 4-chloro benzaldehyde (5 g, 35.6 mmol) in methanol (100 mL) were added NH2OH·HCl 
(3 g, 47.7 mmol) and NaHCO3 (3.6 g, 42.7 mmol). The mixture was refluxed under stirring 
for 2 h, subsequently water (100 mL) was added and the solvent was evaporated under 
vacuum. The aqueous phase was extracted with ethyl acetate (3 x 30 mL), the organic solvent 
dried over Na2SO4 and evaporated under reduced pressure to obtain the oxime intermediate 3 
as a white solid (5.43 g, 34.9 mmol). 
• Yield: 98%  
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.60 
• 
1H NMR (CDCl3) 7.42-7.47 (d, 2H, J= 9.6 Hz, ArH), 7.50-7.56 (d, 2H, J= 9.6 Hz, 
ArH), 8.10 (s, 1H, CH), 10.00 (s, 1H, NH). 
 
4-chloro benzoyl chloride oxime (4) 
 
 
 
 
The intermediate 3 (5.45 g, 35 mmol) and NCS (4.67 g, 35 mmol) were dissolved in 
dimethylformamide (150 mL) and the solution was stirred for 12 h at rt. After addition of 
water (100 mL) to the reaction mixture, the aqueous solution was extracted by ethyl acetate (3 
x 50 mL). The organic phases were collected, dried over Na2SO4 and evaporated under 
vacuum to give a yellow oil of crude hydroxylimino derivative 4 that was directly used 
without further purification in the next reaction. 
• TLC (petroleum ether/ethyl acetate 9:1) Rf = 0.60 
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2-(4-chlorophenyl)-2-(hydroxyimino)acetonitrile (5) 
 
 
 
 
The derivative 4 (6.65 g, 35 mmol) was dissolved in diethyl ether (100 mL) and cooled at 
0°C. A solution of KCN (4.56 g, 70 mmol) dissolved in water (100 mL) was added and the 
reaction mixture was stirred at rt for 5 h, subsequently water (30 mL) was added and the 
aqueous phase was extracted by ethyl acetate (3 x 30 mL). The organic solvent was dried over 
Na2SO4 and evaporated under reduced pressure. The residue was purified by flash 
chromatography (eluent: petroleum ether/ethyl acetate 9:1) to obtain 5 as a light yellow solid 
(5.67 g, 31.5 mmol).  
• Yield: 90% 
• TLC (petroleum ether/ethyl acetate 8:2) Rf = 0.50 
• 
1H NMR (CDCl3) 7.55-7.63 (d, 2H, J= 9.6 Hz, ArH), 7.65-7.73 (d, 2H, J= 9.6 Hz, 
ArH), 8.95 (br s, 1H, OH). 
 
2-(4-chlorophenyl)-N’-hydroxy-2-(hydroxyimino)acetamidine (6) 
 
 
 
 
To the intermediate 5 (5.69 g, 31.5 mmol) in methanol (150 mL) were added NH2OH·HCl 
(3.27 g, 47 mmol) and NaHCO3 (3.95 g, 47 mmol). The mixture was refluxed under stirring 
for 12 h. After addition of  water (100 mL), the solvent was removed under vacuum. The 
aqueous phase was extracted by ethyl acetate (3 x 30 mL), the organic solvent dried over 
Na2SO4 and evaporated under reduced pressure to give the crude acetamidine intermediate 6 
that was directly used without further purification in the next reaction. 
• TLC (petroleum ether/ethyl acetate 6:4) Rf = 0.30 
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4-(4-chlorophenyl)-1,2,5-oxadiazol-3-amine (1e) 
 
 
 
 
The derivative 6 (6.72 g, 31.5 mmol) was dissolved in 2 N NaOH (100 mL) and the solution 
was refluxed under stirring for 12 h. The mixture was cooled to rt and the formed precipitate 
was collected by filtration and washed with water. Compound 1e was obtained as a white 
crystalline solid (2.7 g, 13.8 mmol).  
• Yield: 44% 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.6 
• 
1H NMR (CDCl3) 4.20 (br s, 2H, NH2), 7.50-7.55 (d, 2H, J=9.6 Hz, ArH), 7.62-7.67 
(d, 2H, J=9.6 Hz, ArH). 
 
 
5.2.2 Synthesis of the 4-substituted 1,2,5-oxadiazol-3-yl ureido 
derivatives  (F1a-f)  
 
1-(4-methyl-1,2,5-oxadiazol-3-yl)-3-phenylurea (F1a)  
 
 
 
 
3-amino-4-methyl-1,2,5-oxadiazole 1a (5 x 10-2 g, 0.50 mmol) was solubilized in 
tetrahydrofurane and phenyl isocyanate (8.1 x 10-2 g, 0.68 mmol) was added. The mixture was 
stirred at rt for 24 h. The reaction mixture was evaporated and purified with flash 
chromatography on silica gel eluting with petroleum ether/ethyl acetate 7:3 to give F1a as 
white solid (6.55 x 10-2 g, 0.3 mmol).  
• Yield: 60% 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.3 
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• 
1H NMR (CDCl3) 2.35 (s, 3H, CH3), 7.20-7.60 (m, 5H, ArH), 8.95 (br s, 1H, NH), 
9.40 (br s, 1H, NH). 
 
Synthesis of 1-(4-methyl-1,2,5-oxadiazol-3-yl)-3-benzylurea (F1aa)  
 
 
 
 
3-amino-4-methyl-1,2,5-oxadiazole (1a) (50 mg, 0.50 mmol) was mixed with benzyl 
isocyanate (101 mg, 0.76 mmol) in neat conditions. The mixture was stirred at rt for 2 days. 
The reaction mixture was purified with flash chromatography on silica gel eluting with 
cyclohexane/ethyl acetate/methanol 6:3.8:0.2 to give F1aa (9.4 x 10-2 g, 0.40 mmol). 
• White solid 
• Yield: 80% 
• 
1H NMR (CDCl3) 2.35 (s, 3H, CH3), 4.55 (d, 2H, CH2), 7.20-7.40 (m, 5H, ArH), 7.90 
(br s, 1H, NH), 9.90 (br s, 1H, NH). 
 
General procedure A for the synthesis of the 4-substituted-1,2,5-oxadiazol-3-yl ureido 
derivatives (F1b-f) under microwave irradiation.  
 
To a solution of the appropriate 3-amino-1,2,5-oxadiazole (0.50 mmol) in toluene (1.5 mL), 
the suitable isocyanate (0.60 mmol) was added at rt. The reaction mixture was irradiated in a 
microwave synthesizer at 300 Watts at a temperature of 90 °C for 20 min. Purification 
conditions are specified in the description of each product. 
 
Methyl 4-(3-phenylureido)-1,2,5-oxadiazole-3-carboxylate (F1b) 
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General procedure A was followed to prepare the final compound F1b from intermediate 1b. 
Purification by flash chromatography (petroleum ether/ethyl acetate  8:2) gave F1b as a white 
solid. 
• Yield: 60%  
• TLC (petroleum ether/ethyl acetate 1:1) Rf = 0.4 
• M.p. 200-201 °C  
• 
1H NMR (CDCl3) 4.0 (s, 3H,OCH3), 6.45 (s, 2H, NH), 7.30-7.40 (m, 5H, ArH). 
 
(4-(3-benzylureido)-1,2,5-oxadiazol-3-yl)methyl methyl carbonate (8)166 
 
 
 
 
General procedure A was followed to prepare the final compound 8 from intermediate 7. 
After the cooling of the vial, a white jelly-like solid began to precipitate. The solid 8 was 
filtrated and washed with toluene. 
• Yield: 35% 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.3 
• 
1H NMR (CDCl3) 3.80 (s, 3H, OCH3), 5.40 (d, 2H, CH2O), 7.20 (d, 2H, ArH), 7.40 
(t, 2H, ArH), 7.60 (t, 2H, ArH), 8.60 (s, 1H, NH), 9.20 (s, 1H, NH). 
 
(4-(3-phenylureido)-1,2,5-oxadiazol-3-yl)methyl methyl carbonate (9)166 
 
 
 
 
General procedure A was followed to prepare the final compound 9 from intermediate 7. 
After the cooling of the vial, a white jelly-like solid began to precipitate. The solid 9 was 
filtrated and washed with toluene. 
• Yield: 31% 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.3 
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• 
1H NMR (CDCl3)  3.80 (s, 3H, OCH3), 5.40 (d, 2H, CH2O), 7.20 (d, 2H, ArH), 
7.40 (t, 2H, ArH), 7.60 (t, 2H, ArH), 8.60 (s, 1H, NH), 9.20 (s, 1H, NH). 
 
Synthesis of 1-phenyl-3-3(4-phenyl-1,2,5-oxadiazol-3-yl)urea (F1d) 
 
 
 
 
 
General procedure A was followed to prepare the final compound F1d from intermediate 1d. 
Purification by flash chromatography (eluent: dichloromethane/petroleum ether/ethyl acetate  
7:2.5:0.5) gave F1d as a white solid. 
• Yield: 86%  
• M.p. 151-152 °C 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.3 
• 
1H NMR (CDCl3) 6.85 (br s, 1H, NH), 7.20-7.60 (m, 10H, ArH), 9.35 (br s, 1H, NH). 
 
1-benzyl-3-(4-phenyl-1,2,5-oxadiazol-3-yl)urea (F1dd) 
 
 
 
 
 
General procedure A was followed to prepare the final compound F1dd from intermediate 1d. 
Purification by flash chromatography (eluent: petroleum ether/ethyl acetate  7.5:2.5) gave 
F1dd as a yellowish solid. 
• Yield: 20%  
• M.p. 154-155 °C  
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.3 
• 
1H NMR (CDCl3) 4.55 (d, 2H, CH2), 7.10 (br s, 1H, NH), 7.25-7.65 (10H, m, ArH), 
7.75 (br s, 1H, NH). 
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Synthesis of 1-phenyl-3-3(4-phenyl-1,2,5-oxadiazol-3-yl)urea (F1ddd) 
 
 
 
 
 
General procedure A was followed to prepare the final compound F1d from intermediate 1d. 
Purification by flash chromatography (eluent: dichloromethane/petroleum ether/ethyl acetate  
7:2.5:0.5) gave F1ddd as a white solid. 
• Yield: 70%  
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.35 
• 
1H NMR (CDCl3) 6.85 (br s, 1H, NH), 7.30-7.70 (m, 9H, ArH), 9.35 (br s, 1H, NH). 
 
General procedure B for the deprotection of the carbonate protecting group to obtain 
the products F1c and F1cc.166  
 
The appropriate carbonate (0.21 mmol) was dissolved in 1% solution of K2CO3 in methanol 
(2 mL) and the resulting solution was stirred at reflux for 2 h. After completion of the 
reaction, methanol was removed in vacuo. The residue was diluted with ethyl acetate (3 mL) 
and washed with water (2 x 1 mL). The organic phase was dried with Na2SO4 and evaporated 
to obtain the final alcohol. 
 
1-(4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl)-3-phenylurea (F1c) 
 
 
 
 
General procedure B was followed to prepare the final compound F1c (white solid) from 
intermediate 8.  
• Quantitative yield.  
• TLC (petroleum ether/ethyl acetate 6:4) Rf = 0.3 
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• 
1H NMR (CD3OD) 4.85 (d, 2H, CH2), 7.10 (d, 1H, ArH), 7.30 (t, 2H, ArH), 7.50 (t, 
2H, ArH). 
 
1-(4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl)-3-benzylurea (F1cc) 
 
 
 
 
 
General procedure B was followed to prepare the final compound F1cc (white solid) from 
intermediate 9.  
• Quantitative yield.  
• M.p. 159.3-162 °C  
• TLC (petroleum ether/ethyl acetate 6:4) Rf = 0.3 
• 
1H NMR (CDCl3) 4.55 (d, 2H, CH2), 4.80 (s, 2H, CH2), 7.25-7.40 (m, 5H, ArH), 8.10 
(s, 1H, NH), 10.30 (s, 1H, NH). 
 
General procedure C for the synthesis of the cyclic hemiaminals 10 and 11166  
 
To an ice-cold solution of the suitable alcohol (0.20 mmol) in dry dichloromethane
 
(1.5 
mL), Dess-Martin Periodinane (0.31 mmol) was added in one portion. The reaction was 
stirred at 0 °C for 30 min and then at rt for 24 h. The reaction was quenched at 0 °C by 
stirring with a saturated aqueous solutions of Na2S2O3 (1 mL) and of NaHCO3 (1 mL) for 
10 min, to destroy any unreacted Dess-Martin reagent. The organic phase was then 
separated, dried over Na2SO4 and concentrated in vacuo. The crude product was purified 
by flash chromatography (eluent: petroleum ether/ethyl acetate 6:4) to give the cyclic 
hemiaminal. 
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6-phenyl-7-hydroxy-6,7-dihydro-[1,2,5]oxadiazol-[3,4-d]-pyrimidin-5(4H)-one (10)  
 
General procedure C was followed to prepare the final compound 10 (light yellow solid) from 
intermediate F1c.  
• Yield: 80% 
• TLC (petroleum ether/ethyl acetate 1:1) Rf = 0.7 
• M.p. 182-184 °C 
• 
1H NMR (CDCl3) 6.35 (d, 1H, CH), 7.30-7.50 (m, 5H, ArH), 7.55 (d, 1H, OH), 
11.40 (s, 1H, NH). 
 
6-benzyl-7-hydroxy-6,7-dihydro-[1,2,5]oxadiazol-[3,4-d]-pyrimidin-5(4H)-one (11).  
 
General procedure C was followed to prepare the final compound 11 (light yellow solid) from 
intermediate F1cc. 
• Yield 85%  
• TLC (petroleum ether/ethyl acetate 1:1) Rf = 0.7 
• M.p. 194-196 °C 
• 
1H NMR (DMSO-d6) 4.40 (d, 1H, J=15 Hz, CH2), 4.90 (d, 1H, J=15 Hz, CH2), 6.10 
(d, 1H, J=9 Hz, CH, collapses to a singlet on D2O exchange), 7.20-7.30 (m, 5H, 
ArH), 7.40 (d, 1H, J=9 Hz, -OH, exchangeable with D2O), 11.3 (s, 1H, -NH-, 
exchangeable with D2O); 13C NMR (DMSO-d6) 40.80 (CH2), 70.35 (CH-OH), 
120.80 (CHaro), 120.85 (2 x CHaro), 120.90 (2 x CHaro), 130.80 (Cq), 140.40 
(CHqaro), 150.05 (Cq), 150.10 (C=O). 
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General procedure D for the synthesis of the styryl derivatives (E/Z-F1g and E/Z-
F1gg)166 
 
A mixture of the required cyclic hemiaminal (0.20 mmol), benzyltriphenylphosphonium 
chloride (0.23 mmol), K2CO3 (0.43 mmol), 18-crown-6 (catalytic quantity), and 
tetrahudrofurane (2 mL) as a solvent was stirred at reflux for 1 h. The solvent was 
evaporated in vacuo, the residue was treated with brine and extracted with ethyl acetate (3 
x 1 mL). The organic layer was dried over Na2SO4 and evaporated in vacuo. The products 
were purified by flash chromatography (eluent: petroleum ether/ethyl acetate 7:3).  
 
1-phenyl-3-(4-styryl-1,2,5-oxadiazol-3-yl)urea (E,Z-F1g)  
  
 
 
 
 
General procedure D was followed to prepare the final compound E,Z-F1g from intermediate 
10.  
Derivative E-F1g (yellow solid) 
• Yield: 55% 
• TLC (cyclohexane/ethyl acetate 6:4) Rf = 0.7 
• M.p. 201-203 °C  
• 
1H NMR (CDCl3) 7.03 (d, 1H, J= 15.1 Hz, CH), 7.10-7.57 (m, 10H, ArH), 7.61 (d, 
1H, J= 15.1 Hz, CH), 8.70 (br s, 1H, NH), 9.45 (br s, 1H, NH); 
Derivative Z-F1g (yellow solid)  
• Yield: 25% 
• TLC (cyclohexane/ethyl acetate 6:4) Rf = 0.5 
• M.p. 173-175 °C   
• 
1H NMR (CDCl3) 6.51 (d, 1H, J= 12.1 Hz, CH), 7.03 (br s, 1H, NH), 7.19 (d, 1H, 
J= 12.1 Hz, CH), 7.10-7.50 (m, 10H, ArH), 9.17 (br s, 1H, NH). 
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1-benzyl-3-(4-styryl-1,2,5-oxadiazol-3-yl)urea (E,Z-F1gg).  
 
General procedure D was followed to prepare the final compound E,Z-F1gg from 
intermediate 11.  
Derivative E-F1gg (pale yellow solid)  
• Yield: 50%  
• TLC (cyclohexane/ethyl acetate 6:4) Rf = 0.7 
• M.p. 192-194 °C  
• 
1H NMR (CDCl3) 4.59 (d, 2H, J=5.7 Hz, CH2), 7.20 (d, 1H, J= 15.5 Hz, CH), 7.20-
7.67 (m, 10H, ArH), 7.60 (d, 1H, J= 15.5 Hz, CH), 7.98 (t, 1H, J=5.7 Hz, NH), 
9.96 (br s, 1H, NH); 
Derivative Z-F1gg (yellow solid)  
• Yield: 19%  
• TLC (cyclohexane/ethyl acetate 6:4) Rf = 0.5 
• M.p. 170-172 °C  
• 
1H NMR (CDCl3) 4.48 (d, 2H, J=5.7 Hz, CH2), 6.44 (d, 1H, J= 12.2 Hz, CH), 7.11 
(d, 1H, J= 12.2 Hz, CH), 7.20-7.40 (m, 10H, ArH), 7.58 (t, 1H, J=5.7 Hz, NH), 
9.60 (s, 1H, NH).  
 
5.2.3 Synthesis of the 4-substituted 1,2,5-oxadiazol-3-yl amido 
derivatives   (F2a-e)  
 
Method 1 (F2a, c). To a solution of the suitable amine 1a, c (0.51 mmol) in dry 
tetrahydrofurane (2 mL) cooled at 0 °C, phenyl acetyl chloride (0.070 mL, 0.53 mmol) in dry 
tetrahydrofurane (0.5 mL) was added dropwise. NaHCO3 (0.53 mmol) was then added and the 
resulting mixture was stirred at room temperature for 3 h. The reaction was monitored by 
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TLC until completion, then quenched with distilled water (2 mL) and extracted with ethyl 
acetate (3 × 1 mL). The combined organic layers were dried with Na2SO4, filtrated and 
concentrated under vacuum.  
 
Method 2 (F2d, e). A solution of the suitable amine 1d, e (0.31 mmol) in dry toluene (0.6 
mL) and diethyl ether (0.2 mL) was cooled to 0 °C with an ice/water bath and treated with 
pyridine (0.03 mL). Phenyl acetyl chloride (0.05 mL, 0.33 mmol) was then added dropwise. 
The mixture was stirred for 30 min at 0 °C and then for 5 h at rt. The solvent was removed 
under vacuum and the crude product was purified by flash chromatography.  
 
N-(4-methyl-1,2,5-oxadiazol-3-yl)-2-phenylacetamide (F2a) 
 
 
 
 
Method 1 was followed for the synthesis of F2a starting from 1a. Purification with flash 
chromatography (eluent: petroleum ether/ethyl acetate  8:2) was performed as to obtain F2a 
as a white solid. 
• Yield: 90% 
• TLC (petroleum ether/ethyl acetate  8:2) Rf = 0.35 
• M.p. 135.7-137 °C 
• 
1H NMR (CDCl3) 2.40 (s, 3H, CH3), 3.80 (s, 2H, CH2), 7.30-7.50 (m, 5H, ArH), 8.50 
(br s, 1H, NH). 
 
4-(2-phenylacetamido)-1,2,5-oxadiazole-3-methylcarboxylate (F2b) 
 
 
 
 
To a solution of 1b (5 x 10-2 g, 0.35 mmol) in dichloromethane (1 mL), phenyl acetyl chloride 
(0.049 mL, 0.42 mmol) and EDAC (8.05 x 10-2 mg, 0.42 mmol) were added. The solution 
 Chapter 5 – EXPERIMENTAL SECTION: CHEMISTRY 
122 
 
was brought to pH 7 with 2 drops of N-methylmorfoline and stirred for 24 h at rt. Then 
solvent was removed under vacuum, the residue diluted with dichloromethane
 
(4 mL) and  
washed respectively with: 1N HCl (3 × 1 mL), saturated solution of NaHCO3 (3 × 1 mL), 
water (2 × 1 mL) and brine (2 × 1 mL). The solvent was dried with Na2SO4 and evaporated. 
The crude product was purified by flash chromatography (eluent: petroleum ether/ethyl 
acetate  8:2) to obtain the white solid F2b (6 x 10-2 mg, 0.23 mmol).  
• Yield: 66%  
• TLC (petroleum ether/ethyl acetate  8:2) Rf = 0.4 
• M.p. 98-99°C 
• 
1H NMR (CDCl3) 3.90 (2 H, s, CH2), 3.95 (3 H, s, OCH3), 7.35-7.50 (5 H, m, ArH), 
8.80 (1 H, br s, NH). 
 
N-(4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl)-2-phenylacetiamide (F2c) 
 
 
 
 
Method 1 was followed for the synthesis of F2c starting from 1c. Purification with flash 
chromatography (eluent: petroleum ether/ethyl acetate  7.5:3.5) was performed as to obtain 
F2c as a white solid.  
• Yield: 22%  
• TLC (petroleum ether/ethyl acetate  7.5:3.5) Rf = 0.35 
• M.p. 133-134°C 
• 
1H NMR (CDCl3) 3.20 (1 H, br s, NH), 3.85 (2 H, s, CH2), 4.80 (2 H, s, OCH2), 7.30-
7.50 (5 H, m, ArH), 8.10 (1 H, br s, OH). 
 
2-phenyl-N-(4-phenyl-1,2,5-oxadiazol-3-yl)acetamide (F2d) 
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Method 2 was followed for the synthesis of F2d starting from 1d. Purification with flash 
chromatography (eluent: petroleum ether/ethyl acetate  9:1) was performed as to obtain F2d 
as a white solid.  
• Yield: 58% 
• TLC (petroleum ether/ethyl acetate  9:1) Rf = 0.4 
• M.p. 97-98.5°C  
• 
1H NMR (CDCl3) 1.55 (1 H, br s, NH), 3.85 (2 H, s, CH2), 7.30-7.50 (10 H, m, ArH). 
 
N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl)benzamide (F2e) 
 
 
 
 
 
Method 2 was followed for the synthesis of F2e starting from 1e. Purification with flash 
chromatography (eluent: petroleum ether/ethyl acetate  9:1) was performed as to obtain F2e as 
a white solid.  
• Yield: 50%  
• TLC (petroleum ether/ethyl acetate  9:1) Rf = 0.4 
• M.p. 111-114°C  
• 
1H NMR (acetone-d6) 7.54-7.59 (d, 2H, ArH), 7.85-7.89 (m, 2H, ArH), 7.93 (d, 2H, 
J=8.1 Hz, ArH), 8.25 (d, 2H, J=8.1 Hz, ArH)  
• 
13C NMR (acetone-d6) 124.9, 125.9, 126.0, 128.3, 128.51, 133.5, 133.9, 136.4, 136.5, 
150.04, 151.0, 165.4 
• Cell proliferation assay: see Appendix I 
 
5.2.4 Synthesis of the 4-substituted 1,2,5-oxadiazol-3-yl sulfonamido 
derivatives (F3a-e)  
 
General procedure E for the synthesis of the 4-substituted 1,2,5-oxadiazol-3yl 
sulfonamido derivatives (F3a-e). To a solution of the corresponding 3-amino-1,2,5-
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oxadiazole (0.50 mmol) in pyridine (2 mL), the suitable benzyl sulfonyl chloride (1 mmol) 
was added portionwise at rt. The reaction mixture was monitored by TLC until completion, 
then evaporated to dryness and the residue treated with 2 N HCl (6 mL) until pH = 1. The 
resulting mixture was stirred at rt for 1 h, the precipitated filtered and washed with 2 N HCl 
and dried. 
 
N-(4-methyl-1,2,5-oxadiazol-3-yl)-1-phenylmethanesulfonamide (F3a) 
 
 
 
 
General procedure E was followed to prepare compound F3a starting from 1a. Purification by 
flash chromatography (eluent: dichloromethane/methanol 9.5:0.5) was performed to obtain 
compound F3a as a brown solid.  
• Yield: 40%  
• TLC (dichloromethane/methanol 9.5:0.5) Rf = 0.3 
• M.p. 168-169.2 °C  
• 
1H NMR (CD3OD3) 2.25 (s, 3H, CH3), 4.65 (s, 2H, CH2), 7.35-7.45 (m, 5H, ArH). 
 
4-(phenylmethylsulfonamido)-1.2.5-oxadiazole-3-methylcarboxylate (F3b) 
 
 
 
 
General procedure E was followed to prepare compound F3b starting from 1b. Purification by 
flash chromatography (eluent: dichloromethane/methanol 9.5:0.5) was performed to obtain 
compound F3b as a brown solid.  
• Yield 50% 
• TLC (dichloromethane/methanol 9.5:0.5) Rf = 0.3  
• M.p. 121-122.5 °C 
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• 
1H NMR (CDCl3) 1.60 (br s, 1H, NH), 4.00 (s, 3H, OCH3), 4.70 (s, 2H, CH2), 7.35-
7.45 (m, 5H, ArH). 
 
(4-phenylmethylsulfonamido-1,2,5-oxadiazole-3-yl)methyl-methyl-carbonate (12) 
 
 
 
 
General procedure E was followed to prepare compound 12 starting from 7. Purification by 
flash chromatography (eluent: dichloromethane/methanol 9.5:0.5) was performed to obtain 
compound 12 as a dark green solid. 
• Yield: 50%  
• TLC (dichloromethane/methanol 9.5:0.5) Rf = 0.35 
• 
1H NMR (CDCl3) 3.70 (s, 3H, CH3), 4.50 (s, 2H, CH2), 5.15 (s, 2H, CH2O), 7.20-7.40 
(m, 5H, ArH).  
 
N-(4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl)-1-phenylmethylsulfonamido (F3c) 
 
 
 
 
General Procedure B was followed for the synthesis of F3c from 12 as a brown solid.  
• Quantitative yield. 
• TLC (dichloromethane/methanol 9:1) Rf = 0.4 
• M.p. 130-132 °C  
• 
1H NMR (CDCl3) 3.65 (br s, 1H, OH), 4.00 (br s, 1H, NH), 4.45 (s, 2H, CH2), 4.55 (s, 
2H, CH2OH), 7.20-7.30 (m, 5H, ArH). 
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N-(4-phenyl-1,2,5-oxadiazol-3-yl)-1-phenylmethanesulfonamide (F3d) 
 
 
 
 
General procedure E was followed to prepare compound F3d starting from 1d. Purification by 
flash chromatography (eluent: dichloromethane/methanol 9.5:0.5) was performed to obtain 
compound F3d as a brown solid.  
• Yield: 59%  
• TLC (dichloromethane/methanol 9.5:0.5) Rf = 0.35  
• M.p. 121-123 °C 
• 
1H NMR (CDCl3) 4.75 (s, 2H, CH2), 7.25 (br s, 1H, NH), 7.30-7.65 (m, 10H, ArH). 
 
N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl)benzenesulfonamide 
(F3e) 
 
 
 
 
General procedure E was followed to prepare compound F3e starting from 1e. Purification by 
flash chromatography (eluent: dichloromethane/methanol 9.5:0.5) was performed to obtain 
compound F3e as a dark green solid. 
• Yield: 20%  
• TLC (dichloromethane/methanol 9.5:0.5) Rf = 0.3  
• M.p. 129-130.4 °C  
• 
1H NMR (CDCl3) 7.15 (br s, 1H, NH), 7.35 (d, 2H, ArH), 7.55 (d, 2H, ArH), 7.75 (d, 
2H, ArH), 7.95 (d, 2H, ArH). 
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5.3 Experimental procedures: the pyridazinone derivatives 
 
5.3.1 Synthesis of the six-membered ring compounds (P1-18) 
 
General procedure F for the synthesis of 1-oxo-3,4-dihydronaphthalene-2(1H)-ylidene) 
acetic acids (13a-c) 
To a mixture of the appropriate tetralones (20.5 mmol) and glyoxylic acid (6.08 g, 82.1 
mmol) in 29 mL of water, a solution of NaOH (102 mmol) in water (49 mL) and of ethanol 
(25 mL) was added dropwise at a temperature between 10 ˚C and 15 ˚C. The solution was 
stirred at room temperature for 1 h and then refluxed for 3 h. The solution was cooled to room 
temperature and acidified with 6 N HCl until pH = 2. The precipitated solid was filtered, 
washed with water and dried to give the final unsaturated acids which were used in the next 
reaction without further purification.  
 
1-oxo-3,4-dihydronaphthalene-2(1H)-ylidene) acetic acid (13a) 
 
General procedure F was followed for the synthesis of 13a from α-tetralone. 
• White solid 
• Yield: 55% 
• TLC (dichloromethane/methanol 8:2)  Rf
 
= 0.3 
• 
1H NMR (CDCl3) 2.95 (t, 2H, CH2), 3.09 (t, 2H, CH2), 6.39 (s, 1H, CH=C), 7.46-7.73 
(m, 4H, ArH), 11  (br s, 1H, COOH) 
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5,7-dimethoxy-1-oxo-3,4-dihydronaphthalene-2(1H)-ylidene) acetic acid (13b) 
 
General procedure F was followed for the synthesis of 13b from 5,7-dimethoxy tetralone. 
• Bright yellow solid 
• Yield: 70% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.3 
• 
1H NMR (CDCl3) 2.90 (t, 2H, J=5.4 Hz, CH2), 3.40 (t, 2H, J=5.4 Hz, CH2), 3.85 (s, 
1H, CH3), 3.87 (s, 1H, CH3), 6.65 (s, 1H, CH=C), 6.85 (s, 1H, ArH), 7.20 (s, 1H, ArH) 
 
6-chloro-1-oxo-3,4-dihydronaphthalene-2(1H)-ylidene) acetic acid (13c) 
 
General procedure F was followed for the synthesis of 13a from 6-chloro-tetralone. 
• Yellow oil 
• Yield: 73% 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.4 
• 
1H NMR (CDCl3) 3.0 (t, 2H, J=5.4 Hz, CH2), 3.45 (t, 2H, J=5.4 Hz, CH2), 6.90 (s, 1H, 
CH=C), 7.30 (s, 1H, ArH), 7.35 (d, 2H, J=10.7 Hz, ArH), 8.05 (d, 1H, J=10.7 Hz, 
ArH) 
 
General procedure G for the synthesis of 2-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-
yl)acetic acids (14a-c) 
The suitable unsaturated acid (11.4 mmol) was solubilized in a mixture of  39 mL of acetic 
acid and 14 mL of water. Zinc dust (0.85 g, 13 mmol) was then added and the suspension was 
stirred at reflux for 40 min. The suspension was then filtered to remove the zinc dust and 
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extracted with ethyl acetate (3 x 10 mL). The organic layer was dried over anhydrous sodium 
sulfate and evaporated under reduced pressure. The final saturated acid was used in the 
following reaction without further purification. 
 
2-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acids (14a) 
 
General procedure G was followed for the synthesis of 14a from 13a. 
• Red solid 
• Quantitative yield  
• TLC (dichloromethane/methanol 9:1)  Rf = 0.4 
• 
1H NMR (CD3OD) 1.91-2.60 (m, 1H, CH), 2.21-2.30 (m, 1H, CH), 2.42-2.52 (m, 1H, 
CH), 2.82-2.92 (m, 1H, CH), 2.94-3.05 (m, 1H, CH), 3.08-3.20 (m, 1H, CH), 3.44-
3.53 (m, 1H, CH) 7.25-8.0 (m, 4H, ArH) 
 
5,7-dimethoxy-2-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acids (14b) 
 
General procedure G was followed for the synthesis of 14b from 13b.  
• Red solid 
• Quantitative yield 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.6 
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6-chloro-2-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acids (14c) 
 
General procedure G was followed for the synthesis of 14c from 13c. 
• Yellow/orange solid 
• Quantitative yield  
• TLC (dichloromethane/methanol 9:1)  Rf = 0.7 
• 
1H NMR (CDCl3) 1.90-2.10 (m, 1H, CH), 2.20-2.30 (m, 1H, CH), 2.40-2.60 (m, 1H, 
CH), 2.80-3.10 (m, 4H, CH2), 7.25 (m, 2H, ArH), 7.95 (d, 1H, ArH) 
 
General procedure H for the synthesis of 4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-
ones (P1a-c) 
The suitable acid (11.26 mmol) was dissolved in ethanol (3 mL) and hydrazine monohydrate 
was added (13.6 mmol). The solution was stirred at reflux for 3 h. The final 
benzocinnolinones precipitated in the reaction mixture. They were filtered, washed with 
ethanol and dried. 
 
4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one (P1a) 
N
H
N O
O COOH
14a P1a
 
General procedure H was followed for the synthesis of P1a from 14a. 
• Light yellow solid 
• Yield: 81% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.5 
• M.p. 200 ˚C 95 
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• 
1H NMR (CD3OD) 1.41 (m, 1H, CH), 1.7-1.5 (m, 2H, CH2), 2.3-2.1 (m, 2H, CH2), 
2.85-2.75 (t, 2H, CH2), 7.0 (br s, 1H, NH), 7.30-7.78 (m, 4H, ArH) 
• Cell proliferation assay (Appendix III) 
 
5,7-dimethoxy-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one (P1b) 
 
General procedure H was followed for the synthesis of P1b from 14b. 
• Grey solid 
• Yield: 72% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.7 
• 
1H NMR (CDCl3) 2.10-2.45 (m, 2H, CH), 2.65-2.85 (m, 2H, CH2), 3.10-3.20 (m, 2H, 
CH2), 3.85 (s, 3H, CH3), 3.87 (s, 3H, CH3), 6.45 (s, 1H, ArH), 7.20 (s, 1H, ArH), 8.45 
(br s, 1H, NH) 
 
6-chloro-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one (P1c) 
 
General procedure H was followed for the synthesis of P1c from 14c. 
• Light brown solid 
• Yield: 60% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.5 
• 
1H NMR (CDCl3) 1.60 (m, 1H, CH), 2.20-2.35 (m, 2H, CH2), 2.60-2.75 (m, 2H, CH2), 
2.80-2.95 (m, 2H, CH2), 7.20 (m, 2H, ArH), 7.95-8.05 (m, 1H, ArH), 8.45 (br s, 1H, 
NH) 
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5,6-dihydrobenzo[h]cinnolin-3(2H)-one (P2a) 
 
 
 
 
 
A mixture of compound P1a (0.1 g, 0.50 mmol), sodium m-nitro-benzenesulfonate (0.112 g, 
0.50 mmol), NaOH (8 x 10-2 g, 2 mmol) in water (2 mL) was refluxed for 30 min. After 
cooling, compound P2a was extracted with ethyl acetate (3 x 1 mL). The organic layer was 
dried over anhydrous Na2SO4, filtered and the solvent was evaporated under reduced pressure. 
The obtained residue was purified by flash chromatography (eluent: 
dichloromethane/methanol 9.7:0.3). 
• Yellow solid 
• Yield: 90% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.4 
• 
1H NMR (CDCl3) 2.90 (m, 4H, CH2), 6.80 (s, 1H, CH), 7.20-7.40 (m, 3H, ArH), 8.0-
8.10 (m, 1H, ArH), 10.45 (br s, 1H, NH) 
 
General procedure I for the synthesis of ethyl 2-(3-oxo-4,4a,5,6-tetrahydrobenzo[h] 
cinnolin-2(3H)-yl)esters (P3-8a, P5b,  P5c) and of ethyl-7,9-dimethoxy-2-(3-oxo-5,6-
dihydrobenzo[h] cinnolin-2(3H)-yl)butanoate (P15b) 
To a solution of the required benzocinnolinone derivative (0.25 mmol) in dry 
dimethylformamide (2 mL), NaH (7.2 x 10-3 g, 0.3 mmol) and the Br(CH2)nCOOCH2CH3 (0.3 
mmol) were added. The mixture was stirred at 70 ˚C for 15 h. It was then evaporated under 
reduced pressure to remove the solvent and extracted with ethyl acetate (3 x 2 mL). The 
organic layers were collected, dried over Na2SO4, and evaporated under reduced pressure. 
Upon purification by flash chromatography thick oils of the final products were obtained. 
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Ethyl 2-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)acetate (P3a) 
 
General procedure I was followed for the synthesis of P3a from P1a. 
• Light yellow oil 
• Yield: 71% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.6 
• 
1H NMR (CDCl3) 1.29 (t, 3H, CH3), 1.41 (dq, 1H, CH), 1.7-1.5 (dd, 2H, CH2), 2.3-2.1 
(dd, 2H, CH2), 2.85-2.75 (dd, 2H, CH2), 4.13 (q, 2H, CH2), 4.16 (d, 2H, CH2), 7.30-
7.78 (m, 4H, ArH) 
 
Ethyl 3-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)propanoate (P4a) 
 
General procedure I was followed for the synthesis of P4a from P1a. 
• Light yellow oil 
• Yield: 61% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.75 
• 
1H NMR (CDCl3) 1.29 (t, 3H,CH3), 1.41 (dq, 1H, CH), 1.7-1.5 (dd, 2H, CH2), 2.3-2.1 
(dd, 2H, CH2), 2.65 (d, 2H, CH2), 2.85-2.75 (d, 2H, CH2), 3.59 (dd, 2H, CH2), 4.13 
(dq, 2H, CH2), 7.30-7.78 (m, 4H, ArH) 
• Cell proliferation assay (Appendix III) 
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Ethyl 4-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)butanoate (P5a) 
 
General procedure I was followed for the synthesis of P5a from P1a. 
• Light yellow oil 
• Yield: 60% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.73 
• 
1H NMR (CDCl3) 1.29 (t, 3H,CH3), 1.41 (dq, 1H, CH), 1.7-1.5 (dd, 2H, CH2), 2.04 (d, 
2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.47 (d, 2H,CH2), 2.85-2.75 (dd, 2H, CH2), 3.20 (q, 
2H, CH2), 4.13 (dq, 2H, CH2), 7.30-7.78 (m, 4H, ArH) 
• Cell proliferation assay (Appendix III) 
 
Ethyl-7,9-dimethoxy-4-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)butanoate 
(P5b) and ethyl-7,9-dimethoxy-2-(3-oxo-5,6-dihydrobenzo[h]cinnolin-2(3H)-yl)butanoate 
(P15b) 
 
General procedure I was followed for the synthesis of P5b and P15b from P1b. 
Compound P5b: 
• Yellow solid 
• Yield: 56% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.7 
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• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 1.45 (m, 1H, CH), 2.0-2.40 (m, 6H, CH2), 2.60-
2.80 (m, 2H, CH2), 3.15 (m, 2H, CH2), 3.81 (s, 3H, CH3), 3.85 (s, 3H, CH3), 3.95 (m, 
2H, CH2), 4.15 (q, 2H, CH2), 6.45 (s, 1H, ArH), 7.25 (s, 1H, ArH) 
Compound P15b: 
• Yellow solid 
• Yield: 20% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.6 
• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 2.20-2.25 (m, 2H, CH2), 2.35-2.45 (m, 2H, CH2), 
2.75-2.85 (m, 4H, CH2), 3.85 (s, 3H, CH3), 3.89 (s, 3H, CH3), 4.15 (q, 2H, CH2), 4.30 
(t, 2H, CH2), 6.50 (s, 1H, ArH), 6.80 (s, 1H, CH), 7.20 (s, 1H, ArH) 
 
Ethyl-8-chloro-4-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)butanoate (P5c) 
 
General procedure I was followed for the synthesis of P5c from P1c 
• Yellow solid 
• Yield: 60% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.75 
• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 1.50 (m, 1H, CH), 2.20-2.40 (m, 6H, CH2), 2.60-
2.95 (m, 4H, CH2), 3.80-4.0 (m, 2H, CH2), 4.10 (q, 2H, CH2), 7.10-7.25 (m, 3H, ArH), 
8.05 (d, 1H, ArH) 
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Ethyl 5-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)pentanoate (P6a) 
 
General procedure I was followed for the synthesis of P6a from P1a. 
• Yellow oil 
• Yield: 50% 
• TLC  (dichloromethane/methanol 95:5)  Rf = 0.65 
• 
1H NMR (CDCl3) 1.29 (t, 3H,CH3), 1.41 (dq, 1H, CH), 1.52 (d, 2H, CH2), 1.64 (d, 2H, 
CH2), 1.7-1.5 (dd, 2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.32 (d, 2H,CH2), 2.85-2.75 (dd, 
2H, CH2), 3.20 (q, 2H, CH2), 4.13 (dq, 2H, CH2), 7.30-7.78 (m, 4H, ArH) 
 
Ethyl 6-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)hexanoate (P7a) 
 
General procedure I was followed for the synthesis of P7a from P1a. 
• Yellow oil 
• Yield: 70% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.82 
• 
1H NMR (CDCl3) 1.29 (t, 5H, CH3, CH2), 1.41 (dq, 1H, CH), 1.52 (t, 2H, CH2), 1.64 
(t, 2H, CH2), 1.7-1.5 (dd, 2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.32 (dd, 2H,CH2), 2.85-
2.75 (dd, 2H, CH2), 3.20 (t, 2H, CH2), 4.13 (dq, 2H, CH2), 7.30-7.78 (m, 4H, ArH) 
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Ethyl 7-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)heptanoate (P8a) 
 
General procedure I was followed for the synthesis of P8a from P1a. 
• Yellow oil 
• Yield: 70% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.8 
• 
1H NMR (CDCl3) 1.29 (m, 7H, CH3, CH2, CH2), 1.41 (dq, 1H, CH), 1.52 (d, 2H, 
CH2), 1.64 (d, 2H, CH2), 1.7-1.5 (dd, 2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.32 (d, 
2H,CH2), 2.85-2.75 (dd, 2H, CH2), 3.20 (t, 2H, CH2), 4.13 (dq, 2H, CH2), 7.30-7.78 
(m, 4H, ArH) 
 
General procedure J for the synthesis of 4-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-
2(3H)-yl)carboxilic acids (P4aa, P5aa) 
The required ester (0.464 mmol) was dissolved in ethanol (5 mL) and an aqueous solution of 
1 N NaOH (3 mL) was added. The solution was stirred at reflux for 2 h. Then the solvent was 
removed under reduced pressure and the residue was diluted with water (5 mL) and extracted 
with ethyl acetate (1 x 2 mL). The aqueous layer was acidified with 6 N HCl (1 mL) and 
extracted with ethyl acetate (3 x 2 mL). The organic layer was dried over Na2SO4 anhydrous 
and evaporated under reduced pressure.  
 
4-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)propanoic acid (P4aa) 
 
General procedure J was followed for the synthesis of P4aa from P4a. 
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• Yellow solid 
• Yield: 97% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.40 
• 
1H NMR (CDCl3) 1.41 (dq, 1H,CH), 1.7-1.5 (t, 2H, CH2), 1.92 (d, 2H, CH2) , 2.3-2.1 (t, 
2H, CH2), 2.3 (d, 2H, CH2), 2.85-2.75 (dd, 2H, CH2) 3.20 (d, 2H, CH2), 7.30-7.78 (m, 4H, 
ArH), 11 (s, 1H, OH) 
 
4-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)butanoic acid (P5aa) 
 
General procedure J was followed for the synthesis of P5aa from P5a. 
• Yellow solid 
• Yield: 97% 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.50 
• 
1H NMR (CDCl3) 1.55-1.70 (m, 1H, CH), 2.0-2.50 (m, 6H, CH2), 2.70-3.0 (m, 4H, CH2), 
3.90-4.0 (m, 2H, CH2), 7.15-7.35 (m, 3H, ArH), 8.15 (d, 1H, ArH) 
• Cell proliferation assay (Appendix III)  
 
N-ethyl-4-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)butanamide (P9a) 
 
 
 
 
 
 
 
To a solution of compound P5aa (3.7 x 10-2 g, 0.13 mmol) in dichloromethane (3 mL), the 
coupling agent HATU (7.41 x 10-2 g, 0.20 mmol), ethylamine (0.02 mL, 0.35 mmol) and N-
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methyl morpholine (until ph =7) were added. The mixture was stirred at room temperature for 
1 h and then washed with 1 N HCl solution (2 x 1 mL), with saturated NaHCO3 solution (2 x 
1 mL) and finally with brine (2 x 1 mL). The organic layer was separated, dried over 
anhydrous Na2SO4 and evaporated under reduced pressure to obtain P9b. 
• Pale pink solid 
• Yield: 83% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.65 
• 
1H NMR (CDCl3) 1.04 (m, 3H, CH3), 1.41 (dq,1H, CH), 1.7-1.5 (dd, 2H, CH2), 1.93 
(m, 2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.34 (dd, 2H, CH2), 2.85-2.75 (m, 2H, CH2), 
3.11 (t, 2H, CH2), 3.20 (dq, 2H, CH2), 7.30-7.78 (m, 4H, ArH), 8.03 (br s, 1H, NH) 
 
2-(4-bromobutyl)-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one (18) 
 
 
 
 
 
 
 
 
To a solution of P1a (5 x10-2 mg, 0.25 mmol) in dry dimethylformamide, NaH (7.2 x 10-3 g, 
0.3 mmol) and Br(CH2)4Br (0.036 mL, 0.3 mmol) were added. The mixture was irradiated for 
10 min at 60 ˚C in a microwave synthesizer. The solution was evaporated under reduced 
pressure to remove dimethylformamide and extracted with ethyl acetate (3 x 2 mL). The 
organic layer was separated, dried over anhydrous Na2SO4, and evaporated under reduced 
pressure. Upon purification by flash chromatography (eluent: petroleum ether/ethyl acetate  
7:3) compound 18 was obtained. 
• White solid 
• Yield: 64% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.73 
• 
1H NMR (CDCl3) 1.41 (dq, 1H, CH), 1.52 (d, 2H, CH2), 1.7-1.5 (dd, 2H, CH2), 1.82 
(d, 2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.85-2.75 (m, 2H, CH2), 3.20 (dq, 2H, CH2), 3.51 
(t, 2H, CH2), 7.30-7.78 (m, 4H, ArH) 
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2-(4-(ethylamino)butyl)-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one (P10a) 
 
 
 
 
 
 
 
 
To a solution of compound 18 (4.6 x 10-2 g, 0.14 mmol) in dimethylformamide (2 mL), 
ethylamine (0.011 mL, 0.17 mmol) and triethylamine (0.024 mL, 0.17 mmol) were added and 
the mixture was stirred at 50 °C for 7 h. The solvent was removed under reduced pressure and 
the residue diluted with water (2 mL) and extracted with ethyl acetate (3 x 1 mL). The organic 
layer was dried over anhydrous Na2SO4 and evaporated under reduced pressure. Upon 
purification by flash chromatography (eluent: dichloromethane/methanol 9:1) P10a was 
obtained. 
• Yellow oil 
• Yield: 50% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.17 
• 
1H NMR (CDCl3) 1.02 (t, 3H, CH3), 1.38 (m, 2H, CH2), 1.41 (dq, 1H, CH), 1.52 (dd, 
2H, CH2), 1.7-1.5 (dd, 2H, CH2), 2.0 (br s, 1H, NH), 2.3-2.1 (dd, 2H, CH2), 2.55 (d, 
2H, CH2), 2.59 (d, 2H, CH2), 2.85-2.75 (dd, 2H, CH2), 3.20 (dq, 2H, CH2), 7.30-7.78 
(m, 4H, ArH) 
Genral procedure K for the synthesis of 2-alkyl-4,4a,5,6-tetrahydrobenzo[h]cinnolin-
3[2H]-ones (P11a, P12a) 
To a solution of P1a (0.25 mmol) in dry dimethylformamide (2 mL), NaH 60% in mineral oil 
(1.2 x 10-2 g, 0.3 mmol) and Br(CH2)nCH3 (0,3 mmol) were added and the mixture was stirred 
at 80 ˚C for 15 h. The solvent was evaporated under reduced pressure and the residue was 
extracted with ethyl acetate (3 x 2 mL). The organic layers were collected, dried over 
anhydrous Na2SO4, and evaporated under reduced pressure. Upon purification by flash 
chromatography (eluent: petroleum ether/ethyl acetate  8:2) the final products were obtained 
as yellow oils.  
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2-butyl-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3[2H]-ones (P11a) and 2-butyl-4,4a,5,6-
tetrahydrobenzo[h]cinnolin-3[2H]-ones (P17a) 
 
General procedure K was followed for the synthesis of P11a and P17a from P1a.  
Compound P11a: 
• Yellow oil 
• Yield: 75% 
• TLC (petroleum ether/ethyl acetate  8:2)  Rf = 0.70 
• 
1H NMR (CDCl3) 0.95 (t, 3H, CH3), 1.30-1.45 (m, 2H, CH2), 1.50-1.75 (m, 5H, CH), 
2.15-2.30 (m, 2H, CH2), 2.60-3.95 (m, 4H, CH2), 3.75-4.0 (m, 2H, CH2), 7.15-7.35 
(m, 3H, ArH), 8.15 (d, 1H, ArH) 
Compound P17a: 
• Yellow oil 
• Yield: 25% 
• TLC (petroleum ether/ethyl acetate  8:2)  Rf
 
= 0.60 
• 
1H NMR (CDCl3) 0.95 (t, 3H, CH3), 1.30-1.45 (m, 2H, CH2), 1.80-1.95 (m, 2H, CH), 
2.80-3.0 (m, 4H, CH2), 4.20-4.30 (m, 2H, CH2), 6.75 (s, 1H, CH), 7.15-7.35 (m, 3H, 
ArH), 8.15 (d, 1H, ArH) 
 
2-pentyl-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3[2H]-ones (P12a) and  
 
General procedure K was followed for the synthesis of P12a and P18a from P1a. 
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Compound P12a: 
• Yellow oil 
• Yield: 80% 
• TLC (petroleum ether/ethyl acetate  8:2)  Rf
 
= 0.70 
• 
1H NMR (CDCl3) 0.95 (t, 3H, CH3), 1.20-1.35 (m, 4H, CH2), 1.50-1.80 (m, 4H, CH), 
2.15-2.30 (m, 2H, CH2), 2.60-3.95 (m, 4H, CH2), 3.75-4.0 (m, 2H, CH2), 7.15-7.35 
(m, 3H, ArH), 8.15 (d, 1H, ArH) 
Compound P18a: 
• Yellow oil 
• Yield: 80% 
• TLC (petroleum ether/ethyl acetate  8:2)  Rf = 0.60 
• 
1H NMR (CDCl3) 0.95 (t, 3H, CH3), 1.30-1.50 (m, 4H, CH2), 1.80-1.95 (m, 2H, CH), 
2.80-3.0 (m, 4H, CH2), 4.20-4.25 (m, 2H, CH2), 6.75 (s, 1H, CH), 7.15-7.35 (m, 3H, 
ArH), 8.15 (d, 1H, ArH) 
 
2-(3-hydroxypropyl)-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one (19) 
 
 
 
 
 
 
 
 
A mixture of P1a (5.7 x 10-2 g, 0.28 mmol) in dimethylformamide (2 mL) and NaH 60% in 
mineral oil (1.34 x 10-2 g, 0.56 mmol) was stirred for 15 min. Then Cl(CH2)3OH (0.025 mL, 
0.30 mmol) was added and the mixture was stirred for further 4 h at 60 ˚C. The solvent was 
removed under reduced pressure, the residue was diluted with water (2 mL) and extracted 
with ethyl acetate (3 x 1 mL). The organic layer was dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. Upon purification by flash chromatography (eluent: 
petroleum ether/ethyl acetate  1:1) 19 was obtained. 
• Light yellow oil 
• Yield: 53% 
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• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.49 
• 
1H NMR (CDCl3) 1.41 (dq, 1H, CH), 1.7-1.5 (m, 2H, CH2), 1.75 (d, 2H, CH2), 2.3-2.1 
(dd, 2H, CH2), 2.85-2.75 (dd, 2H, CH2), 3.20 (t, 2H, CH2), 3.50 (dq, 2H, CH2), 3.65 (s, 
1H, OH), 7.30-7.78 (m, 4H, ArH) 
 
3-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)propyl 2-(tert-butoxycarbonyl 
amino)-3-phenylpropanoate (20) 
 
 
 
 
 
 
 
 
To a solution of 19 (4 x 10-2 g, 0.15 mmol) in dichloromethane (3 mL) N-Boc-Phe-OH (1.1 x 
10-2 g, 0.40 mmol) and the coupling agent HATU (8.8 x 10-2 g, 0.23 mmol) were added. The 
solution was brought to pH = 7 with drops of N-methylmorpholine. It was stirred at room 
temperature for 24 h. The solvent was removed under reduced pressure, the residue diluted 
with dichloromethane
 
(3 mL) and washed respectively with: 1 N HCl (3 × 1 mL), saturated 
solution of NaHCO3 (3 × 1 mL) and brine (2 × 1 mL). The solvent was dried with Na2SO4 and 
evaporated. The crude product was purified by flash chromatography (eluent: 
dichloromethane/ethyl acetate  85:15) to obtain compound 20. 
• Yellow oil 
• Yield: 33% 
• TLC (dichloromethane/ethyl acetate  75:25)  Rf
 
= 0.38 
• 
1H NMR (CDCl3) 1.38 (m, 9H, 3CH3), 1.41 (dq, 1H, CH), 1.7-1.5 (t, 2H, CH2), 1.84 
(d, 2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.85-2.75 (dd, 2H, CH2), 3.20 (dq, 2H, CH2), 
3.23-2.98 (dd, 2H, CH2), 4.08 (t, 2H, CH2), 4.68 (dq, 1H, CH), 7.27-7.40 (m, 5H, 
ArH), 7.30-7.78 (m, 4H, ArH), 8.03 (br s, 1H, NH) 
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3-(3-oxo-4,4a,5,6-tetrahydrobenzo[h]cinnolin-2(3H)-yl)propyl 2-amino-2-hydroxyacetate 
(P13a) 
 
 
 
 
 
 
 
 
Compound 20 (3 x 10-2 g, 0.06 mmol) was dissolved in dichloromethane (3 mL) and the 
solution was cooled to 0 ˚C with an ice bath. Trifluoroacetic acid (0.05 mL, 0.71 mmol) was 
slowly added and the solution was stirred at room temperature for 3 h. The reaction was 
monitored by TLC until completion. The mixture was cooled to 0 ˚C and treated with  a 
slolution of 0.5 N NaOH (1 mL) and extracted with dichloromethane (3 x 1.5 mL). The 
organic layer was dried over anhydrous Na2SO4 and evaporated under reduced pressure. Upon 
purification by flash chromatography (eluent: dichloromethane/ethyl acetate /methanol 
6:3.5:0.5) P13a was obtained. 
• Yellow oil 
• Yield: 50% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.59 
• 
1H NMR (CDCl3) 1.41 (dq, 1H, CH), 1.7-1.5 (m, 2H, CH2), 1.84 (d, 2H, CH2), 2.3-2.1 
(dd, 2H, CH2), 2.85-2.75 (dd, 2H, CH2), 3.20 (t, 2H, CH2N), 3.65 (dq, 1H, OH), 4.08 
(m, 2H, CH2O), 5.11 (br s, 2H, NH2), 5.19 (s, 1H, COCH), 7.30-7.78 (m, 4H, ArH) 
 
 
General procedure L for the synthesis of ethyl 2-(3-oxo-5,6-dihydrobenzo[h]cinnolin-
2(3H)-yl)esters (P14-P16a) 
The required pyridazinone (0.25 mmol) was suspended in toluene (1.5 mL) and KOH (0.33 
mmol), TBAF · 3H2O (0.025 mmol) and the corresponding bromoalkyl ester (0.33 mmol) 
were added. The mixture was heated at 50 °C for 3 h. The mixture was then extracted with 
ethyl acetate (3 x 1mL) and the collected organic layer was washed with acqueous 5% NaOH 
(1 x 2mL) and with acqueous 5% HCl. The organic phase was dried over over anhydrous 
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Na2SO4 and evaporated under reduced pressure. Purification with flash chromatography was 
performed to obtain the final esters derivative. 
 
Ethyl 2-(3-oxo-5,6-dihydrobenzo[h]cinnolin-2(3H)-yl)propanoate (P14a) 
 
General procedure L was followed for the synthesis of P14a from P2a. A purification of the 
crude product with flash chromatography (eluent: dichloromethane/ethyl acetate  6:4) was 
performed.  
• Yellow oil 
• Quantitative yield 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.60 
• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 1.50-1.65 (m, 2H, CH2), 2.80-3.0 (m, 4H, CH2), 
4.15 (q, 2H, CH2), 4.25-4.30 (t, 2H, CH2), 6.75 (s, 1H, CH), 7.20-7.40 (m, 3H, ArH), 
8.0-8.10 (m, 1H, ArH) 
 
Ethyl 2-(3-oxo-5,6-dihydrobenzo[h]cinnolin-2(3H)-yl)butanoate (P15a) 
 
General procedure L was followed for the synthesis of P15a from P2a. A purification with 
flash chromatography (eluent: dichloromethane/ethyl acetate  6:4) was performed. 
• Yellow oil 
• Quantitative yield 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.70 
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• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 2.15-2.27 (m, 2H, CH2), 2.38-2.48 (m, 2H, CH2), 
2.80-2.95 (m, 4H, CH2), 4.10 (q, 2H, CH2), 4.25-4.32 (t, 2H, CH2), 6.75 (s, 1H, CH), 
7.20-7.40 (m, 3H, ArH), 8.0-8.10 (m, 1H, ArH) 
Ethyl 2-(3-oxo-5,6-dihydrobenzo[h]cinnolin-2(3H)-yl)pentanoate (P16a) 
 
General procedure L was followed for the synthesis of P16a from P2a. A purification with 
flash chromatography (eluent: dichloromethane/ethyl acetate  6:4) was performed. 
• Yellow oil 
• Quantitative yield 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.75 
• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 2.15-2.27 (m, 2H, CH2), 2.38-2.48 (m, 2H, CH2), 
2.80-2.95 (m, 4H, CH2), 4.10 (q, 2H, CH2), 4.25-4.32 (t, 2H, CH2), 6.75 (s, 1H, CH), 
7.20-7.40 (m, 3H, ArH), 8.0-8.10 (m, 1H, ArH) 
 
4-(3-oxo-5,6-dihydrobenzo[h]cinnolin-2(3H)-yl)carboxilic acids (P14aa, P15aa) 
 
4-(3-oxo-5,6-dihydrobenzo[h]cinnolin-2(3H)-yl)propanoic acid (P14aa) 
 
General procedure J was followed for the synthesis of P14aa from P14a.  
• Yellow solid 
• Quantitative yield 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.50 
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• 
1H NMR (CDCl3) 1.50-1.65 (m, 2H, CH2), 2.80-3.0 (m, 4H, CH2), 4.25-4.30 (t, 2H, CH2), 
6.75 (s, 1H, CH), 7.20-7.40 (m, 3H, ArH), 8.0-8.10 (m, 1H, ArH) 
 
4-(3-oxo-5,6-dihydrobenzo[h]cinnolin-2(3H)-yl)butanoic acid (P15aa) 
 
 
 
General procedure J was followed for the synthesis of P15aa from P15a.  
• Yellow solid 
• Quantitative yield 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.60 
• 
1H NMR (CDCl3) 2.15-2.27 (m, 2H, CH2), 2.38-2.48 (m, 2H, CH2), 2.80-2.95 (m, 4H, 
CH2), 4.25-4.32 (t, 2H, CH2), 6.75 (s, 1H, CH), 7.20-7.40 (m, 3H, ArH), 8.0-8.10 (m, 1H, 
ArH) 
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5.3.2 Synthesis of the five- and seven-membered ring compounds 
(P19-26) 
 
Synthesis of the unsaturated carboxylic acid 21 and 23 
 
2-(1-oxo-1H-inden-2(3H)-ylidene)acetic acid (21) 
 
General procedure F was followed for the synthesis of 21 from 1-indanone. In this case the 
reaction mixture was stirred at rt for 2 h. 
• Light yellow solid 
• Yield: 64% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.32 
• 
1H NMR (CDCl3) 3.68 (d,2H, CH2), 6.32 (dd, 1H, CH=C), 7.45-7.66 (m, 4H, ArH), 11.0  
(br s, 1H, COOH) 
 
2-(5-oxo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-ylidene)acetic acid (23) 
 
General procedure F was followed for the synthesis of 37 from 1-benzosuberone. In this case the 
reaction mixture was stirred at rt for 4 h. 
• White solid 
• Quantitative yield 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.33 
• 
1H NMR (CDCl3) 1.66 (d, 2H, CH2), 1.96 (d, 2H, CH2), 2.85 (d, 2H, CH2), 6.39 (dd, 1H, 
CH=C), 7.46-7.73 (m, 4H, ArH), 11.0  (br s, 1H, COOH) 
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Synthesis of the saturated carboxylic acid 22 and 24 
 
2-(1-oxo-2,3-dihydro-1H-inden-2-yl)acetic acid (22) 
 
General procedure G was followed for the synthesis of 22 from 21. 
• Yellow solid 
• Yield: 95% 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.5 
• 
1H NMR (CDCl3) 2.71-2.46 (dd, 2H, CH2), 2.83-2.58 (dt, 2H,CH2), 3.70 (q, 1H, CH), 
7.35-7.92 (m, 4H, ArH), 11.0 (br s, 1H, COOH) 
 
2-(5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)acetic acid (24) 
COOHOCOOHO
23 24
 
General procedure G was followed for the synthesis of 24 from 23. 
• Yellow/orange oil 
• Quantitative yield 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.61 
• 
1H NMR (CDCl3) 1.56-1.31 (m, 2H, CH2), 1.90-1.80 (m, 2H, CH2), 2.71-2.46 (dd, 2H, 
CH2), 2.88-2.84 (dd, 2H,CH2), 3.31 (q, 1H, CH), 7.35-7.92 (m, 4H, ArH), 11.0  (br s, 1H, 
COOH) 
 
Synthesis of the pyridazinones P19 and P23 
 
4a,5-dihydro-2H-indeno[1,2-c]pyridazin-3(4H)-one (P19) 
 
General procedure H was followed for the synthesis of P19 from 22. 
• white crystalline solid 
 Chapter 5 – EXPERIMENTAL SECTION: CHEMISTRY 
150 
 
• Yield: 79% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.48 
• 
1H NMR (CDCl3) 2.29 (t, 1H, CH), 2.3-2.1 (dd, 2H, CH2), 2.7-2.4 (dd, 2H,CH2), 7.0 (br 
s, 1H, NH), 7.30-7.78 (m, 4H, ArH) 
• Cell proliferation assay (Appendix III)  
 
2,4,4a,5,6,7,-hexahydro-3H-benzo[6,7]-cyclohepta[1,2-c]pyridazin-3-one (P23) 
 
General procedure H was followed for the synthesis of P23 from 24. 
• white crystalline solid     
• Yield: 75% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.57 
• M.p. 187˚C 95 
• 
1H NMR (CDCl3) 1.41 (m, 1H, CH), 1.4-1.2 (dd, 2H, CH2), 1.90-1.80 (dd, 2H, CH2), 2.3-
2.1 (dd, 2H, CH2), 2.88-2.84 (m, 2H,CH2), 7 .0 (br s, 1H, NH), 7.30-7.78 (m, 4H, ArH) 
• Cell proliferation assay (Appendix III)  
 
2H-indeno[1,2-c]pyridazin-3(5H)-one (P20) 
 
 
 
 
 
 
General procedure H was followed for the synthesis of P20 from 21. In this case, the product 
needed a purification with flash chromatography (eluent: dichloromethane/ethyl 
acetate/methanol 8:1.8:0.2). 
• Yellow solid     
• Yield: 57% 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.50 
• 
1H NMR (CDCl3) 3.95 (s, 2H, CH2), 7.0 (s, 1H, CH), 7.40-7.55 (m, 3H, ArH), 7.80-7.90 
(m, 1H, ArH) 
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2,5,6,7-tetrahydro-3H-benzo[6,7]-cyclohepta[1,2-c]pyridazin-3-one (P24) 
 
 
 
 
 
 
The procedure for the synthesis of compound P24, starting from P23, was the same to that used 
for the synthesis of compound P2a.  
• Light yellow solid 
• Yield: 75% 
• TLC (dichloromethane/methanol 9:1)  Rf
 
= 0.50 
• 
1H NMR (CDCl3) 2.10-2.20 (m, 2H, CH2), 2.40-2.50 (m, 2H, CH2), 2.60-2.70 (m, 2H, 
CH2), 6.85 (s, 1H, CH), 7.20-7.25 (m, 2H, ArH), 7.35-7.40 (m, 2H, ArH), 7.50-7.55 (m, 
1H, ArH) 
 
Synthesis of the saturated esters P21 and P25 
 
Ethyl 4-(3-oxo-3,4,4a,5-tetrahydro-2H-indeno[1,2-c]pyridazin-2-yl)butanoate (P21) 
 
General procedure I was followed for the synthesis of P21 from P19. 
• Yellow oil 
• Yield: 55% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.75 
• 
1H NMR (CDCl3) 1.29 (t, 3H, CH3), 2.0-2.10 (m, 2H, CH2), 2.25-2.40 (m, 3H, CH, CH2), 
2.65-2.80 (m, 1H, CH2), 2.85-2.95 (m, 1H, CH2), 3.0-3.20 (m, 1H, CH2), 3.35-45 (m, 1H, 
CH), 3.75-3.90 (m, 1H, CH), 3.95-4-15 (m, 3H, CH, CH2), 7.30-7.45 (m, 3H, ArH), 7.70-
7.80 (m, 1H, ArH) 
• Cell proliferation assay (Appendix III)  
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Ethyl-4-(3-oxo-2,5,6,7-hexahydro-3H-benzo[6,7]-cyclohepta[1,2-c]pyridazin-3-yl) 
butanoate (P25) 
 
General procedure I was followed for the synthesis of P25 from P23. 
• Yellow oil 
• Yield: 33% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.77 
• 
1H NMR (CDCl3) 1.29 (t, 3H, CH3), 1.4-1.2 (m, 2H, CH2), 1.41 (m, 1H, CH), 1.90-1.80 
(m, 2H, CH2), 2.04 (q, 2H, CH2), 2.3-2.1 (dd, 2H, CH2), 2.47 (dd, 2H, CH2CO), 2.88-
2.84 (dd, 2H,CH2), 3.20 (t, 2H, CH2N), 4.13 (t, 2H, CH2O), 7.30-7.78 (m, 4H, ArH) 
 
 
Synthesis of the unsaturated esters P22 and P26 
 
 
Ethyl 4-(3-oxo-3,5-dihydro-2H-indeno[1,2-c]pyridazin-2-yl)butanoate (P22) 
 
General procedure L was followed for the synthesis of P22 from P20. A purification with flash 
chromatography (eluent: dichloromethane/ethyl acetate  6:4) was performed. 
• Yellow oil 
• Yield: 68% 
• TLC (dichloromethane/methanol 95:5)  Rf
 
= 0.80 
• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 2.15-2.25 (m, 2H, CH2), 2.35-2.45 (m, 2H, CH2), 
3.90 (s, 2H, CH2), 4.05-4.15 (q, 2H, CH2), 4.25-4.35 (m, 2H, CH2), 6.95 (s, 1H, CH), 
7.40-7.50 (m, 3H, ArH), 7.80-7.90 (m, 1H, ArH) 
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Ethyl-4-(3-oxo-2,5,6,7-tetrahydro-3H-benzo[6,7]-cyclohepta[1,2-c]pyridazin-3-yl) 
butanoate (P26) 
 
General procedure L was followed for the synthesis of P26 from P24. A purification with flash 
chromatography (eluent: petroleum ether/ethyl acetate  7:3) was performed. 
• Yellow oil 
• Yield: 68% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.80 
• 
1H NMR (CDCl3) 1.25 (t, 3H, CH3), 2.05-2.25 (m, 4H, CH2), 2.35-2.45 (m, 4H, CH2), 
2.80-2.90 (m, 2H, CH2), 4.05-4.15 (q, 2H, CH2), 4.25-4.35 (m, 2H, CH2), 6.80 (s, 1H, CH), 
7.20-7.30 (m, 1H, ArH), 7.30-7.40 (m, 2H, ArH), 7.50-7.60 (m, 1H, ArH) 
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5.4 Experimental procedures: the chimera compounds 
 
5.4.1 Synthesis of the chimera compounds C1a,b and C2 
 
4-oxo-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid (25)201 
 
 
 
 
 
A mixture of α-phenylglutaric anhydride (0.5 g, 2.69 mmol)  and 2 g of polyphosphoric acid 
was heated to 100-110 °C and kept at that temperature for 15 min. Another 1 g of 
polyphosphoric acid was added and the mixture was heated for 15 min at the same 
temperature. The solution appeared as a dense brown oil. The mixture was cooled with an ice 
bath, treated with water and extracted with ethyl acetate (3 x 2 mL). In order to purify the 
reaction mixture from the unreacted starting material, the organic phase was firstly treated 
with 1 N NaOH (2 mL) and then the collected alkaline aqueous solution, which contained the 
sodium salt of compound 25, was acidified with 6 N HCl  (1 mL) and extracted with ethyl 
acetate (3 x 1 mL). The organic layer was dried over anhydrous Na2SO4 and evaporated under 
reduced pressure to afford 25. 
• Brown oil 
• Yield: 90% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.5 
• 
1H NMR (CDCl3) 2.25-2.40 (m, 1H, CH2-2), 2.45-2.55 (m, 1H, CH2-2), 2.55-2.70 (dt, 
1H, CH2-3), 2.85-2.95 (m, 1H, CH2-3), 3.96 (t, 1H, CH-1), 7.30-7.40 (m, 2H, ArH), 
7.40-7.55 (m, 1H, ArH), 8.05 (d, 1H, ArH), 11.15 (s, 1H, OH, exchangeable with 
D2O) 
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4-oxo-N-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide (26) 
 
 
 
 
 
To a solution of compound 25 (0.2 g, 1.05 mmol) in dichloromethane (6 mL) the coupling 
agent TBTU (0.46 g, 1.42 mmol), N-methylmorpholine (up to pH=7) and 4-
(trifluoromethyl)aniline (0.4 mL, 3.21 mmol) were added. The resulting mixture was stirred at 
room temperature for 24 h. The product was extracted with dichloromethane (3 x 2 mL). The 
organic layer was washed first with 1 N HCl (1 x 2 mL), then with a saturated solution of 
sodium hydrogencarbonate (1 x 2 mL) to neutralize the excess of TBTU and finally with 
brine (1 x 2 mL). The organic phase was dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to provide a yellow solid. The residue was purified by flash 
chromatography (eluent: cyclohexane/ethyl acetate 7:3) to afford the intermediate 26.  
• White solid 
• Yield: 62% 
• TLC (petroleum ether/ethyl acetate 7:3) Rf = 0.3 (Compound 26 was visualized by 
dipping TLC plates into a solution of phosphomolybdic acid in ethanol)  
• 
1H NMR (CDCl3) 2.35-2.45 (m, 1H, CH2-2), 2.60-2.85 (m, 3H, [1H, CH2-2; 2H, CH2-
3]), 3.90-3.95 (t, 1H, CH-1), 7.1-7.6  (m, 7H, ArH), 8.11 (dd, 1H, ArH) 
 
(Z)-2-(1-oxo-4-(4-(trifluoromethyl)phenylcarbamoyl)-3,4-dihydronaphthalen-2(1H)-
ylidene)acetic acid (27) 
 
 
 
 
 
A solution of NaOH (0.26 g, 6.53 mmol)  in water (3.1 mL) and ethanol (1.63 mL) was added 
dropwise to an ice-cooled solution (0 °C) of compound 26 (0.44 g, 1.33 mmol) and glyoxylic 
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acid (0.49 g, 5.27 mmol) in water (1.8 mL). This solution was stirred at room temperature for 
1 h and then ethanol was removed under reduced pressure. The obtained acqueous mixture 
was acidified with 6 N HCl and the precipitate was filtered, washed with 6 N HCl  (1 x 1 mL) 
and dried to give a yellow residue. The crude solid was purified by flash chromatography 
(eluent: dichloromethane/methanol 9:1 with 0.02 mL of acetic acid) to provide compound 27.   
• White solid 
• Yield: 47% 
• TLC (dichloromethane/methanol 9:1 with 0.02 mL of acetic acid)  Rf = 0.4 
• 
1H NMR (CD3OD) 3.10-3.20 (m, 1H, CH2-3), 4.10-4.25 (m, 2H, [1H, CH2-3; 1H, CH-
4]), 6.90 (d, 1H, CH-9), 7.40 -7.80  (m, 7H, ArH), 8.11 (dd, 1H, ArH)  
• 
19F NMR (CD3OD) 64 (s, 3F, CF3) 
 
2-(1-oxo-4-(4-(trifluoromethyl)phenylcarbamoyl)-1,2,3,4-tetrahydronaphthalen-2-
yl)acetic acid (28) 
 
 
 
 
 
A mixture of compound 27 (0.173 g, 0.44 mmol) and zinc dust (0.34 g, 0.52 mmol) in acetic 
acid (4.95 mL) and water (1.24 mL) was heated at 60 °C for 20 min. Since the amount of zinc 
was minimal, it was not necessary to filter the suspension to remove the excess of zinc, 
whereas the acetic acid was removed under reduced pressure. Compound 28 was extracted 
with ethyl acetate (3 x 2 mL) and the organic layer was dried over anhydrous Na2SO4, filtered 
and the solvent was evaporated. 
• Light yellow solid 
• Yield: 91% 
• TLC (dichloromethane/methanol 9:1) Rf = 0.4 (Compound 8 was visualized by 
dipping TLC plates into a solution of phosphomolybdic acid in ethanol)  
• 
1H NMR (CD3OD) 2.30 (dd, 1H, CH2-9), 2.40-2.60 (m, 2H, CH2-3), 2.95 (dd, 1H, 
CH-2), 3.05-3.20 (m, 1H, CH2-9), 4.30 (dd, 1H, CH-4), 7.25-8.11 (m, 8H, ArH) 
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 3-oxo-N-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydrobenzo[h]cinnoline-6-
carboxamide (C1a, C1b) 
 
 
 
 
 
To a solution of compound 28 (0.15 g, 0.38 mmol) in ethanol, hydrazine monohydrate (0.09 
mL, 1.93 mmol) was added dropwise and the obtained yellow solution was refluxed for 2 h.  
After evaporation of the solvent, the reaction mixture was extracted with ethyl acetate (5 x 1 
mL). The organic layer was dried over anhydrous Na2SO4, filtrated and the solvent was 
evaporated under reduced pressure. The two diastereoisomers C1a and C1b was separated by 
flash chromatography (eluent: dichloromethane/methanol 9.8:0.2). 
• Total yield: 64%  (diastereomeric excess C1a:C1b = 8:2) 
Compound C1a: 
• Yellow solid  
• TLC (dichloromethane/methanol 9:1) Rf = 0.53 (Compounds C1a was visualized also 
with iodine) 
• Melting point: 230.2-232.4 °C  
• 
1H NMR (CD3OD) 1.80-2.00 (m, 2H, CH2-6), 2.00-2.15 (m, 1H) 2.40-2.50 (m, 2H), 
2.65-2.75 (m, 1H), 4.05-4.10 (m, 1H), 7.20-7.30 (m, 3H, ArH), 7.50-7.55 (m, 2H, 
ArH), 7.70-7.75 (m, 2H, ArH), 8.05-8.10 (m, 1H, ArH);  
Compound C1b 
• White solid 
• TLC (dichloromethane/methanol 9:1) Rf = 0.48 (Compounds C1b was visualized also 
with iodine)  
• 
1H NMR (DMSO) 1.80-2.00 (m, 1H) 2.20-2.40 (m, 2H), 2.40-2.45 (m, 1H), 2.85-3.00 
(m, 1H), 3.90-4.00 (m, 1H), 7.15-7.20 (m, 1H, ArH), 7.30 (d, 2H, ArH), 7.75 (d, 2H, 
ArH), 7.90 (d, 2H, ArH), 8.05 (d, 1H, ArH) 
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3-oxo-N-(4-(trifluoromethyl)phenyl)-2,3,5,6-tetrahydrobenzo[h]cinnoline-6-carboxamide 
(C2) 
 
 
 
 
 
A mixture of compound C1a (5 x 10-2 g, 0.13 mmol), sodium m-nitro-benzenesulfonate (2.9 x 
10-2 g, 0.13 mmol), NaOH (2.1 x 10-2  g, 0.52 mmol) in water (1 mL) was refluxed for 30 
min. After cooling, the reaction mixture was extracted with ethyl acetate (3 x 1 mL) and the 
organic layer was dried over anhydrous Na2SO4, filtrated and the solvent was evaporated 
under reduced pressure. The obtained residue was purified by flash chromatography (eluent: 
dichloromethane/methanol 9.7:0.3) to afford C2. 
• Yellow solid 
• Yield: 85%.  
• TLC (dichloromethane/methanol 9:1)  Rf = 0.4 
• 
1H NMR (CD3OD) 3.25 (t, 1H, CH2), 4.15 (t, 1H, CH2), 4.30 (t, 1H, CH), 6.85 (s, 1H, 
CH),7.40-7.55 (m, 3H, ArH), 7.60 (d, 2H, ArH), 7.65 (d, 2H, ArH), 8.15-8.25 (m, 1H, 
ArH) 
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5.4.2 Synthesis of the chimera compound C3  
β-benzoyl-γ-butyrolactone (29)183 
                          
 
 
 
 
Formaldehyde 37% (0.25 mL, 3.08 mmol) was added to a stirred solution of 3-benzoyl 
propionic acid (0.5 g, 2.81 mmol) in a solution 0.5 N NaOH (6.2 mL, 3.1 mmol) (molar ratio 
of 3-benzoyl propionic acid/CH2O/NaOH = 1.0 : 1.1 : 1.1). After 1 h at room temperature, the 
mixture was acidified with concentrated hydrochloric acid (~ 0.31 mL) and stirred for 
additional 12 h. The mixture was extracted with ethyl acetate (3 x 5 mL) and the combined 
organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo. The crude was 
purified by flash chromatography (eluent: petroleum ether/ethyl acetate 7:3) to obtain 
intermediate 29.  
• Transparent oil 
• Yield: 69% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.8 
• 
1H NMR (CDCl3) 2.75-3.05 (m, 2H, CH2), 4.35-4.50 (m, 2H, CH2), 4.60-4.65 (m, 1H, 
CH), 7.50-7.95 (m, 5H, ArH). 
 
5-hydroxymethyl-6-phenyl-4,5-dihydro-3(2H)-pyridazinone (30)184 
 
To a solution of compound 29 (5 x 10-2 g, 0.26 mmol) in ethanol (2 mL), hydrazine 
monohydrate (0.037 mL, 0.78 mmol) was added and the mixture was refluxed for 1.5 h. The 
solvent was then removed in vacuo and the residue was extracted with ethyl acetate (5 x 3 
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mL). The organic layer was dried over anhydrous Na2SO4, evaporated and the crude was 
directly used without purification in the next reaction. 
• Pale yellow solid 
• Yield: 67% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.3 
• 
1H NMR (CDCl3) 2.65-2.95 (m, 2H, CH2), 3.25-3.55 (m, 1H, CH), 3.70-3.90 (m, 2H, 
CH2), 7.20-7.80 (m, 5H, ArH), 8.50 (br s, 1H, NH, exchangeable with D2O). 
 
6-phenyl-5-hydroxymethyl-4,5-dihydro-3(2H)-pyridazinone acetate (31) 
 
 
 
To a solution of 30 (5 x 10-2 g, 0.25 mmol) in pyridine (2 mL), acetic anhydride (0.045 mL, 
0.48 mmol) was added and the mixture was stirred at rt for 4 h. The pyridine was then 
removed under reduced pressure and the residue was extracted with ethyl acetate (5 x 3 mL). 
The organic layer was dried over anhydrous Na2SO4, evaporated and the crude was purified 
by flash chromatography (eluent cyclohexane/ethyl acetate 3:7) to afford intermediate 31.   
• Pale yellow solid 
• Yield: 98% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.5 
• 
1H NMR (CDCl3) 2.0 (s, 3H, CH3), 2.70-2.80 (m, 2H, CH2), 3.60-3.70 (m, 1H, CH), 
4.0-4.10 (m, 1H, CH), 4.30-4.40 (m, 1H, CH), 7.40-7.85 (m, 5H, ArH), 8.80 (br s, 1H, 
NH, exchangeable with D2O). 
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6-phenyl-5-hydroxymethyl-3(2H)-pyridazinone acetate (32) 
 
 
 
A mixture of 31 (5 x 10-2 g, 0.20 mmol) and activated manganese dioxide (0.184 g, 2.1 mmol) 
in dry dichloromethane (2 mL) was refluxed for 24 h. After cooling, the oxidant was removed 
by filtration through Celite and the manganese dioxide was washed with dichloromethane. 
The obtained filtrate was concentrated to give a solid residue, which was purified by flash 
chromatography (eluent: dichloromethane/ethyl acetate 8:2).  
• White solid 
• Yield: 60%  
• TLC (dichloromethane/methanol 95:5)  Rf = 0.4 
• 
1H NMR (CDCl3) 2.15 (s, 3H, CH3), 4.9 (s, 2H, CH2), 7.05 (s, 1H, CH), 7.38-7.49 (m, 
5H, ArH), 11.13 (br s, 1H, NH, exchangeable with D2O). 
 
6-phenyl-5-hydroxymethyl-3(2H)-pyridazinone (33) 
 
 
 
A solution of 32 (5 x 10-2 g, 0.20 mmol) in ethanol (3 mL) was treated with 2N HCl (1 mL) 
and the mixture was heated to reflux for 4 h. After cooling, the solvent was removed in vacuo 
and the residue extracted with with ethyl acetate (4 x 3 mL). The organic layer was dried over 
anhydrous Na2SO4 and concentrated in vacuo to obtain intermediate 33 as white solid. 
• Quantitative yield 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.3 
• 
1H NMR (CD3OD) 4.38 (s, 2H, CH2), 7.2 (s, 1H, CH), 7.05 (s, 1H, CH), 7.43-7.50 (m, 
5H, ArH). 
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6-phenyl-5-formyl-3(2H)-pyridazinone (34) 
 
A solution of 33 (5 x 10-2 g, 0.25 mmol) in dry tetrahydrofurane (2 mL) was stirred with 
activated manganese dioxide (0.27 g, 2.5 mmol) for 48 h at rt. The suspension was filtered 
through Celite and the manganese dioxide was washed with tetrahydrofurane. The obtained 
filtrate was concentrated to give a solid residue, which was purified by flash chromatography 
(eluent: dichloromethane/methanol 95:5).  
• Yellow solid 
• Yield: 81% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.3 
• 
1H NMR (CDCl3) 7.43 (s, 1H, CH), 7.45-7.55 (m, 5H, ArH), 9.92 (s, 1H, CHO). 
 
6-phenyl-5-carboxy-3(2H)-pyridazinone (35) 
 
A solution of aldehyde 34 (5 x 10-2 g, 0.25 mg) and silver nitrate (0.212 g, 1.25 mmol) in 
ethanol (0.5 mL) and water (0.6 mL) was stirred rapidly under nitrogen atmosphere. A 10% 
NaOH solution was added until the pH of the reaction mixture reached 12. The resulting black 
suspension was stirred at room temperature for 15 h and then filtered. The filtrate was 
concentrated under reduced pressure, then acidified with 6N HCl, extracted with diethyl ether 
(3 x 2 mL), dried over anhydrous Na2SO4 and concentrated in vacuo.  The obtained crude was 
purified with flash chromatography (dichloromethane/methanol 9:1) to give intermediate 35.  
• Yellow solid 
• Yield: 60% 
• TLC (dichloromethane/methanol 9:1)  Rf = 0.2 
• 
1H NMR (DMSO) 7.15 (s, 1H, COOH), 7.46 (s, 5H, ArH). 
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1-(6-oxo-3-phenyl-1,6-dihydropyridazin-4yl)-3-(4-(trifluoromethyl) phenyl)urea (C3) 
 
The carboxylic acid 35 (5 x 10-2 g, 0.23  mmol) was suspended in a mixture of dry toluene (8 
mL) and dry tetrahydrofurane (8 mL) under nitrogen atmosphere, and DPPA (0.078 mL, 0.36 
mmol) was added. Triethylamine (0.032 mL, 3.6 mmol) was then added dropwise and the 
mixture stirred at room temperature for 30 min. The solution was heated at 80 °C for 2 h and 
then  p-trifluoromethyl aniline (0.036 mL, 0.29 mmol) in THF (3 mL) was added together 
with triethylamine (0.032 mL, 3.6 mmol). The mixture was stirred at 80 °C overnight and  
then was diluted with 10 mL of water and extracted with ethylacetate (3 x 10 mL). The 
organic phase was then extracted with 1 M HCl (1 x 10 mL). The organic layer was dried 
over anhydrous Na2SO4 and concentrated in vacuo to obtain the chimera C3. 
• White solid 
• Yield: 20% 
• TLC (dichloromethane/methanol 95:5)  Rf = 0.4 
• 
1H NMR (CD3OD) 7.50-7.60 (m, 10H, ArH), 7.85 (s, 1H, CH). 
• 
13C NMR (CD3OD) 110, 118, 126, 129, 130, 133, 142, 143, 152, 164 
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5.5 Experimental procedures: the oxidized compounds 
 
5.5.1 Synthesis of the ortho-quinone derivative O1 
 
3-methyl-2-morpholino-2,3-dihydrobenzofuran-5-ol (36)199, 200 
 
 
To a solution of propionaldehyde (0.174 g, 3 mmol) in toluene (4 mL), morpholine (0.26 g, 3 
mmol) was added dropwise and the mixture was stirred at room temperature for 18 h until the 
consumption of the starting material (the reaction was monitored by 1H NMR). 
The mixture was cooled to 0 °C and a solution of p-benzoquinone (150 mg, 3 mmol) in 
toluene (1 mL) was added. The mixture was stirred at 0 °C for 2.5 h and then it was 
concentrated in vacuo to obtain the crude product (dark red solid) used without further 
purifications. 
 
3-methylbenzofuran-5-ol (38) 
 
A solution of 37 (5 x 10-2 g, 0.21 mmol) in tetrahydrofuran (1 mL) was acidified with 3 mL of 
5N HCl and it was refluxed for 2 h. The mixture was then extracted with diethyl ether (3 x 2 
mL), dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. 
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The obtained crude was purified by flash chromatography (eluent: ciclohexane/ethyl acetate 
8:2 → 7:3 → 6:4). 
• Yield over two steps: 3% 
• TLC  (ciclohexane/ethyl acetate 7:3) Rf = 0.53 
• 
1H NMR (CDCl3) 2.2 (s, 3H, CH3), 5.2 (s, 1H, OH), 6.8-6.9 (m, 1H, ArH), 6.9 (s, 1H, 
ArH), 7.25-7.35 (m, 1H, ArH), 7.4 (s, 1H, CH) 
 
3-methylbenzofuran-4,5-dione (O1) 
 
IBX 45 wt. % (0.21 g, 0.34 mmol) was added to a solution of 38 (5 x 10-2 g, 0.34 mmol) in 
dichloromethane (1.5 mL) and the resulting mixture was stirred at room temperature for 24 h. 
The reaction was then diluted with water (2 mL) and extracted with dichloromethane (3 x 2 
mL). The combined organic layers were washed with brine, dried over Na2SO4 and 
evaporated in vacuo.  
• Purple solid 
• Yield: 3.6% 
• TLC (cyclohexane/ethyl acetate 7:3)  Rf = 0.2 
• 
1H NMR (CDCl3)  2.0 (s, 3H, CH3), 7.25 (s, 1H, ArH),7.5 (d, 1H, ArH), 8.07 (d, 1H, 
CH). 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 5 – EXPERIMENTAL SECTION: CHEMISTRY 
166 
 
5.5.2 Synthesis of the ortho-quinone derivatives (RS)-O2 
 
4-(allyloxy)-2,3-dimethylphenol (39)  
 
 
Allyl iodide (1 mL, 10.91 mmol) and potassium carbonate (2 g, 14.05 mmol) were added to a 
solution of 2,3-dimethyl hydroxyl hydroquinone (1 g, 7.24 mmol) in acetone (4 mL). The 
resulting mixture was stirred under reflux for 18 h. Then the solvent was removed in vacuo 
and the remaining residue was poured into water and extracted with diethyl ether. Flash 
chromatography (eluent: ciclohexane/ethylacetate 95:5 → 8:2)  of the crude product gave two 
products: the desired monoallyl ether 39 and its correspondent diallylether. 
• Yield (monoallyl ether 39): 30% 
• TLC (ciclohexane/ethyl acetate  8:2)   Rf monoallyl ether 39  = 0.38 ; Rfdiallyl ether = 0.76 
• 
1H NMR (monoallyl ether 39) (CDCl3) 2.18 (s, 3H, CH3), 2.2 (s, 3H, CH3), 4.45 (d, 
2H, CH2), 5.2 (dd, 1H, CH), 5.4 (dd, 1H, CH), 6.1 (m, 1H, CH), 6.6 (d, 2H, ArH). 
 
5-allyl-2,3-dimethylbenzene-1,4-diol (40) 
 
A solution of monoallyl ether 39 (0.2 g, 1.12 mmol) in decalin (1 mL) is heated to 220 ºC for 
7 h in autoclave and then cooled to room temperature. A light grey solid product was 
separated by filtration and washed with n-hexane. The precipitation could be enhanced by 
leaving the autoclave in freezer overnight. The crude product was purified by flash 
chromatography (eluent: cyclohexane/ethyl acetate 95:5 → 9:1 → 8:2). 
• Yield: 92% 
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• TLC (ciclohexane/ethylacetate 8:2) Rf = 0.28 
• 
1H NMR (CDCl3) 2.14 (s, 3H, CH3), 2.16 (s, 3H, CH3), 3.25 (d, 2H, CH2), 4.20 (s, 1H, 
OH),  4.50 (s, 1H, OH), 5.09 (s, 1H, CH2), 5.10 (d, 1H, CH2), 5.85-6.0 (m, 1H, CH), 
6.40 (s, 1H, ArH). 
 
2,6,7-trimethyl-2,3-dihydrobenzofuran-5-ol (41) 
 
p-toluenesulfonic acid (0.36 g, 2.1 mmol) was added to a solution of 40 (0.2 g, 1.12 mmol) in 
toluene (1.5 mL) and the reaction mixture was heated at 80 °C for 8 h. To the mixture, cooled 
to room temperature, a solution of saturated NaHCO3 (3 mL) was added and it was extracted 
with ethyl acetate (3 x 2 mL). The organic layer was dried over anhydrous Na2SO4 and 
evaporated in vacuo. Purification of the obtained crude solid was carried out by flash 
chromatography (eluent: cyclohexane/ethyl acetate 8:2) to afford compound 41. 
• White solid 
• Yield: 99% 
• TLC (cyclohexane/ethyl acetate 8:2)  Rf = 0.5 
• 
1H NMR (CDCl3) 1.47 (s, 3H, CH3), 2.01 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.7 (dd, 1H, 
CH2), 3.1 (dd, 1H, CH2), 4.8-5.1 (m, 1H, CH), 6.4 (s, 1H, ArH). 
 
2,6,7-trimethyl-2,3-dihydrobenzofuran-4,5-dione (O2)  
 
IBX 45% wt. (0.18 g, 0.29 mmol) was added to a solution of 41 (5 x 10-2 g, 0.28 mmol) in 
dichloromethane (1 mL). The resulting mixture was stirred at room temperature for 24 h. The 
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reaction was then diluted with water (2 mL) and extracted with dichloromethane (3 x 2 mL). 
The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and 
evaporated in vacuo. The crude product was purified by gradient flash chromatography 
(ciclohexane/ethyl acetate  8:2 → 7:3). 
• Red solid 
• Yield: 3.6% 
• TLC (cyclohexane/ethyl acetate 8:2) Rf = 0.2 
• 
1H NMR (CDCl3) 1.45 (s, 3H, CH3), 1.9 (s, 3H, CH3), 2.0 (s, 3H, CH3), 2.6 (dd, 1H, 
CH2), 3.2 (dd, 1H, CH2), 5.0-5.15 (m, 1H, CH). 
• 
13C NMR (CDCl3) 30, 128, 129, 130, 134, 172. 
 Chapter 6 – EXPERIMENTAL SECTION: BIOLOGY 
169 
 
6. EXPERIMENTAL SECTION: BIOLOGY 
 
6.1 Dual luciferase assay159  
 
Cell culture. The cancer cell lines were obtained from American Type Culture Collection. 
Human colon cancer cells (HTC-116) were maintained in RPMI 1640 (Gibco/BRL). Human 
colon cancer cell line (HCT-116) was maintained in McCoy's 5A (Gibco/BRL). All culture 
media were supplemented with 10% heat-inactivated fetal bovine serum (Gibco/BRL). Cell 
cultures were maintained at 37 °C under a humidified atmosphere of 5% CO2 in an incubator. 
Transient transfection and dual-luciferase assays. HCT-116 cells were seeded at a density 
of 10x105 cells in 100 mm2 culture plate. On the following day, the cells were co-transfected 
with pSTAT3-TA-Luc carrying firefly luciferase gene, which is dependently expressed by 
STAT3 activity, and pRL-TK carrying Renilla luciferase gene, which is independently 
expressed by STAT3 activity. Renilla luciferase activity was determined to calibrate 
transfection efficiency and cytotoxicity of chemicals. Beetle luciferin and coelenterazine were 
used as substrates for the two enzymes, respectively. The transfection was carried out using 
TransFectin (Bio-Rad). After 5 h of transfection, the cells were trypsinized and seeded onto 
sterilized black bottom 96-well plates at a density of 1 x 104 cells per well. On the following 
day, cells were treated with the tested compounds at different concentration and incubated for 
24 h. Firefly and Renilla luciferase activity was measured using a dual-light reporter gene 
assay kit (Promega). Renilla luciferase activity was determined to calibrate transfection 
efficiency and cytotoxicity of chemicals. Relative STAT3 activity was calculated by dividing 
the firefly luciferase activity with Renilla luciferase activity in each transfection experiment. 
The values of STAT3 inhibitory activity were the means of 3 experiments and the maximum 
deviation from the mean was less than 10%. 
 
As shown in Figure 37, the activities of Firefly  and Renilla  luciferases are measured 
sequentially from a single sample. Measurement of the luminescent signal from the two 
luciferase reporter enzymes was performed immediately following preparation of lysates with 
passive lysis buffer. Both Renilla and firefly luciferase exhibit glow-type reaction kinetics 
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when each specific substrates are added to lysates.  The firefly luciferase reporter is measured 
first by adding Luciferase Assay Reagent II (LAR II) to generate a stabilized luminescent 
signal. After quantifying the firefly luminescence, this reaction is quenched, and the Renilla 
luciferase reaction is simultaneously initiated by adding Stop & Glo Reagent to the same tube. 
The Stop & Glo Reagent also produces a stabilized signal from the Renilla luciferase, which 
decays slowly over the course of the measurement. Both of luminescence was measured by 
Wallac Victor™ 2 luminometer (Perkin-Elmer, Inc., Wellesley, MA). 
 
 
 
Figure 37.  Dual-luciferase report assay. 
 
 
 
 
 
 
 
 
Colorectal carcinoma HCT-116 cells 
treated with the test compound and 
incubated for 24 h 
Cell lysis by 1xPLB (passive lysis buffer) 
LARII (luciferase assay reagent II) 
Stop & Glo Reagent 
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6.2 AlphaScreen-based assay protocol  
 
The AlphaScreen-based assay was performed in a final reaction volume of 25 µL of the assay 
buffer containing 10 mM HEPES-NaOH (pH=7.4), 50 mM NaCl, 1 mM EDTA (pH = 8.0), 
0,1% NP-40, and 10 ng/µL BSA, in a 96-well microtiter plate at 25 °C. Phospho-Tyr (pTyr) 
peptide probes used in this study were 5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3, 
FITC-GpYDKPHVL for STAT1 and FITC-PSpYVNVQN for Grb2. Firstly, 75 nM of each 
SH2-conteining protein was incubated with a test compound for 15 min. Each protein sample 
was then incubated for 90 min with 50 nM of its corresponding  FITC-pTyr peptide, and 
mixed with streptavidin-coated donor beads and anti-FITC acceptor beads simultaneously 
before detection at 570 nm using EnVision Xcite (PerkinElmer). 
 
6.3 Cell proliferation assays 
The anti-proliferative assay was performed according to the US NCI protocol.173 The human 
tumor cancer cell lines of the screening panel were grown in RPM 1640 medium containing 
5% fetal bovine serum and 2 mM L-glutamine. Cells were inoculated into 96-well microtiter 
plates in 100 µL of complete medium at densities ranging from 5000 to 40.000 50 cells/well. 
The microtiter plates containing the cells were incubated for 24 h at 37 °C, 5% CO2, 95% air 
and 100% relative humidity prior to addition of the experimental drug. This latter was 
solubilized in dimethyl sulfoxide at 400-fold the desired final maximum test concentration 
and stored frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate 
was thawed and diluted twice to the desired final maximum test concentration with complete 
medium containing 50 µg/mL gentamicin. Additional four, 10-fold serial dilutions were made 
to provide a total of five drug concentrations plus control. Aliquots of 100 µL of these 
different drug dilutions were added to the appropriate microtiter wells already containing 100 
µL of medium, resulting in the required final drug concentrations. Following the addition of 
the compound, the plates were incubated for an additional 48 h at 37 °C, 5% CO2, 95% air, 
and 100% relative humidity. Cells were fixed by the gentle addition of 50 µL of cold 50% 
(w/v) trichloroacetic acid (TCA) and incubated for 60 min at 4 °C. After washing with tap 
water and air drying, Sulforhodamine B (SRB) 70 solution (100 µL) at 0.4% (w/v) in 1% 
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acetic acid was added to each well, and plates were incubated for 10 min at room temperature. 
After removing the unbound dye by washing with 1% acetic acid, the bound stain was 
subsequently solubilized with 10 mM Trizma base and the absorbance was measured on a 
microplate reader. Dose response parameters (GI50, TGI, LD50) were calculated as reported in 
the NCI protocol.173 
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7 . Appendix  
Appendix I 
Mean optical densities, percent growth,  GI50, TGI and LC50 of F2e evaluated on a panel of 58 human 
tumor cell lines (data obtained from NCI). 
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Appendix II 
Dose-response curves showing the percentage growth inhibition of compound F2e in panel/cell lines 
(data obtained from NCI in vitro disease oriented tumor cell screen). 
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Appendix III 
Growth inhibitory % of pyridazinone compounds (P1a, P4a, P5a, P5aa, P19, P21, P23) evaluated by 
cell proliferation assay against a panel of 58 cell lines at a single dose of 10 µM. 
 
Growth inhibition % 
 P1a P4a P5a P5aa P19 P21 P23 
LEUKEMIA 
 
 
     
CCRF-CEM n.a. 13.76 n.a. 7.49 n.a. 8.2 8.2 
HL-60(TB) 5.5 3.68 n.a. 6.86 2.14 4.71 n.a. 
K-562 2.52 n.t. 10.73 1.74 2.87 7.68 n.a. 
MOLT-4 1.76 9.03 14.7 n.a n.a. 5,1 n.a. 
RPMI-8226 0.7 n.a. n.a. n.a n.a. n.a. 12.3 
SR 11.84 20.07 22.2 4.57 7.26 9.98 1.47 
NON-SMALL 
CELL LUNG 
CANCER  
 
     
A549/ATCC n.a. 0.84 7.92 n.a 0.82 1,24 n.a. 
EKVX 36.08 9.32 3.62 2.41 19.93 n.a. 4.93 
HOP62 n.a. n.a. n.a. n.a n.a. n.a. 1.05 
HOP92 5.17 1.62 0.22 14.32 12.06 n.a. n.a. 
NCI H226 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
NCI H23 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
NCI H322M n.a. n.a. n.a. n.a n.a. n.a. n.a. 
NCI H460 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
NCI H522 17.4 n.a. 10.7 2.54 3.97 n.a. 6.37 
COLON 
CANCER        
COLO 205 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
HCC 2998 n.a. n.a. n.a. 2.13 n.a. n.a. n.a. 
HCT 116 n.a. n.a. n.a. 1.58 n.a. n.a. n.a. 
HCT 15 2.64 n.a. n.a. n.a n.a. n.a. n.a. 
HT29 3.17 n.a. 4.15 n.a n.a. n.a. n.a. 
KM12 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
SW620 n.a. n.a. n.a. n.a n.a. 0.59 n.a. 
CNS CANCER  
      
SF 268 0.09 n.a. n.a. n.a n.a. n.a. n.a. 
SF 295 n.a. 11.23 8.9 6.85 1.78 n.a. n.a. 
SF 539 2.27 0.85 n.a. n.a 1.51 n.a. 0.04 
SNB 19 n.a. n.a. n.a. 1,2 n.a. n.a. n.a. 
SNB 75 5.55 n.a. 3.55 4.99 n.a. 4.17 4.86 
U251 2.05 5.00 n.a. 5.17 n.a. n.a. 1.72 
MELANOMA  
      
LOX IMVI n.a. n.a. n.a. n.a n.a. n.a. n.a. 
 Chapter 7 – APPENDIX 
176 
 
MALNE 3M n.a. 10.17 n.a. n.a 1.7 n.a. n.a. 
M14 1.91 n.a. n.a. 1.19 n.a. n.a. n.a. 
MDA-MB-435 n.a. 0.95 n.a. n.a n.a. 0.18 n.a. 
SK MEL 2 n.a. n.a. n.a. n.a 12.31 n.a. n.a. 
SK MEL 28 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
SK MEL 5 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
UACC-257 2.68 n.a. 1.12 2.95 4.16 0.66 n.a. 
UACC-62 n.a. n.a. n.a. 1.48 n.a. n.a. n.a. 
OVARIAN 
CANCER        
IGROV 1 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
OVCAR 3 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
OVCAR 4 n.a. 2.65 1.12 n.a n.a. n.a. n.a. 
OVCAR 5 5.23 n.a. n.a. 5.39 n.a. n.a. 2.69 
OVCAR 8 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
NCI/ADR-RES n.a. n.a. n.a. n.a n.a. n.a. n.a. 
SK-OV-3 n.a. n.a. n.a. n.a n.a. n.a. 0.13 
RENAL 
CANCER        
786-0 10.19 16.89 12.96 2.77 n.a. 1.24 1.32 
A498 2.54 n.a. 11.93 n.a n.a. 1.42 2.08 
ACHN 2.59 n.a. n.a. 4.35 n.a. n.a. n.a. 
CAKI-1 n.a. 6.94 3.82 1.5 3.22 n.a. n.a. 
SN 12C n.a. n.a. n.a. 4.64 n.a. n.a. n.a. 
TK-10 4.36 5.51 0,97 n.a 11.99 n.a. 0,3 
UO-31 14.44 1.01 6.55 7.34 19.05 n.a. 11,87 
PROSTATE 
CANCER        
PC 3 4,14 n.a. 1,77 6,42 n.a. n.a. n.a. 
DU 145 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
BREAST 
CANCER        
MCF7 0.94 2.96 9.82 5.64 n.a. 8 n.a. 
MDA-MB-
231/ATCC n.a. n.a. n.a. 1,85 n.a. n.a. n.a. 
HS 578T n.a. n.a. 9,48 n.a n.a. 14.12 n.a. 
BT 549 n.a. n.a. n.a. n.a n.a. n.a. n.a. 
T-47D n.a. n.a. n.a. n.a 0.84 n.a. n.a. 
MDA-MB-468 n.a. n.a. n.a. n.a n.a. n.a. 6.64 
 
n.a. not active 
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